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Abstract  
This thesis has examined prescribing practices for patients with mild/moderate 
community-acquired pneumonia (CAP) at outpatient settings in Mongolia. 
The principal aim was to determine the extent of and factors influencing 
prescribing practices and to understand reasons for inappropriate prescribing 
and providing of antibiotic and non-antibiotic medicines, including injections 
for treatment of mild/moderate CAP. It was envisaged that the results of this 
research would produce essential data on prescribing for CAP in Mongolia 
and enlighten policy makers, emphasizing several issues such as appropriate 
use of antibiotics and patient safety (safe injection practices).    
CAP is a significant cause of morbidity and mortality in all age groups 
worldwide. The mortality rate for children aged less than five was 34.4% in 2011 
in Mongolia. It was the second most common reason for all hospitalizations in 
2011 (46%). This is the first study that has assessed prescribing practices for the 
treatment of outpatients diagnosed with mild/moderate CAP in Mongolia.  
The thesis consists of three types of studies; first a systematic review on 
prescribing practices for patients with mild/moderate CAP at outpatient 
settings in developing countries. The systematic review extracted 29 studies of 
which nine were classified as of relevance. Of the retrieved studies, 17 
assessed the effect of Integrated Management of Childhood Illnesses (IMCI) 
case management training on the use of antimicrobials among community 
health workers treating young children at first level health facilities. The overall 
extent of patients with mild/moderate CAP receiving a correct antibiotic was 
59% and a correct treatment was 48%. There was a paucity of studies 
evaluating prescribing for CAP in developing countries.  
The primary study evaluated prescriptions submitted to community 
pharmacies in Mongolia with a diagnosis of mild/moderate CAP written on 
each prescription by doctors, with prescriptions collected prospectively and 
sequentially. All prescribed drugs, including their dosage, duration, route of 
administration and demographic information of patients were extracted from 
the prescriptions. Each drug was evaluated for rational prescribing based on 
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the Standard Treatment Guidelines of Mongolia (2005, 2008), WHO/IMCI 
guidelines for treatment of mild/moderate pneumonia in children aged two 
to 59 months and Australian guidelines for the management of non-severe 
pneumonia. 
The site selection was based on the WHO Operational package for assessing, 
monitoring and evaluating country pharmaceutical situations. The principle 
for selecting private pharmacies in the urban and provinces was to sample 
the closest private pharmacy to each public health facility surveyed. A 
convenience selection method was applied for pharmacies in rural areas 
based on discussion with local professionals. The selection criteria were based 
on retail volume, operational activity and close location to hospital or health 
centres.  
In addition, questionnaire studies were completed with community members, 
medication providers (pharmacists, including pharmacy technicians) and 
prescribers (doctors), to assess the veracity of the results obtained from the 
prescription study.  
The selection of pharmacists and doctors was based on their location and 
accessibility. For the study, three public central hospitals, five district hospitals, 
20 family group practices (FGPs) and three private hospitals were selected. 
Thirty community pharmacies were conveniently selected from the chosen 
five districts that represented a range of pharmacies regarding size, 
accessibility and distance from clinics, based on discussions with local 
professionals, ensuring that no particular type of pharmacy was excluded.  
Prescriptions were collected from 22 pharmacies and represented the 
prescribing practices of 118 doctors. The study enrolled 394 (193 adults and 
201 children) patients, with a median age for children of 2.0 years (range: 
0.033-12) and adults of 33.0 years (range: 13-92). The questionnaire studies 
enrolled 474 community members, 34 pharmacists, plus 27 pharmacy 
technicians, 22 general doctors (GP) and 49 specialists.  
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The study found that a wide range of antibiotics and non-antibiotic medicines 
were prescribed and provided for the treatment of CAP. The prescription 
study showed the most commonly prescribed drugs were aminopenicillins 
(16%), vitamins (13.3%), and mucolytics (5.6%). Similarly, questionnaire results 
with prescribers and providers confirmed a wide range of antibiotics and non-
antibiotics being prescribed. Commonly dispensed antibiotics with 
prescriptions were oral and injectable penicillins with extended spectrum and 
oral sulfonamides. Oral macrolides were dispensed more frequently than 
injetactables whereas in contrast, injectable quinolones and injectable 
cephalosporins were more frequently dispensed than oral forms.  Other 
medicines dispensed with a prescription for treatment of CAP included 
mucolytics, vitamins and antihistamines. Additionally, injectable 
corticosteroids and injectable xanthines were frequently dispensed non-
antibiotics. The most commonly dispensed antibiotics without prescription 
were similar to those with prescription: oral and injectable penicillins with 
extended spectrum and oral sulfonamides. Additionally, non-prescribed oral 
and injectable cefalosporins were frequently dispensed. In contrast, 
tetracyclines and injectable macrolides were less frequently issued.  
The prescription study found the overall level of inappropriate prescribing for 
all patients based upon the standard treatment guidelines was 84.0% 
(845/1100). A total of 95 were not assessable against the Mongolian guidelines 
because of lack of information in the current guidelines for children aged 
between six to 15 years.  
Inappropriate drug selection was similar for adults (57.7%) and children 
(56.6%), and was the major reason for overall frequency of inappropriate 
prescribing which for adults was 89.0% and for children 78.0%. Doctors in urban 
areas prescribed more inappropriate drugs than those in rural areas for both 
children and adults χ2 [(1, n=575) =10.25, p =.0014]. 
The assessment of prescriptions for adults with mild/moderate CAP, compared 
against Australian therapeutic guidelines revealed that a similar extent of 
inappropriate medicines were prescribed for adults (91.5%) when compared 
with results of the assessment of prescriptions using Mongolian standards 
(89.0%). The prescribing practice of inappropriate drugs for children was 
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higher using Australian therapeutic guidelines (91.2%) than Mongolian 
standards (78.0%). Similar to the evaluation compared against Mongolian 
standards, doctors in urban areas tended to select more inappropriate drugs 
compared with their counterparts in rural areas χ2 [(1, n=860) =10.77, p = .001].   
A higher extent of inappropriateness was found in the evaluation of 
prescribing practices for treatment of pneumonia in children aged two 
months to 59 months compared against WHO/IMCI guidelines. The total 
inappropriateness of assessable drugs prescribed for children was 90.3%. 
In investigating reasons for not following prescribing guidelines, of 71 doctors 
who were surveyed, 42 of these doctors (59.2%) reported they had to change 
the prescribed antibiotic sometimes/always because the first chosen one 
showed no effect. Additionally, the questionnaire study with providers 
(pharmacists and pharmacy technicians) revealed that a majority (70%) had 
to change the prescription for treatment of CAP sometimes or always 
because the prescribed treatment was inappropriate.   
In addition, the prescription analysis showed that the extent of prescribed 
injections was 28.4% for adults and 9.0% for children. Prescribing of injectables 
was significantly higher for adults in urban areas compared with rural areas 
χ2[(1, n=556)=21.7, p = <.001], but the difference between urban and rural 
prescribing of injectables was not significant for children The administration of 
injections is only legal in hospital settings and only by qualified health 
personnel.  
The discrepancies between the expectations and attitudes towards 
therapeutic injections between prescribers, providers and the public were 
evident in this study. Most prescribers (54%) and providers (70%) specified 
patient’s self-diagnosis and wish as an important factor for 
prescribing/dispensing injections for treatment of CAP. However, this was at 
variance with community views where only a small percentage (16%) stated 
this as important, and it was older respondents who preferred having an 
injection.  
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The attitude on current treatment guidelines was investigated and a majority 
of pharmacists plus pharmacy technicians and doctors considered that the 
current treatment guidelines for CAP were not appropriate (80%, 70%).  
Moreover, most dispensers (70%) were in agreement with prescribers (83%) 
that antibiotics were overused in Mongolia. According to prescribers, the main 
reason for overusing antibiotics was insufficient government control. In 
addition pharmacies allowed patients to purchase antibiotics without 
prescription (35, 59.3%), and a strong public desire was perceived for 
therapeutic injections including antibiotic injections (36, 61.0%).  
The study concluded the currently adopted WHO guidelines need 
replacement with ones that are locally developed based upon local expertise 
including considerations of pathogen resistance patterns, the unusual climatic 
conditions and access of patients to medical care. In addition with respect to 
CAP, guidelines should include any non-antibiotic medicines considered 
appropriate for the Mongolian environment especially considering the low 
winter temperatures. Techniques for successful implementation of guidelines 
are well-known in the literature, such as those adopted by the National 
Prescribing Services (NPS) in Australia. In addition, educational programs 
targeted at improving the public’s, prescribers’ and providers’ knowledge 
and attitude towards prescribing and provision of antibiotics, including 
injectable medicines and safe injection practices should be implemented in 
Mongolia. 
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Chapter	1 Introduction	
1.1 Aims and context of the study  
This thesis investigates the prescribing practices for patients with 
mild/moderate community-acquired pneumonia (CAP) in Mongolia. The 
principal aim is to determine the extent of and factors influencing prescribing 
practices and to understand reasons for inappropriate use of antibiotic and 
non-antibiotic drugs for treatment of mild/moderate CAP in Mongolia. It is 
envisaged that the results of this research will produce scientific evidence and 
enlighten policy makers, emphasizing several issues such as appropriate use 
of antibiotics and patient safety (safe injection practices).    
Community-acquired lower respiratory tract infection (LRTI) is a common 
cause of acute illness both in developing and developed countries.(1, 2) The 
spectrum of diseases ranges from a mild mucosal colonisation or infection, 
acute bronchitis or acute exacerbation of chronic bronchitis/chronic 
obstructive pulmonary disease, to overwhelming symptoms in the patient 
presenting with severe community-acquired pneumonia (CAP). Pneumonia is 
broadly classified into two categories: community-acquired and hospital-
acquired. CAP is a significant cause of morbidity and mortality in all age 
groups, especially the elderly, which is a patient population that continues to 
grow.(1) In a prospective study of prognostic factors of CAP caused by 
bacteraemic pneumococcal disease in five countries, death rates ranged 
from 6% in Canada to 20% in the USA, 13% in the UK and 8% in Sweden.(3) The 
mortality rate of children aged less than five was the highest due to respiratory 
infections in Mongolia. The extent of pneumonia was 34.4% in 2011. And it was 
the second most common reason for all hospitalizations in 2011 (46%) in 
Mongolia.(4) 
Clinical standards and clinical practice guidelines were non-existent until 1992 
in Mongolia. During the past 10 years, clinical treatment guidelines have been 
developed as one of many structures of quality improvement in health care. 
With technical assistance from World Health Organization (WHO), guidelines 
on diagnosis and treatment of common diseases have been developed and 
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disseminated to primary health care facilities as well as Integrated 
Management of Childhood Illness (IMCI) guidelines that have been widely 
distributed. Additionally, the Oxford Handbook on Clinical Medicines and a 
Guideline Book on Maternal and Child Health and Social Welfare were 
translated and distributed for health professionals in the country.(5)  
The Standard Treatment Guidelines of Mongolia for treatment of adults with 
mild/moderate CAP(6) were developed in 2005 and the Mongolian National 
Standard for treatment of children with pneumonia has been available since 
2001, with the latest update in 2008.(7)  
1.2 Specific objectives  
The purpose of this research was to assess the prescribing practices for 
patients with mild/moderate pneumonia at outpatient settings in Mongolia. 
The following specific objectives were addressed:   
1. To complete a systematic review on prescribing practices for 
mild/moderate CAP at outpatient settings in developing countries.  
2. To evaluate the appropriateness of prescribing practices for 
mild/moderate CAP from supplied prescriptions from community 
pharmacies based on the prescribing criteria of drug selection, 
dosage, dosage form, and duration by comparing with the current 
official guidelines in Mongolia.  
3. To establish the level of and determinants that lead to inappropriate 
injection practices and to understand reasons for injectable antibiotics 
and other drugs being prescribed provided and preferred for 
treatment of mild/moderate CAP in Mongolia.  
1.3 Thesis approach 
This thesis used three types of studies in order to examine the prescribing 
practices for mild/moderate CAP in Mongolia. First, a systematic review using 
SIGN guidelines was completed in order to review the literature and assess the 
evidence. Second, this thesis used prescription data with a diagnosis of 
mild/moderate CAP at outpatient settings in Mongolia. Third, questionnaire 
studies were completed with three target groups: (i) community members, (ii) 
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prescribers (doctors), (iii) providers (pharmacists and pharmacy technicians) 
in Mongolia. All data were collected, entered and verified by the researcher. 
Analysis of the data was performed by the researcher and a senior 
biostatistician. Appropriateness of each criterion was completed by the 
researcher and confirmed by the supervisors.  
Chapter 2 contains background information relating to the study. The chapter 
starts with geographic and demographic data about Mongolia, illustrating 
the country specifics including economic diversity and sparse population. In 
addition, the health care delivery system, including the provision of medicines 
is introduced.  The Chapter continues with information about the key elements 
in the provision of health care delivery. Additionally, a literature review of the 
existing treatment guidelines for treatment of CAP is presented in this Chapter.   
Chapter 3 presents results of the systematic review on prescribing practices 
for treatment of mild/ moderate pneumonia at outpatient settings in 
developing countries.  
Methodological aspects used in the study are described in Chapter 4. First, 
prescriptions submitted to community pharmacies in Mongolia with a 
diagnosis of mild/moderate CAP were collected prospectively and 
sequentially. Furthermore, questionnaire studies with three target groups 
(community members, doctors and pharmacists plus pharmacy technicians) 
were completed in order to investigate the extent of and factors influencing 
injection practices in Mongolia.            
Chapter 5 contains detailed information regarding the results of the 
assessment of prescribing practices for treatment of mild/moderate CAP in 
Mongolia with respect to national prescribing guidelines.   
Chapter 6 provides an overview of results of the interviews with community 
members, doctors and pharmacists including pharmacy technicians.  
The discussion of the research findings and their comparison with other 
findings is provided in Chapter 7. Conclusions using information gained 
throughout the study about the use and utility of antibiotics including 
 4 
 
injectables were made in Chapter 8 and a summary of the recommendations 
is presented in Chapter 9.    
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Chapter	2 Background	
2.1 Introduction 
The purpose of this chapter is to present descriptive information that provides 
a context for the study. It starts with an overview of the geographic and 
demographic characteristics of Mongolia. Thereafter, brief introduction of the 
Mongolian health care system is provided, followed by a discussion of the 
pharmaceutical sector and drug procurement procedures.       
This is followed by an introduction to the appropriate use of medicines and 
the concept of essential medicines, emphasizing the evidence-based 
medicine (EBM) and treatment guidelines.   
In addition, the issues of inappropriate use of medicines, in particular antibiotic 
resistance, inappropriate use of injections and its consequences are 
presented in this chapter. Next is a brief introduction of community-acquired 
pneumonia (CAP) and discussion of linked health data regarding its 
management, with an emphasis on treatment guidelines.     
Finally, brief information regarding questionnaire studies and issues relating to 
validity and reliability are provided in this Chapter.  
2.2. Study background  
Mongolia is a landlocked country in north central Asia, bordered by Russia 
and China. It is the 19th largest country in the world, with much of the land 
being desert or semi desert. Administratively, it is divided into 21 aimags 
(provinces), which are divided into 329 soums (districts), each of which is split 
into baghs (smaller districts) plus one municipality, the capital city of 
Ulaanbaatar. The estimated population in 2011 was 2.8 million, with over 40% 
primarily residing in the capital, Ulaanbaatar.(4) The annual growth rate is 1.1% 
and about 70% of the population are aged between 15 and 64.(4)  
Ulaanbaatar consists of nine districts, i.e. Baganuur, Bagakhangai, Bayangol, 
Bayanzurkh, Chingeltei, Khan-Uul, Nalaikh, Songinokhairkhan and Sukhbaatar. 
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Ethnic Mongolians account for 95% of the population, mostly Khalkh and other 
groups such as Kazakh and Buriyat.  
According to the World Bank, Mongolia is classified as a lower-middle income 
country(8) with 22.4% of the population living on less than US $1.25 a day.(9) 
The estimated Gross Domestic Product (GDP) per capita in 2011 was $3,100.(8)  
Despite some improvements of certain health indicators since the transition 
into the free market economy, including of life expectancy, infant mortality 
and child mortality, the country is still facing problems with equitable health 
care.(10)  
According to the health indicator data, respiratory infections accounted for 
most of the morbidity rates among children aged to five years,  with 
pneumonia being the leading cause (34.4%).(4) In addition, one of the main 
reasons for hospitalization in 2011 was pneumonia (46.2%), with an increase of 
1.4% compared to the previous year.(4)   
2.2.1 Health care system in Mongolia  
According to the Health Law of Mongolia, the main purpose of health care is 
to provide qualified care continually, sufficiently, and equally to all 
Mongolians.(11) Health care is provided primarily through the public sector, 
including the primary care level: family hospitals in Ulaanbaatar and aimag 
centres, soum and inter-soum hospitals in aimags; secondary care level: 
districts hospitals in Ulaanbaatar, aimags and rural general hospitals in aimags 
and tertiary care level: tertiary level hospitals and centres in Ulaanbaatar, 
regional diagnosis and treatment centres in aimags. Recent data for 2011 
indicated that there were 15 tertiary level hospitals and centres, four regional 
diagnostic and treatment centres, 17 aimag general hospitals, 12 district 
general hospitals, 6 rural general hospitals, 37 inter-soum hospitals, 274 soum 
hospitals, 219 family group practices (FGPs) and 1184 private hospitals.(4)  
Family health centres, soum or bagh hospitals are the first official point of 
contact for patients and from there they can be referred to higher level health 
facilities. In general, family group practitioners are available for the public; in 
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contrast specialists are mostly located at higher level facilities. Detailed 
referral pathways(5) are summarized in Figure 2.1. 
 
Figure 2.1 Referral pathways for urban and rural areas in Mongolia (adapted 
from WHO, 2012) 
According to the health data, about one-half of all outpatient services were 
provided at FGPs, soum and inter-soum hospitals, whereas about 35% of 
outpatient services were provided at higher level hospitals. In contrast, a 
significant proportion of inpatient service (27%) was provided at primary care 
level.(4) 
2.2.2 Human resource in the health sector 
The Ministry of Health of Mongolia (MoH) has prepared a Health Sector Human 
Resources Development Policy with assistance from the Asian Development 
Bank (ADB), in order to manage and improve sustainable health care services 
in Mongolia.(12) As at 2011, 41,124 employees were engaged in the public 
and private health sector.(4) Most were hospital specialized workers (40.1%), 
followed by nurses (22.9%), doctors (19.3%) and others (17.7%). A majority of 
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doctors and nurses worked in public hospitals, while about 80% of pharmacists 
worked in the private sector(4) (Table 2.1).  
Table 2.1 Number of selected health personnel working in the health sector, 
2011 
Category  Number of employees  Ratio between health 
personnel a Ulaanbaatar Rural 
Doctor 4,907 3,036 1.2 
Nurse 4,697 4,749 
a Ratio was estimated from the number of doctors versus nurses  
There are some deficiencies regarding the distribution of health personnel in 
Mongolia. Compared with other countries, Mongolia has a large number of 
health workers but a shortage of nurses.(13) The ratio between doctors and 
nurses was 1.2, in particular, the ratio of doctors per 10,000 population in 
Ulaanbaatar city was 1.5 times more than that in rural areas.(5) In addition, 
the excessive number of medical schools has been pointed out, in particular, 
the medical doctors are trained for a standard six year curriculum at four state 
and six private universities and colleges with a graduation pool of more than 
2,000 students in Mongolia.(4, 14) However, according to a WHO 
recommendation, it is optimal to have one medical school per three million 
population.(15) Legally, medical graduates are required to spend at least 
three years working at the primary health care (PHC) level before attending 
training to obtain specialization qualifications. However, the medical schools 
admit almost everyone for specialist postgraduate training to increase their 
profit, ignoring the requirement. It has resulted in an overproduction of 
specialists and shortage of doctors at PHC level and in rural areas.(13)     
2.2.3 Pharmaceutical sector in Mongolia 
The National Drug Policy of Mongolia (NDPM) is an integrated part of the 
Comprehensive Policy on the Mongolian National Security and it was 
approved in 2002. The objective of the NDPM is to provide health 
organizations, veterinary hospitals and people with highly effective, qualified, 
registered drugs and medical equipment continually, sufficiently and equally, 
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and to introduce and promote appropriate use of drugs.(16) The NDPM 
consists of seven topics, including legislation, drug selection, manufacturing, 
distributing, drug financing, drug quality assurance and rational use of 
drugs.(16) In addition, the national policy on Traditional Medicines and 
Complementary and Alternative Medicines has been publicly available since 
1999.(17)  The Division of Pharmaceutical and Medical Devices, Ministry of 
Health (MoH) is responsible for the policy, planning and regulatory affairs in 
providing pharmaceutical care in Mongolia. Figure 2.2, represents the 
detailed structures of the regulatory organizations regarding pharmaceuticals 
in Mongolia.  
 
 
Figure 2.2. Drug regulatory organizations of Mongolia (adapted from 
Assessment of the pharmaceutical sector of Mongolia, 2009) 
Aspects of drug regulation, pharmaceutical and medical devices and their 
monitoring are divided amongst several government agencies.  
The Standardization and Technical Regulatory Office of the Centre for 
Standardization and Measurement (CSAM) is responsible for the technical 
standards in local production and its quality control. The special licenses for 
manufacturing, importing, purchasing pharmaceuticals and medical devices 
are granted by the Special Permission Committee, MoH.  
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Registration of doctors, nurses and pharmacists, and pharmaceutical 
companies occurs through the Health Department. In order to improve the 
appropriate use of medicines, drugs are regulated through the Special 
Permission Committee of the Human Drug Council. No drug can be marketed 
without permission. In addition, drug wholesalers are licensed.(18)   
2.2.4 Drug procurement  
In Mongolia, the pharmaceutical procurement sector is 100% privatized. Drugs 
are distributed through organizations such as drug wholesalers and retail drug 
outlets (community pharmacies and revolving drug funds (RDF)). “National 
Standard Requirements for Pharmacy” allows a main community pharmacy 
to have up to two branches, restricting the latter to sale of drugs available 
without a prescription.(19) The latest statistics show there were 703 community 
pharmacies, 75% of which had one to two branches.(4, 20) According to the 
National Guideline for Good Prescribing and Dispensing Practice of Mongolia 
(Regulations), all physicians must record the diagnosis on the prescription. In 
addition, the maximum number of retail prescription drugs per patient 
encounter should be three. At the current time, prescriptions with multiple 
diagnoses for outpatients are often issued by the doctors, however, there is 
no guideline to monitor the regulatory compliance.     
Wholesalers can import and procure drugs with an approval and special 
permission from the Mongolian Minister of Health. In 2011, there were 158 
registered drug wholesaling companies and 42 local drug manufacturing 
companies,(4) some of which act as both wholesalers and retailers. These 
companies were mainly located in the capital city.(4)  
In addition, about 85% of all drugs were imported from other countries(20)  
and 2779 drugs were newly registered in Mongolia in 2011.(4) Most of the 
registered drugs were imported from Russia or India, followed by Germany, 
Slovenia and China.  
2.3 Appropriate use of medicines 
WHO has defined drug use as appropriate (rational) when an appropriate 
drug is prescribed and administered according to the appropriate dosage 
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regimen and the drug should be affordable and available and dispensed 
correctly, that is in correct doses at adequate time periods.(21) The prescriber 
must follow the standard treatment guidelines to prescribe the appropriate 
drug. Moreover, rational dispensing correlates with drug supply procedures 
and also the competency and knowledge of the health care provider.  
Significant demand, limited funds and high prices contribute to frequent 
shortages of drugs in many public health programs, especially in developing 
countries.(22) Despite the existence of standards for drug regulation for many 
years, there are still problems with the safety and quality of medicines in both 
developed and developing countries.(23) 
2.3.1 Inappropriate use of medicines  
It is essential to monitor and promote appropriate drug use, in order to avoid 
medical and economic consequences. Medical consequences of 
inappropriate drug use include unnecessary suffering and death, iatrogenic 
disease, hospital admissions and increased antimicrobial resistance. Likewise, 
the public confidence in the health care system will be diminished and 
curative and preventive services are reduced to cater for the burden 
subsequent to inappropriate drug use. Economically, inappropriate drug use 
is followed by waste of resources and unavailability of drugs for those who are 
in need.(24)  
Inappropriate use of medicines has been reported from both developing and 
developed countries. Observational data from 25 European countries showed 
that the outpatient antibiotic consumption varied significantly in 2003.(25, 26) 
The number of defined daily doses (DDDs) per 1000 population was about 30 
in Greece and France, whereas a lower number was estimated in the 
Netherlands (10).(25) On the other hand, overprescribing of antibiotics was 
found in the Netherlands.(27) According to Vaanane, unnecessary and 
inappropriate self-medication with antibiotics (28% of respondents had 
antibiotics for common cold and sore throat) was common among Finnish 
immigrants in southern Spain.(28) Potentially inappropriate prescribing was 
also observed for about 12% of community-dwelling older people and 40% of 
residents in nursing homes in the USA and Europe.(29)   
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The situation is more serious in developing countries. A systematic review  by 
WHO studied the use of medicines in 97 developing and transitional 
countries.(30) It found that medicine use was not optimum in all countries, 
reporting less than 40% was compliant with clinical guidelines. Further findings 
indicated poor prescribing and dispensing practices, often by unqualified 
staff with a short encounter of one to two minutes.(30) Other studies have also 
identified inappropriate self-medication and availability of antibiotics over the 
counter in developing countries.(31) (32) A comparable situation can be 
observed in Mongolia.(10, 33, 34) (35) 
As summarized by Holloway, determinants of inappropriate medicine use in 
less developed countries include lack of provider knowledge due to 
insufficient training and supervision, prescriber habit, lack of clinical guidelines, 
lack of diagnostic service, poor infrastructure, lack of continuing medical 
education and supervision with regard to prescribing, excessive 
pharmaceutical promotion, economic incentives to the prescriber, perceived 
patient demand by the provider, poor adherence by patients. (36)        
In order to combat inappropriate use of medicines, intervention studies have 
targeted the causes including lack of knowledge.(37) According to the 
Effective Practice and Organisation of Care (EPOC) Cochrane group review, 
only a few studies assessing the impact of education could be reported from 
developing countries.(38) Educational outreach (two intervention studies from 
Indonesia), reporting a significant decrease in prescribing antimicrobials (24%) 
and antidiarrhoeals (40%)(39) and mixed group discussions with prescribers 
and patients (one study from Indonesia reporting a decrease of the 
proportion of injections from 70% to 40%)(40) were effective in improving 
prescribing and dispensing practice. Also, one randomized trial in Zambia 
showed a small positive impact of continuing education meetings on case 
management, for example the number of drugs per prescription decreased 
from 2.3 to 1.9.(41) However, more evidence showed contrary results, 
reporting lack of knowledge may not be a single reason for inappropriate use 
of medicines.(39) Despite the use of oral rehydration salt for patients with 
diarrhoea having improved during the 1980s and 1990s, the median 
percentage of children correctly rehydrated by health workers after 2,000 
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training courses on management of diarrhoea cases and supervision was only 
20%.(39) A study of factors influencing correct performance of health care 
workers who treat ill children in developing countries found no significant 
association between correct treatment and in-service training in the 
treatment of fever or supervision.(42) Results from a study of health workers 
who treated uncomplicated malaria reported similar findings, suggesting that 
disease-specific training and supervision were not followed by improved 
treatment quality.(43)    
Along with improving knowledge and education, a better understanding is 
required as to how and why certain interventions work(44) and also the 
barriers for successful implementation.(45)  
In addition, WHO recommends that countries should implement national 
policies, including establishment of a multidisciplinary national body to 
coordinate policies on medicine use and monitor their impact, development 
of evidence-based clinical guidelines, development of essential drug lists, 
establishment of drug and therapeutic committees in districts and hospitals, 
and integrating problem-based training in pharmacology curriculum to 
promote appropriate use of medicines. Examples of successfully implemented 
approaches to improve the use of medicines can be seen in a few countries, 
for example Australia has the National Prescribing Service (NPS) which focuses 
on the quality use of medicines, by providing information for both community 
and health professionals. For health professionals this includes professional 
education activities using access to a range of information resources (new 
medicines information [NPS RADAR], therapeutic topic review [NPS News], a 
journal on drug and therapeutic issues [Australian Prescriber]). Similarly, 
consumers have access to information regarding how to manage the 
common cold when antibiotics are unnecessary and also about new 
medicines. NPS also offers an online learning module (National Prescribing 
Curriculum) for medical and pharmacy students. Also, a 10-year antibiotic 
program by NPS, involving general doctors, community pharmacists and 
consumers resulted in a successful decline of antibiotic prescribing for upper 
respiratory symptoms.(46, 47) On the other hand, little research has been done 
to identify the impact of such policies implemented in less developed 
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countries and it is difficult to draw any conclusions, mainly due to lack of 
sufficient evidence.(48) Among a few studies that assessed the impact of 
regulatory measures, a decline in antibiotic use among general doctors was 
reported from Korea(49) and reduced antibiotic sale in the private sector in 
Chile.(50) An improved health care service at no or low cost for patients 
mainly in the public sector with appropriate numbers of health professionals 
was observed from Oman. This followed the Government of Oman 
undertaking an intervention including the development of an Approved Drug 
List by selecting medicines on evidence-based medical needs and cost-
effectiveness. In addition to feedback from prescribers and other sources 
regarding appropriate procurement of medicines, the Government 
conducted mass education campaigns targeted at physicians, pharmacists 
and patients.(51)  
2.3.2 Antibiotic resistance 
Inappropriate use of medicines, especially of antibiotics can have unwanted 
side effects and development of resistance to microorganisms. According to 
O’Brien and others, the problems related to antibiotic resistance should be 
considered globally but also each country should monitor and manage these 
issues locally.(52) Until 1967, S.pneumoniae was generally sensitive to 
penicillin.(53, 54) Nevertheless, the resistance rate has been reported as more 
than 20% and multi-drug resistance is very common(55) and a literature review 
indicated that the incidence rate of pneumococci resistance increased from 
6% to 44% within 9 years in Spain.(56) Similar findings about penicillin resistance 
and multi-drug resistant strains of meningococcus can be found 
elsewhere.(57) In the 1970s, penicillin-resistant pneumococci were most 
common in Israel, Papa New Guinea, Poland, South Africa and Spain as well 
as some states in the USA.(58) Furthermore, a few studies documented that 
there are regional variations in the prevalence of antimicrobial-resistant 
pneumococci.(59) For instance, carriage of resistance S. pneumoniae was  
significantly more common in urban and rural children in Asia, the Middle East, 
and Lesotho.(60, 61) A survey of clinical specimens from four Asian countries 
from 1996 to 1997 found that penicillin non-susceptibility ranged from 80% of 
isolates in the Republic of Korea to 4% of isolates in India.(62) In Europe, Spain 
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is a focus of penicillin-resistant pneumococcal strains, with a prevalence of 
non-susceptibility of over 45% of pneumococcal isolates.(58)  
Macrolide resistance is the most prominent example of pneumococcal 
resistance with regard to the prevalence rate and the level of resistance. 
Macrolide resistance is a serious concern in many Asian countries compared 
with the western part of the world. According to the Asian Network for 
Surveillance of Resistance Pathogens  (ANSORP) studies with pneumococcal 
isolates from some Asian countries between 1998 and 2001, Vietnam (88-92%), 
Taiwan (86-87%), Korea (80-85%), Hong Kong (76%), and China (74-75%) 
showed very high prevalence rates of erythromycin resistance.(62) (63) 
Fluoroquinolone resistance would be a potential issue because 
fluoroquinolones are frequently used as the first-line agent for the treatment 
of CAP in many countries. A recent Prospective Resistant Organism Tracking 
and Epidemiology for the Ketolide Telithromycin (PROTEKT) surveillance study 
showed that 14.3% of pneumococcal isolates from Hong Kong were resistant 
to levofloxacin followed by Korea (2.9%) and USA (1.8%). ANSORP surveillance 
also showed that ciprofloxacin resistance (MIC 4 mg/L) was emerging in Hong 
Kong (11.8%), Sri Lanka (9.5%), Philippines (9.1%), and Korea (6.5%).(62-64) In 
the 1970s, Rusinko et al. completed a study on antibiotic sensitivity of 
Staphylococci isolated from two groups including patients in a children’s 
hospital and health workers in two maternity hospitals in Mongolia.(65) They 
found that a large number of strains in both groups were resistant to penicillin 
(93.6% and 95.2%) and streptomycin (66.7% and 87.2%), respectively. Penicillin 
resistant staphylococci were highly (virtually 100%), sensitive to rare antibiotics 
(kanamycin, vankomycin, spiromycin, cephaloridin, linkomycin, pristinamycin, 
fusidic acid and rifamycin) that had never been used in Mongolia.(65) 
According to the latest report from the State Central Hospital of Mongolia, a 
total of 101 hospitalized patients received antibiotics in September, 2009 and 
it has concluded that only 40% of patients (sensitivity analysis confirmed by 
taking blood, urine, and smear samples) were selected correctly. The 
antimicrobial resistance was measured and it was found that penicillin 
resistance was 18%, oxacillin-2%, ampicillin-24%, tetracycline-11%, 
erythromycin-16%, azithromycin-26%, gentamicin-40%, and cephalosporin- 
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63%-85%, respectively. These findings indicated these antibiotics should 
therefore not be prescribed.(66)  
2.3.3 Inappropriate use of injections  
Medicines are introduced into the body by several routes, including taken 
orally, sublingually, rectally or vaginally. Medications can also be sprayed into 
the nose and absorbed through the nasal membranes, inspired into the lungs, 
usually through the mouth (by inhalation), applied to the skin for a local or 
systemic effect, delivered through the skin by a patch for a systemic effect 
and given by injection. Administration by injection (parenteral administration) 
includes the subcutaneous, intramuscular, intravenous, and intrathecal 
routes.(67)  
Injected medicines are commonly used in healthcare settings for the 
prevention, diagnosis, and treatment of various illnesses. Unsafe injection 
practices include re-use of equipment in the absence of sterilization and these 
practices put patients and healthcare providers at risk of infectious and non-
infectious adverse events which have been associated with a wide variety of 
procedures and settings.(68) In developed countries, the consequences of 
unsafe injection practices were recognized in the middle of the last century 
and became more emphasized with the advent of Human Immunodeficiency 
Virus/ Acquired Immune Deficiency Syndrome (HIV/AIDS) in the 1980s.(69, 70) 
It is widely accepted that unsafe healthcare injections could transmit HBV,(71) 
HCV,(72) HIV,(73) viral haemorrhagic fever  and other bloodborne 
pathogens.(74)   
Re-usable glass syringes and re-usable needles were replaced by disposable 
syringes and single-use needles starting from the 1950s and the use of new, 
disposable, sterile syringes became a standard practice in developed 
countries.(75) Nowadays, the risk of infection in therapeutic settings due to 
unsafe injection practices is small in developed countries.(70)  
2.3.3.1 Practice of unsafe injections in developing countries  
The situation in less developed countries is different since more injections are 
prescribed many of which are often unnecessary.(70) The global burden of 
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disease project (WHO) conducted a literature review, and found that the 
annual ratio of injections per person ranged from 1.7 to 11.3. The highest 
proportion was reported from the European region (11.3), followed by the 
Eastern-Mediterranean region (4.3). Overall, the annual number of injections 
per person was 3.4.(76) The proportion of re-used injection equipment without 
sterilization ranged from 1.2% to 75%. South-East-Asia accounted for the 
highest use (75%), followed by the Eastern-Mediterranean region (70%) and 
the Western Pacific Region (30%).(76) Another systematic review of studies 
from 13 developing countries regarding injection use and safety reported that 
for eight of those countries, 25-96% of outpatient visits resulted in at least one 
injection, and for five countries a majority of administered injections were 
unnecessary. Commonly administered parenteral injections were vitamins, 
antibiotics, analgesics and quinines.(77) An assessment of injection practices 
in Mongolia showed a high injection frequency rate; reporting an average of 
13 injections per year among the 65 participants. The estimated needle-stick 
injuries were 2.6 per year and 28% of providers reported re-using the injection 
device.(78) A majority of prescribers and about 50% of community members 
were aware of the potential risks of unsafe injection practice (for example: HIV 
transmission).(78) A latter reassessment conducted by the MoH indicated an 
improved practice, reporting eight injections per year, and almost every 
injection (99%) was administered with new, disinfected and disposable 
equipment.(79) Both of these studies were on small population numbers 
limiting their generalisation. However, given the high prevalence of antibody 
HCV (anti-HCV) in Mongolia (16%-24%),(80) it is essential to monitor and 
reduce unsafe injection practices in the country. 
2.3.3.2 Factors contributing to the popularity of unsafe injections  
Reasons for unsafe and unnecessary practices of parenteral medication in 
developing countries are related to socio-cultural, economic and structural 
factors. The belief in injection as a strong tool for restoring and maintaining 
health is mutually supported by health professionals and community members 
in developing countries.(81) Previous findings have suggested that patient’s 
demand may also force prescribers to administer more injections to satisfy the 
patient,(82) (83) whereas in contrast others indicated that patients were more 
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open to alternatives to injections.(84) A study in Uganda and Indonesia 
questioned the causes for injection prescribing and found that local belief 
about illness and concepts of efficacy, economic incentives of private or 
informal providers and lack of patient-provider communication were the main 
reasons.(85) Previous studies have indicated poor knowledge of associated 
risks and burden of unsafe and unnecessary injection practice, a lack of 
available and affordable injection equipment, and easy access to parenteral 
medication contributes to the popularity of injection in developing 
countries.(86-88) No more recent data are available since 2000.      
2.4 Evidence-based medicine (EBM) 
Evidence-based medicine (EBM) is the rigorous and judicious use of existing 
best evidence in making decisions about the care of individual patients.(89) 
The practice of EBM can be implemented by integrating personal clinical 
know-how with best available external evidence from thorough systematic 
research. Personal clinical expertise is based on proficiency and judgement 
obtained from clinical experience and clinical practice.(89) The best 
available external evidence is research findings, particularly from patient 
centred clinical research into the accuracy and precision of diagnostic tests 
and the efficacy and safety of therapeutic and preventive programmes.(89) 
External clinical evidence not only invalidates but also replaces previously 
accepted diagnostic tests and treatments with new, powerful, accurate, 
efficacious and safer ones.(90) The practice is a life-long, self-directed 
learning journey in which practitioners have to be able to critically appraise 
the evidence for its quality and clinical applicability. Also, they must be able 
to integrate the appraisal with clinical expertise and apply the results in clinical 
practice and be able to evaluate their own performance.(90) Each clinical 
problem is different, and the resources available to solve each problem vary.  
The need for evidence based general practice has been emphasized,(91, 92) 
and the role of evidence based guidelines for conditions which commonly 
occur in general practice has been researched and highlighted.(93) (94) The 
National Health and Medical Research Council (NHMRC) of Australia have 
recognized that the fundamentals of an evidence-based approach to 
clinical or health issues is the evidence itself.(95) This evidence needs to be 
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collected and organized from systematic literature reviews of the particular 
issues in question. In addition, interpreting the evidence is still a major 
challenge for clinical experts compiling clinical practice guidelines. Therefore, 
the NHMRC has been particularly engaged in developing appropriate 
guidelines to assist researchers with using, presenting and assessing the 
evidence. Types of studies such as sy stematic reviews, experimental studies 
and comparative studies are commonly used to assess clinical and public 
health issues. Levels of evidence are summarized in Table 2.2.  
Table 2.2 Designation of evidence levels (adapted from NHMRC, 1999) 
Level of 
evidence  
Study design 
I Evidence obtained from a systematic review of all relevant randomised 
controlled trials. 
II Evidence obtained from at least one properly-designed randomised 
controlled trial. 
III-1 Evidence obtained from well-designed pseudorandomised controlled 
trials (alternate allocation or some other method). 
III-2 Evidence obtained from comparative studies (including systematic 
reviews of such studies) with concurrent controls and allocation not 
randomised, cohort studies, case-control studies, or interrupted time 
series with a control group. 
III-3 Evidence obtained from comparative studies with historical control, two 
or more single arm studies, or interrupted time series without a parallel 
control group. 
IV Evidence obtained from case series, either post-test or pretest/post-test. 
The quality of evidence considers the methods used by the investigators 
during the study to minimise bias and control confounding issues within a study 
type. Quality criteria are suggested for non-randomised controlled studies 
(including cohort and case-cohort studies).(96)  
On the other hand, dependence on EBM may have some disadvantages 
such as potential lack of applicability of the biomedical perspectives and the 
role of opinion in tailoring evidence to a patient context and preferences.(97) 
Despite these arguments, EBM aims to address the persistent problem of 
clinical practice variations with help of numerous tools, including standardized 
practice guidelines.  
 20 
 
2.4.1 Guidelines and programmes towards improved treatment outcomes   
According to the Institute of Medicine (IOM), “clinical guidelines are 
systematically developed statements to assist practitioner and patient 
decisions about appropriate health care for specific clinical 
circumstances.”(98)Practice guidelines should be applicable to any part of 
clinical care and should inform about when to order and provide medical 
services, how these should be performed and how long the patients should 
receive the medical service.(99) Previous researchers have concluded that 
the adherence to treatment guidelines is most likely related to an 
improvement in the prognosis of patients with CAP.(100) It is however 
important to bear in mind that guidelines integrate some degree of 
uncertainty arising from heterogeneity of the patient’s clinical condition and 
differences in etiologic microorganisms and the quality of the evidence is 
difficult to establish.(101-103) 
On the other hand, the efficacy of treatment based on guidelines can be 
assessed by several parameters, such as the influence of change in treatment 
practices on mortality, morbidity and health-care related costs.(100) As 
recommended by the Australian Commission on Safety and Quality in 
Healthcare, antimicrobial use should be optimised by managing through a 
number of interventions, often referred to as antimicrobial stewardship 
programs.(104) An essential core to implement the antimicrobial stewardship 
programs is monitoring of prescribing with respect to the the guidelines on 
appropriate use of antibiotics.(105) Other interventions include the restriction 
of selected antibiotics and “stop-orders” after predetermined time periods. 
The goals of an antimicrobial stewardship include optimization of clinical 
outcomes while minimizing unintended consequences of antimicrobial use 
such as toxicity, the selection of pathogenic organisms and the emergence 
of resistance. Moreover, it is aimed to reduce unnecessary costs associated 
with health care.(106)  
In addition, clinical guidelines are widely available in many countries.(107, 
108) These guidelines should consider different risk factors, such as age, 
comorbidity and initial clinical severity(109) and there should be evidence-
based implementation strategies at a local level in each country.  
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Interventions to improve antibiotic prescribing behaviour were reported in a 
Cochrane review and indicated that there was insufficient evidence to 
support the choice of intervention.(110) While single interventions may be as 
effective as multiple ones due to existing health infrastructure in developed 
countries, multiple intervention packages were shown to be more beneficial 
in less developed countries. These intervention packages often include 
building infrastructure, such as supervisory systems, that are likely to increase 
their impact.(36) In addition, tailoring interventions to target specific barriers 
to compliance was reported to be effective in improving professional 
practice.(98, 111, 112) 
2.4.2 Essential Drug Concept 
Essential medicines are those that fulfil the priority health care needs of the 
population. They are selected with due regard to public health relevance, 
evidence on efficacy and safety and comparative cost effectiveness. 
Essential medicines are intended to be available within the context of 
functioning health systems at all times in adequate amounts, in the 
appropriate dosage forms, with assured quality and adequate information, 
and at a price the individual and the community can afford.(113) The 
implementation of the concept of essential medicines is intended to be 
flexible and adaptable to many different situations. Exactly which medicines 
are regarded as essential remains a national responsibility.(113) 
The concept of essential medicines is that a limited number of carefully 
selected medicines based on agreed clinical guidelines leads to rational 
prescribing, to an improved supply of drugs and lower costs.(113, 114)  
The practical implication of the essential medicines concept is that national 
essential medicines lists and national drug formularies, together with clinical 
guidelines, should serve as a basis for formal education and in-service training 
of health professionals, and of public education about drug use.(115) They 
should also serve as the main basis for public sector drug procurement and 
distribution, insurance reimbursement, as well as for drug donations.(114) 
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The first National Essential Drug List of Mongolia (NEDM) was adopted in 1991 
using the WHO Model Essential Drug List as a basis in order to provide health 
facilities with medicines. The revision of the NEDM is completed every four 
years on the basis of the recommendations of WHO and country specific 
data. Currently, the sixth edition of NEDM is available in Mongolian throughout 
the country. The latest edition includes a total of 328 drugs in 419 drug 
formulations.(116)  
12.5 Management of CAP in developing countries  
Although, there are many studies available in relation to CAP, there is relatively 
little known about the treatment of CAP and its antibiotic use in developing 
countries. A systematic review on prescribing practices for treatment of CAP 
in developing countries at outpatient settings delivered 29 studies. Most 
studies assessed the prescribing practice of antibiotics for the treatment of 
children aged less than five diagnosed with pneumonia at outpatient setting. 
Only one intervention study contained information regarding the treatment of 
adults diagnosed with pneumonia at outpatient setting in developing 
countries.(117)       
The latest observational study on antibiotics used for hospitalized patient 
treatment of pneumonia in Mongolia was completed by Renbat in 2002 and 
it showed that most hospitalized patients (85%) received more than one 
antibiotic including, penicillin, 47.4% received aminoglycosides, 4.2% received 
macrolides, 2.0% received cefalosporins and 25.3% received sulfonamide 
preparations.(118) However, that study did not assess the appropriate use of 
antibiotics and broader issues such as safety, efficacy and cost.(118)  To date, 
no studies have assessed the prescribing practice for treatment of outpatients 
diagnosed with mild/moderate CAP in Mongolia.  
2.5.1 Management of CAP in adults  
Over the past decade or so, professional organisations and societies from 
many countries have developed guidelines for empiric treatment of adults 
with CAP, aiming to produce a helpful prescrbing tool. As it is mentioned 
earlier, the best of guidelines are evidence-based, with recommendations 
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made only after extensive review and grading of studies in the literature, and 
supported by expert opinion.(119) At first glance, treatment guidelines share 
common themes, however there is considerable variation in the way in which 
they have been developed. Drug recommendations vary reflecting local 
issues, in addition patient classification schemes are different, for example 
whether or not nursing home residents or immunocompromised patients.(119) 
Although the great majority of LRTIs are of viral origin, CAP is most often a 
bacterial disease with a substantial annual mortality; ranging from 0.2% for 
elderly persons in the community(120) to 14% for those hospitalized with 
CAP(121), and as high as ≥50% in subgroups of patients presenting with septic 
shock.(122) Thus, pneumonia should in general, be treated with antibiotics. 
Additionally, the treatment should start promptly because a delay of more 
than eight hours in treatment is associated with increased mortality.(123) 
CAP is often diagnosed based on clinical symptoms, such as cough, sputum 
production (if adequate specimen obtained but rare for children), laboured 
breathing, or fever. These symptoms are non-specific and might also be 
present in patients with upper -respiratory-tract infections, other lower 
respiratory infections such as acute bronchitis and chronic bronchitis, and 
non-infectious diseases (reactive airways disease, atelectasis, congestive 
heart failure, vasculitis, pulmonary embolism, and malignant disease). 
Laboratory diagnosis is associated with high cost and difficulties and the vast 
majority of pneumonia cases are treated empirically in developing countries 
without identifying the etiological agent.(59)  
Typical organisms in CAP are Streptococcus pneumonia (S 
pneumoniae),(124) worldwide, however the incidence of less common 
organisms is variable and dependent upon geography, healthcare setting 
and the availability of suitable diagnostic tests. In Africa, pneumonia was the 
most common clinical presentation and the causative agent in 69% of all 
childhood pneumonia cases was the pneumococcus.(125)   
Atypical pneumonia refers to pneumonia caused by organisms such as 
Mycoplasma pneumonia, Chlamydia pneumonia, and Legionela spp. 
According to previous findings, M. pneumoniae was found to be the etiologic 
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organism in up to 37% of patients treated out of hospital.(94) A restrospective 
study found that atypical organisms were involved in 22% of cases of 
CAP.(126) 
Nowadays, the illness severity and site of care plays an important role in the 
treatment of CAP. The decision about whether or not a patient should be 
admitted to hospital might have an effect on the extent of diagnostic testing 
as well as the choice of empirical antibiotic treatment. The general consensus 
is that most patients can be safely treated as outpatients.(127) The 
advantages of not admitting patients for CAP are important and include 
decreased cost, patient preference and avoidance of iatrogenic 
complications in hospitals. However, selected patients should be admitted if 
they have special requirements such as the need for close observation, 
respiratory support, intravenous antibiotics, or other concerns. Many variables 
attribute to the decision to admit a patient with CAP including severity of 
illness, associated disease, adequacy of home support, and probability of 
adherence to treatment. Risk factors for increased mortality of patients with 
CAP include extremes of age, comorbidity, for example: malignant disease, 
alcoholism, abnormality of vital signs, and several laboratory and 
radiographic findings. In addition to the clinician’s judgement, prognostic 
scoring rules have been developed to support the decision.(124, 128, 129)   
The Pneumonia Severity Index was developed by the American Thoracic 
Society and Patient Outcomes Research Team (PORT) and it identifies patients 
at risk of death with a point system based on several variables. This method 
was recognized as an effective tool to identify low risk patients who can be 
treated at home.(130-133) On the other hand, the British guidelines 
recommend an assessment of severity based on the presence of ‘adverse 
prognostic features’(134) including, age over 50 years, coexisting disease, and 
four additional specific core features: mental confusion, elevated urea 
nitrogen, respiratory rate more than 30 breaths/min, and low blood pressure 
(CURB-65). The scoring method was developed by the British Thoracic Society 
and assessed by several studies.(135) Antibiotic management adapted from 
Therapeutic Guidelines were developed and approved by the Western 
Australian Therapeutic Advisory Group and they recommend the CURB-65 
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assessment, based on the British Thoracic Society guidelines. Assessment of 
CAP using the Pneumonia Severity Index(135) is also recommended but 
requires additional clinical and laboratory information. Only a minority of 
patients (approximately 10%) will meet the criteria for severe pneumonia. It is 
important that treatment is matched with disease severity. The clinical status 
may change following initial assessment and alter the risk category.  
2.5.2 Recommendations for empirical therapy for inpatients with CAP 
Treatment options are simplified if the pathogen is established or strongly 
suspected. According to File, the information on the causative agent is of 
importance when a patient is switched from parenteral to oral therapy.(124)   
The guidelines of the British Thoracic Society and the Australian and North 
American Guidelines on empirical treatment for inpatients are similar: β 
lactam plus macrolide or monotherapy with a flouroquinolone for inpatients. 
The length of antibiotic therapy recommended by the British Thoracic Society 
is usually about seven days for patients treated in the community and ten days 
for severe patients whereas the American Thoracic Society recommends at 
least five days for uncomplicated pneumonia. But other studies have shown 
that short course therapy was as efficacious as the longer courses currently 
recommended by guidelines.(119, 136) An early switch (after two to three 
days) from intravenous to oral antibiotics in patients who had responded to 
therapy has also been shown to reduce the hospital stay without risk for the 
patient.(137-139) Once a patient is stable, the switch of therapy from 
intravenous to oral, and  discharge from hospital is generally preferred, since 
it has advantages including economic, care and social benefits.(55, 140) And 
in some countries, for example Australia and Sweden, injection administration 
during the whole duration of hospital stay has never been a common 
practice.(141) 
2.5.3 Recommendations for empirical therapy for outpatients with CAP 
The key guidelines that have been used in this assessment are summarised in 
Table 2.3 and comprise the most recent statements from North America 
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(American Thoracic Society, Infectious Diseases Society of America),  Europe 
(British Thoracic Society), Australia and Mongolia.  
The British Thoracic Society guidelines recommend β-lactams (amoxicillin 500-
1000mg thrice daily), not macrolides as primary agents.(134) Similarly, 
because of high-resistance rates to macrolides in Europe, they are not 
regarded as optimum first line empirical agents to treat S. pneumonia.(124) In 
contrast, the North American guidelines variably recommend macrolides as 
first line, doxycycline, an antipneumococcal fluoroquinolone (e.g. 
levofloxacin, gatifloxacin, moxifloxacin) or the combination of β-lactam plus 
macrolide as treatment options for outpatients (Table 2.3). The rationale is that 
the macrolides are effective against most pathogens, such as S. pneumonia, 
as well as atypical organisms (M. pneumonia, C. pneumoniae).  
Table 2.3 Empirical therapy of CAP in adults (adapted from File, 2004) 
Guideline type Outpatient treatment*  
North American guidelines 
ATS/evidence-based  
 
 
 
 
 
 
 
 
 
 
IDSA/evidence-based  
No cardiopulmonary disease. No modifying factors: 
macrolide (eg, azithromycin, clarithromycin) or 
doxycycline 
Cardiopulmonary disease ± modifying factors: β-
lactam 
(eg, cefuroxime, high-dose amoxicillin, 
amoxicillin/clavulanate)  (macrolide or doxycycline) 
or 
antipneumococcal fluoroquinolone 
Macrolide, doxycycline, or antipneumococcal 
fluoroquinolone 
(alternative: β-lactam (eg, amoxycillin/clavulanate, 
cefuroxime), but these agents not active against 
atypical pathogens) 
For older patients with comorbidities, the 
fluoroquinolone may be a preferred choice 
European guidelines  
British Thoracic Society/ 
evidence-based 
Non-severe disease: β-lactam (eg, amoxicillin) or 
macrolide (for patients with β-lactam intolerance) 
* All drugs given orally, unless otherwise indicated.  
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2.5.3.1 Management of mild/moderate pneumonia in adults, Australia  
The Australian Therapeutic Guidelines (TG)(142) for mild/moderate 
pneumonia recommends amoxicillin oral OR (if atypical organism suspected) 
doxycycline oral OR clarithromycin oral to adult outpatients (In rural and 
remote areas, for patients in whom orally administered antibiotics may be 
unsuitable procaine penicillin 1.5 g intramuscular daily may be substituted for 
amoxicillin until substantial improvement has occurred: generally five days is 
required.)  
Table 2.4 Management of adult outpatients with mild/ moderate pneumonia 
(Australia) 
Australian 
Therapeutic 
Guidelines: 
pneumonia, 
2010, V14 
Amoxicillin 1 g orally, 8 hourly for 5-7 days 
OR (if Mycoplasma pneumonia, Chlamydophila Chlamydia 
pneumonia or Legionella is suspected  
Doxycycline 200mg orally, for the first dose, then 100mg daily 
for a further 5 days 
OR  
Clarithromycin 250 mg orally, 12-hourly for 5 to 7 days 
 
For patients hypersensitive to penicillin, use doxycycline or 
clarithromycin.  
If clinical failure is observed, consider switching to to an 
alternative drug (eg cefuroxime 500mg orally, 12-hourly if the 
patient is not hypersensitive to penicillin or moxifloxacin 400 mg 
orally, daily if patient has immediate penicillin hypersensitivity.  
 
2.5.3.2 Management of mild/moderate CAP in adults, Mongolia  
The Standard Treatment Guidelines of Mongolia for treatment of adults with 
mild/moderate pneumonia recommends oral administration of amoxicillin 
(ampicillin) 500mg every 6 hour or alternatively erythromycin 500mg every 6 
hour for adult patients.(6)  
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Table 2.5 Treatment guidelines for mild/moderate CAP in adults (Mongolia) 
Adults  Mild/ moderate CAP 
Mongolian Standard 
Treatment Guidelines for 
Common Diseases: 
Pneumonia (2005) 
Oral amoxicillin (ampicillin) 500mg every 6 hour, or 
erythromycin 500mg every  6 hour 
 
 
2.6 Management of CAP in children  
As documented earlier, official recommendations regarding the treatment of 
pneumonia in adults have been available in countries including Britain, the 
United States, Canada and Australia.(94, 108, 143) However, in contrast there 
have been only a few attempts to develop treatment guidelines for children 
mostly in Europe or North America mainly due to controversies that surround 
etiologic process of pediatric CAP.(144, 145) In addition, further 
recommendations on pneumonia in children classified to the cause are 
available.(146-148)  
2.6.1 Treatment for children aged two to 59 months with CAP, recommended 
by World Health Organization (WHO) 
Approximately 10 million children in less developed countries die before they 
turn five every year and many during their first year of life. Among the causes 
acute respiratory infections (ARIs) (mostly pneumonia) are the main killers in 
children, causing a loss of 119 million Disability Adjusted Life Years (DALY) a 
year, or 10% of the total burden of disease in developing countries.(149)   
In order to respond to this challenge, a strategy for Childhood Illness (IMCI) 
was initiated by the Department of Child and Adolescent Health and 
Development (CAH) of the WHO and United Nations Children’s Fund (UNICEF). 
The major element of this strategy is improvement in case management skills 
of health staff by providing locally adapted guidelines on management of 
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childhood illness and activities to promote their use. The latest technical 
updates of IMCI have considered and accumulated new evidence and 
recommendations in six areas, such as antibiotic treatment of severe and non-
severe pneumonia, low osmolarity oral rehydration salt (ORS) and antibiotic 
treatment for bloody diarrhoea, treatment of fever/ malaria, treatment of ear 
infections, infant feeding and treatment of helminthiasis.(150) 
Evidence-based documents regarding treatment of pneumonia in children, 
inform countries directly about IMCI adaptations(150) and these are 
summarized in Table 2.6.  
Table 2.6 WHO recommendations for the treatment of pneumonia in children 
aged two to 59 months 
Summary of 
recommendations 
For children with non-severe pneumonia, use:  
Oral amoxicillin (15 mg/ kg of body weight/ dose) thrice daily  
OR 
Oral cotrimoxazole (4 mg of trimethoprim/kg/dose) twice 
daily.  
Oral amoxicillin should be given for three days for non-severe 
pneumonia in children 2-59 months of age.  
Oral cotrimoxazole should be given for three days for non-
severe pneumonia in children 2-59 months of age in low HIV 
prevalent countries. 
For children with severe pneumonia, use:  
Where referral is difficult and injection is not available, oral 
amoxicillin in 45 mg/kg/ dose twice daily  
For children with very severe pneumonia, use:  
Injectable ampicillin plus injectable gentamicin is a better 
choice than injectable chloramphenicol for very severe 
pneumonia in children 2-59 months of age. A pre-referral dose 
of 7.5 mg/kg injection gentamicin IM and 50 mg/kg injection 
ampicillin can be used.  
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2.6.3 Management of non-severe (mild/moderate) CAP in children, Australia  
Oral antibiotics are preferred in non-severe cases and are used to complete 
the treatment in more serious cases (Table 2.7).(142)  In rural and remote 
areas, where hospitalisation may be difficult, daily IM procaine penicillin may 
be substituted for benzylpenicillin and administered under close supervision as 
initial therapy; continue until substantial improvement has occurred, generally 
5 days is required.  
Table 2.7 Management of CAP in children (Australia) 
Birth to 1 
week 
Benzylpenicillin 60mg/kg IV, 12-hourly for 7 days 
PLUS Gentamicin (neonate less than 34 weeks postconceptional age: 
3mg/kg or more postconceptional age: 3.5mg/kg) IV, daily for 7 days 
1 week to 
less than 4 
months 
If patient is febrile, is only mildly unwell and has the typical clinical 
features of pneumonia, use:  
  Azithromycin 10mg/kg orally, daily for 5 days 
OR (if child more than 1 month old) 
  erythromycin 10mg/kg orally, 6-hourly for 7 to14 days or    
  erythromycin 20mg/kg orally, 6-hourly for 7 to 14 days.  
If patient is febrile, does not have bronchiolitis, but the typical features 
of pneumonia, use:  
Benzylpenicillin 30mg/kg IV, 6-hourly for up to 7 days 
For severe disease, seek expert advice. Use:  
Cefotaxime 25 mg/kg IV, 8-hourly  
4 months to 
less than 5 
years 
For non-severe disease, use:  
Amoxicillin 25 mg/kg orally, 8-hourly for 3 days  
If there is not an adequate response after 3 days, review diagnosis 
and adherence to treatment. 
If oral therapy is not tolerated, use:  
Benzylpenicillin 30 mg/kg IV, 6-hourly for up to 7 days. (in rural and 
remote areas) 
5 to 15 years  
amoxicllin 25 mg/kg up to 1 g orally, 8-hourly for 5 to 7 days  
OR (if M. pneumoniae is suspected) 
clarithromycin 7.5 mg/kg up to 250 mg orally, 12-hourly for 5 to 7 days  
OR roxithromycin 4 mg/kg up to 150 mg orally, 12-hourly for 5 to 7 days 
For more serious disease, use:  
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Benzylpenicillin 30 mg/kg up to 1.2 gIV, 6-hourly until significant 
improvement, then amoxicillin 25 mg/kg up to 1 g orally, 8-hourly for a 
total of 7 days 
PLUS ( if M. pneumoniae is suspected) 
clarithromycin 12.5 mg/kg up to 500 mg orally, 12-hourly for 7 days 
OR roxithromycin 4 mg/kg mu pro 150 mg orally, 12-hourly for 7 days.  
2.6.4 Treatment guidelines for children with mild/moderate CAP in Mongolia 
Mongolian National Standard for treatment of children CAP recommends 
benzylpenicillin, aminoglycoside (gentamicin) injection for infants and semi-
synthetic penicillin (50mg/kg/4 times), plus gentamicin 7.5mg/kg/once)-
injection for children aged till five years. It also recommends any of 
salbutamol, euphyllin, epinephrine or prednisolone, if considered as 
necessary.(7) Detailed treatment regimen is demonstrated in Table 2.8. 
Table 2.8 Treatment guidelines of mild/moderate CAP in children(Mongolia)  
Children Mild /moderate CAP 
Mongolian National 
Standard: Pneumonia 
in children  
MNS 5836:2008 
Infants: Benzylpenicillin, 
aminoglycoside (gentamicin) 
injection 
Up to five years old: Semi-
synthetic penicillin (50mg/kg/4 
times) plus gentamicin 
7.5mg/kg/once injection 
If available chloramphenicol 
(75mg/kg/3 times a day) 
Additional option: Cephalosporin 
II-III  
If considered 
necessary, any of the 
following could be 
prescribed:  
Salbutamol, euphyllin, 
epinephrine 
Prednisolone, 
dexamethasone 
Vitamin C, A E 
 
It is notable no guidelines are available for children of six years and above. 
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2.7 Questionnaire studies 
Survey research using questionnaires is the most common method employed 
in pharmacy practice research. Questionnaires are assumed to be a cost-
effective tool to collect information from large samples in a relatively short 
time. Other advantages of questionnaires include the capacity to collect 
good factual information with short answers and closed questions and 
collection of relevant information in a systematic way.        
Developing a questionnaire to assess attitudes is a difficult task.(151, 152) A 
researcher has to explore and examine the factors and dimensions that are 
important underlying determinants of attitude. The questionnaire instruments 
should have a sound conceptual and theoretical foundation and the 
statements should be understandable to respondents. As in any 
questionnaire, all items must be reviewed to avoid potential problems arising 
from question structure or interpretation.(151) There are three ways to structure 
a self-administered questionnaire. Firstly, open-ended questionnaire with no 
answer choice. The other ways are to use as close-ended questions with 
ordered or unordered response categories.(152) As Dillman reported, there 
may be differences in the responses obtained from a self-administered 
questionnaire and an interview questionnaire. The responses obtained from 
an interview may be influenced by an interaction with another person 
delivering socially desirable answers for potentially embarrassing behaviour, 
such as drug use.(152) However, it is practical to tailor the design of surveys 
mixing interview with self-administered methods to reduce the differences in 
responses.(152)             
2.7.1 Validity and reliability of the questionnaires   
Along with the clear and comprehensiveness, the issues of reliability and 
validity must be addressed. In case of questionnaire design, reliability refers to 
the extent which the questions produce reproducible responses and are 
internally consistent. Questions regarding age and details of recent activities 
are usually reliable, however for other questions that require recall of events 
the reliability may be of concern. In order to check the reliability, a number of 
ways can be found from the literature. For example, information provided in 
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the questionnaire can be checked against another source, such as 
medication use against prescription data. This sometimes is referred to as 
‘triangulation’. Combining data from different sources is reported to be 
effective to assess the accuracy of information. Also, a consistency between 
responses of individuals to different questions can be checked. Poor reliability 
in a study can weaken the value of work and the dependability of the study 
findings, therefore it is crucial to control and improve the reliability of 
data.(151)  
On the other hand, validity is a more complex concept, and it can be defined 
as the extent to which the questions provide a true measure of what they are 
designed to measure. Sometimes respondents may be reluctant to report 
what they really do (for example: unhealthy behaviour) instead of adhering 
to health advice and it is difficult to conclude the questionnaire reflects an 
accurate view or behaviour. In observational studies, it is well-known that 
people change their behaviour intentionally or non-intentionally and data will 
often not reflect the actual situation. In self-completion questionnaires 
respondents may tend to under or overestimate on some variables (for 
example: smoking habits). Moreover, the questionnaire can provide reliable 
but not valid responses. As suggested by others,(151, 153) four types of validity 
can be considered to identify and address potential issues: 
1. Face validity is the first check to make and it may highlight a poorly 
worded item or topics that may be important but not included.(151) 
2. Criterion validity provides evidence about how well scores on the new 
measures of the same construct of very similar underlying contructs that 
theoretically should be related. At the same time, it is very important 
that the criterion must be valid itself. Predictive validity is one type of 
criterion-related validty and the criterion measurement is taken at 
some time after the administration of the questionnaire and the ability 
of the questionnaire to predict the criterion is assessed. For example: 
the researcher asks respondents about their prescribed medicines and 
compares their responses with data from records.(153)  
3. Construct validity applies to complex variables and the evaluation of 
construct validity requires examining the relationship of the measure 
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being evaluated with variables known to be related or theoretically 
related to the construct measured by the instrument. It is important that 
in establishing construct validity, scores on an instrument are 
associated with scores on another (criterion) measure of the same 
construct that is measured concurrently in the same subjects. The 
criterion measure would be considered to be the gold standard 
measure of the construct. An example is a researcher developing a 
self-administered version of an instrument that had been validated for 
person-to-person interviewer administration.(153)  
4. Content validity is the extent to which the data collected cover all the 
issues relevant to the study objectives. Because of non-availability of 
statistical tests determining whether a measure adequately covers a 
content area or adequately represents a construct, content validity 
usually depends of on the judgement of experts in the field.(153)  
One of the biggest threats to external validity (generalisation) is non-response. 
According to previous studies, non-responders are likely to differ from 
responders in ways that would result in biased study results.(151) To increase 
the response rate, the development and design(152) and details of the 
questionnaire are of importance. Also, a pre- testing on a similar group is 
recommended to obtain the content validity.(154) Moreover, improving the 
recruitment process (clear purpose of the study, remuneration for 
participation or issues with confidentiality) and to assess the impact of the 
response bias on the study results can be useful to increase the response 
rate.(151) 
Apart from validity and reliability, the questionnaire organization and layout is 
important. In contrast to interview, respondents may look at the questionnaire 
and make an assessment of its value, complexity and required time. These 
factors may contribute to the decision whether they complete it or not.(151)  
2.7.2 Data collection: prospective method 
Prospective collection of data is a powerful method that can be time 
consuming. The information relates to real-life scenarios and it can be more 
accurate than relying on recall. In some studies data can be collected by a 
researcher who is physically present at a study site and observes and records 
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details of events. In non-participant observation, the researcher aims to be 
discrete and not interfere with the normal activity. Participant observation is 
where the researcher acts as a study or group member. The biggest challenge 
in observation studies is known as “Hawthorne effect” where the presence of 
researcher can have effect on the validity of the data. Therefore, it is 
beneficial when the purpose of the study is clearly explained; assurance of 
the confidentiality of data is provided to the respondents and the researcher 
is unobtrusive when collecting data.(151)    
2.8 Summary  
The study was conducted in Mongolia which is located in north central Asia. 
The estimated population in 2011 was 2.8 million, with over 40% primarily 
residing in the capital, Ulaanbaatar. Mongolia is a low-income country with 
22.4% of the population living on less than US $1.25 a day. Health indicator 
data showed that there are problems with equitable health care. Respiratory 
infections accounted for most of the morbidity rates among children aged to 
five years, with pneumonia being the leading cause (34.4%). More reports 
suggested that inappropriate use of medicines; including injections are 
common in Mongolia.  
Drug use is appropriate/ rational when an appropriate drug is prescribed and 
administered according to the appropriate dosage regimen. In addition, the 
drug should be affordable and available and dispensed correctly, that is in 
correct doses at adequate time periods (WHO).  
Consequences of inappropriate drug use include unnecessary suffering and 
death, iatrogenic disease, hospital admissions and increased antimicrobial 
resistance. The reports from developing countries indicated that less than 40% 
was compliant with clinical guidelines. Also, inappropriate self-medication 
and availability of OTC antibiotics are common in developing countries, 
including in Mongolia.  
In order to combat with inappropriate use of medicines and improve the 
quality of health care, WHO recommends that countries should implement 
national policies.  NPS of Australia is one of the few successful examples which 
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focus on the quality use of medicines, by providing information for both 
community and health professionals.  
Development of resistance to microorganisms and unwanted side effects are 
consequences that inappropriate use of medicines, especially of antibiotics 
can have. As the literature review indicated, the incidence rate of 
pneumococci resistance increased from 6% to 44% within 9 years. Similar 
findings about penicillin resistance and multi-drug resistant strains of 
meningococcus can be found elsewhere.(57) Macrolide resistance is a serious 
concern in many Asian countries compared with the western part of the 
world.  
Further examples of inappropriate use of medicines include unnecessary and 
overusing of injections which are common in less developed countries. 
Possible explanation for injection overuse in developing countries is related to 
socio-cultural, economic and structural factors. Data from 13 developing 
countries regarding injection use and safety reported that for eight of those 
countries, 25-96% of outpatient visits resulted in at least one injection, and for 
five countries a majority of administered injections were unnecessary. 
Mongolia showed a high injection frequency rate; reporting an average of 13 
injections per year among the 65 participants. A latter assessment of injection 
practice was conducted by MoH and it observed an improved practice, 
reporting eight injections per year, and almost every injection (99%) was 
administered with new, disinfected and disposable equipment. However, the 
generalisation of these studies is limited due to a small population numbers.  
Although, there are many studies available in relation to CAP, there is relatively 
little known about the treatment of CAP and its antibiotic use in developing 
countries. A systematic review on prescribing practices for treatment of CAP 
in developing countries at outpatient settings delivered 29 studies. Most 
studies assessed the prescribing practice of antibiotics for the treatment of 
children aged less than five years diagnosed with pneumonia at outpatient 
setting. Only one study contained information regarding the treatment of 
adults diagnosed with pneumonia at outpatient setting in developing 
countries. To date, no studies have assessed the prescribing practice for 
treatment of outpatients diagnosed with mild/moderate CAP in Mongolia.  
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Evidence obtained from research studies are an essential part of EBM. This 
evidence needs to be collected and organized from systematic literature 
reviews, experimental studies or comparative studies of the particular issues in 
question. The NHMRC of Australia have recognized that the fundamentals of 
an evidence-based approach to clinical or a health issues is the evidence 
itself. In addition, interpreting the evidence is still a major challenge for clinical 
experts compiling clinical practice guidelines.  
While therapeutic guidelines with detailed antibiotic regimen are available in 
most developed countries, it is notable that no guidelines are available in 
Mongolia for children of six years and above.  
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Chapter	3 Systematic	review	on	appropriate	prescribing	of	
antibiotics	for	the	treatment	of	mild/moderate	CAP	at	
outpatient	settings	in	developing	countries	
This Chapter presents data obtained from a systematic review conducted for 
the period from January 1990 to March, 2013. A systematic appraisal and a 
comparison of the research data assessing the prescribing practices of 
antibiotics for the treatment of mild/moderate CAP at outpatient settings in 
developing countries was conducted.    
3.1 Introduction 
A systematic review is the application of scientific strategies that limit bias by 
the systematic assembly, clinical assessment, and synthesis of all relevant 
studies on a specific topic.(155)  
Systematic reviews and meta-analyses require expertise in both the subject 
matter and review methodology. The rules of Evidence-Based Medicine (EBM) 
that must be followed, suggest that a formal set of rules must be 
accompanied by medical training and clinical experience of clinicians to 
integrate the results of clinical research effectively. Along with expertise in 
review methods, expertise in the subject matter and technical competence 
is very important for a systematic review.(155)  
It is well-known that high quality studies can be identified by searching 
standard electronic databases and the more explicit and careful the search 
strategy is, the more likely a systematic review will include all of the significant 
papers. Moreover, “snowballing” methods or tracking references of 
references and electronic citations are reported to be particularly powerful 
for identifying high quality sources. The final step in a systematic review is 
usually a meta-analysis.(155) This review conducted a meta-analysis of results 
where possible from the studies of higher relevance, in order to establish 
overall significant findings from the selected studies.  
CAP accounts for 95% of all pneumonia cases in the world among children 
aged less than five years of age.(2) Unfortunately, only limited research has 
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been reported in relation to appropriateness of prescribing of antibiotics for 
patients with mild/moderate pneumonia in developing countries. This 
research covers issues relating to poor access to medication and limited 
budgets for medicines, poor health care and high risk of death.(2) 
Appropriate and prompt administration of antibiotic therapy is essential 
especially in resource-poor settings.(156)  
Studies inverstigating effective antibiotics for the treatment of CAP in children 
under 18 years of age were analysed by Kabra(157) and 27 studies enrolling 
11, 928 children were extracted. The review compared ambulatory treatment 
of non-severe pneumonia with various antibiotics and concluded that 
amoxicillin and cotrimoxazole were associated with similar failure rates. 
Considering the limited data on other antibiotics, co-amoxiclavulanic acid 
can be a second-line antibiotic for treatment of non-severe pneumonia in 
children. Furthermore, it was evident that side effects occurred to a lesser 
extent when treatment protocols used azithromycin compared to co-
amoxiclavulanic acid, and a better resolution of radiologic pneumonia was 
achieved with clarithromycin when compared with erythromycin. In 
hospitalized patients, treatment with oral amoxicillin was comparable to 
injectable ampicillin or penicillin. A higher mortality rate was recorded in 
hospitalized children with severe pneumonia treated with chloramphenicol 
compared to those treated with penicillin/ampicillin plus gentamicin. Also, 
oral and injectable amoxicillin were equally effective when compared with 
benzylpenicillin/ampicillin, and cotrimoxazole versus procaine penicillin for the 
treatment of pneumonia.(157)       
Evidence from six randomized controlled trials (RCT) concerning the efficacy 
of different antibiotic treatments for CAP in outpatients older than 12 years of 
age was summarized in a systematic review.(158) Of these six RCTs, two 
studied the same antibiotic pair (clarithromycin and erythromycin(159, 160)) 
and the other four trials studied different antibiotic pairs (clarithromycin versus 
azithromycin microspheres,(161) clarithromycin versus telithromycin,(162) 
azithromycin microspheres versus levofloxacin,(163) and telithromycin versus 
levofloxacin(164)). Therefore, the systematic review was not able to carry out 
a formal meta-analysis of the data. In addition, individual studies did not 
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reveal any significant differences in efficacy between various antibiotics and 
antibiotic groups. However, there were some significant differences regarding 
the extent of side effects. Consequently, the review concluded that a 
recommendation regarding the choice of antibiotic to be used for the 
treatment of CAP in ambulatory outpatients cannot be made owing to a lack 
of evidence. (158) 
RCTs evaluating the efficacy of short-course versus long-course antibiotic 
therapy for non-severe CAP in children aged two months to 59 months have 
been reported previously. The review extracted four studies involving 6177 
children under five. As the evidence from this review suggested, there were 
non-significant differences between a short course (three days) of the same 
antibiotic therapy and a longer treatment (five days) for non-severe CAP. In 
addition, it suggested that a short-course (three days) could be equally 
effective when compared with a long-course (five days) of either oral 
amocixillin or cotrimoxazole for children aged between 2 to 59 months 
diagnosed with non-severe CAP. However, due to a small number of available 
studies (four) further research is needed.(136) 
WHO completed a systematic review of studies published between 1990 and 
2007 about the use of medicines in developing and transitional countries, and 
it found that less than 80% of children less than five years of age who were 
diagnosed with pneumonia were treated with an appropriate antibiotic.(30) 
As the study reported, no improvement was observed during the study period 
and the proportion of pneumonia cases treated appropriately with antibiotics 
ranged from 49% to 67%. Only about 40% of prescribers were reported to treat 
acute respiratory infections (ARI)s in compliance with the guidelines, with 
medical doctors and paramedical health workers having similarly poor 
prescribing practices.(30)  
United Nations Children’s Fund (UNICEF) global databases summarized 
information from different countries regarding the proportion of children aged 
zero to 59 months with suspected pneumonia receiving antibiotics. The 
information was collected from different sources such as Demographic and 
Health Surveys, Multiple Indicator Cluster Surveys and National Family Health 
Surveys.(165) The extent of children aged less than five years with suspected 
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pneumonia receiving antibiotics was as low as 3% in Haiti and as high as 88% 
in the Democratic People's Republic of Korea (DPRK).(165) The primary study 
data are summarised the in Table 3.1. 
Table 3.1 Proportion of children aged less than five with pneumonia receiving 
antibiotics (adapted from UNICEF global survey, 2012) 
Country or territory  Time Period Total (%) Source 
Afghanistan 2010-2011 64 MICS 2010-2011 
Albania 2008-2009 60 DHS 2008-09 
Algeria 2006 59 MICS 2006 
Armenia 2010 36 DHS 2010 
Bangladesh 2011 71 DHS 2011 (Prelim) 
Belarus 2005 67 MICS 2005 
Belize 2006 44 MICS 2006 
Bhutan 2010 49 MICS 2010 
Bolivia (Plurinational State of) a 2008 64 DHS 2008 
Bosnia and Herzegovina 2005-2006 73 MICS 2005-2006 
Burkina Faso 2006 15 MICS 2006 
Burundi 2010 43 DHS 2010 
Cambodia 2010 39 DHS 2010 
Cameroon 2006 38 MICS 2006 
Central African Republic 2010 31 MICS 2010 
(Prelim) 
Chad 2010 31 MICSp 2010 
Côte d'Ivoire 2006 19 MICS 2006 
Cuba 2010-2011 70 MICS 2010-2011 
Democratic People's Republic of Korea 2009 88 MICS 2009 
Democratic Republic of the Congo 2010 42 MICS 2010 
Djibouti 2006 43 MICS 2006 
Dominican Republic 2007 57 DHS 2007 
Egypt 2008 58 DHS 2008 
El Salvador 2003-2008 51 Other 2008 
Ethiopia 2011 7 DHS 2011 
Gambia 2006 61 MICS 2006 
Georgia 2005 56 MICS 2005 
Ghana 2011 56 MICS 2011 
Guinea-Bissau 2010 35 MICS 2010 
Guyana 2009 18 DHS 2009 
Haiti a 2005-2006 3 DHS 2005-2006 
Honduras a 2005-2006 54 DHS 2005-2006 
India 2005-2006 13 DHS 2005-2006 
Iraq 2006 82 MICS 2006 
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Jamaica 2005 52 MICS 2005 
Jordan 2007 79 DHS 2007 
Kazakhstan 2006 32 MICS 2006 
Kenya 2008-2009 50 DHS 2008-2009 
Kiribati 2009 51 DHS 2009 
Kyrgyzstan 2006 45 MICS 2006 
Lao People's Democratic Republic 2006 52 MICS 2006 
Malawi 2006 30 MICS 2006 
Mauritania 2007 24 MICS 2007 
Mongolia 2010 72 MICS 2010 
(Prelim) 
Montenegro 2005 57 MICS 2005 
Mozambique 2008 22 MICS 2008 
Myanmar 2009-2010 34 MICS 2009-2010 
Nauru 2007 47 DHS 2007 
Nepal 2011 7 DHS 2011 
Nigeria 2008 23 DHS 2008 
Pakistan 2006-2007 50 DHS 2006-2007 
Peru 2010 51 DHS 2010 
Philippines 2008 42 DHS 2008 
Rwanda 2007-2008 13 DHS 2007-2008 
Serbia 2010 82 MICS 2010 
Sierra Leone 2010 58 MICS 2010 
Solomon Islands 2007 23 DHS 2007 
Somalia 2006 32 MICS 2006 
South Sudan 2010 33 MICS 2010 
Sudan 2010 66 MICS 2010 
Suriname 2006 37 MICS 2006 
Swaziland 2010 61 MICS 2010 
Syrian Arab Republic 2006 71 MICS 2006 
Tajikistan 2005 41 MICS 2005 
Thailand 2005-2006 65 MICS 2005-2006 
The former Yugoslav Republic of Macedonia 2005 74 MICS 2005 
Timor-Leste a  2009-2010 45 DHS 2009-2010 
Togo 2010 41 MICS 2010 
(Prelim) 
Trinidad and Tobago 2006 34 MICS 2006 
Turkmenistan 2006 50 MICS 2006 
Uganda a 2006 47 DHS 2006 
Uzbekistan 2006 56 MICS 2006 
Viet Nam 2011 68 MICS 2010-2011 
Yemen 2006 38 MICS 2006 
Zambia 2007 47 DHS 2007 
Zimbabwe 2010-2011 31 DHS 2010-2011 
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a  ARI definition does not specify chest-related problem 
DHS- Demographic and Health Survey 
MICS- Multiple Cluster Survey 
As reported by WHO, the pharmaceutical sector is complex but a vital 
component of the health care system.(166) The assessment and monitoring of 
strategies, in particular pharmaceutical system components, provides 
information regarding the issues and gaps, and inputs in the development of 
health policies. Consequently, relevant authorities, including policy-makers, 
managers, international agencies and donor organizations will then be able 
to prioritise areas where the best impact can be achieved.(166) Therefore, a 
systematic approach to assess the access, quality and rational use of 
medicines has been proposed by WHO.(166) The latter includes adherence 
to standard treatment protocols for tracer conditions such as the use of first-
line (recommended) antibiotics for mild/moderate pneumonia at outpatient 
settings, use of Oral Rehydration Salt (ORS)  for watery diarrhoea and non-use 
of antibiotics for simple ARIs.(166) As reported, at least 20 countries have used 
the operational package and this experience was beneficial to allocate 
country budgets and project grants for monitoring and assessment of the 
pharmaceutical sector.(166) However, the small number of samples (ten 
prescriptions for children diagnosed with pneumonia) make it impossible to 
generalise from these findings.  
WHO has designed interventions to improve the case-management skills of 
health workers in order to reduce child mortality and improve child health and 
development.(167) These interventions are aimed to improve family and 
community practices related to child health in developing countries and skill 
assessment of health workers has been assessed in other studies.(168) 
However, there are only limited studies evaluating the prescribing practice of 
antibiotics for treatment of CAP at outpatient settings in developing countries.   
3.2 Objectives  
The objective of this review was to investigate and summarize published 
studies evaluating inappropriate prescribing practices of antibiotics for the 
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treatment of mild/moderate CAP at outpatient community health settings in 
developing countries and evaluate the existing data. In addition, the study 
aimed to complete meta-analyses of relevant studies with similar 
methodologies.   
3.3 Methods 
A systematic review was completed by using the terms “community-acquired 
pneumonia”, “pneumonia”, “antibiotic”, “antimicrobial”, “developing 
country”, “low-middle income country”, “transitional country”, “appropriate”, 
“rational”, “inappropriate”, “irrational”, “prescribing”, “prescription”, 
“community” and “outpatient”. Consequently, a meta-analysis using a 
random effects model of relevant studies was completed in order to locate 
the power of the findings.  
The term ‘antibiotic’ and ‘antimicrobial’ were used interchangeably, as they 
are used interchangeably in the literature.  
3.3.1 Search strategy  
Electronic databases searched were Medline, Science Direct, Embase, Web 
of Science, Cochrane Library and Pro Quest and additional searches were 
also conducted using Google Scholar. The full electronic databases of WHO 
Library Information System (WHOLIS), WHO Eastern Mediterranean Region 
(WHO/EMR), WHO  Western Pacific Region (WHO/WPR) and WHO Pan 
American Health Organization (PAHO)/Latin American and Caribbean 
Health Sciences Literature (Lilacs), as well as the drug use bibliography 
composed and updated by International Network for Rational Use of Drugs 
(INRUD), and the database of the International Conference on Improving 
Medicines (ICIUM) were also searched.  
Potential studies were identified by using inclusion and exclusion criteria. A 
“snowballing” method was employed and references of all relevant articles 
were retrieved. The final search included publications up until March, 2013.  
According to the World Bank, “low-income or middle-income countries” are 
defined as “developing countries” that had low income of gross national 
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income (GNI) per capita of US$1,026 or less, in addition lower middle income 
countries with GNI per capita between US$1,026 and US$4,036.(169)  
3.3.2 Inclusion and exclusion criteria 
Inclusion:  
 Articles published in English 
 Published between January 1990 and March, 2013.  
 Containing relevant data on appropriate use of antibiotics for CAP at 
outpatient community health settings in developing countries  
Exclusion criteria:  
 Opinions about appropriate prescribing for CAP 
 Not assessing the appropriateness of antibiotic use for CAP  
 Studies completed at inpatient hospital settings  
 Pneumonia cases were not directly indicated or to less than 70% of all 
Acute Respiratory Infections (ARI)/Lower Respiratory Infections (LRI) 
cases reported as aggregated data  
 Assessing viral Upper Respiratory Inspections (URI) where antibiotic is 
not required  
3.3.3 Data extraction and analysis  
Relevant papers from the selected electronic databases were reviewed at 
the abstract level and prospective applicable papers were obtained in full-
text. The analysis of the papers was completed by using the Scottish 
Intercollegiate Guidelines Network (SIGN).(170)  
To collect information on retrieved articles, a data extraction sheet was 
developed that was consistent with the Quality of Reporting of Meta-analyses 
(QUOROM).(171) The data sheet included information about the country, 
demographic characteristics of the participants, study design, conclusions 
and findings summarized by the original authors (Appendix B ). The decisions 
whether to include or exclude the paper and the SIGN rankings were 
completed by consensus by the researcher and supervisors.    
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Full articles were reviewed independently for quality and the review extracted 
the following outcome data:  
1. Study design 
2. Description of participants 
3. Study location 
4. Prescribed antibiotic 
5. Prescribed dose of an antibiotic 
6. Prescribed dosage form of an antibiotic 
7. Prescribed duration of an antibiotic 
8. Prescribed frequency of an antibiotic 
9. Providing information on how to use antibiotic for patients 
10. Prescribed a correct treatment  
11. Intervention 
12. Intervention outcomes  
In addition, key parameters for the assessment of appropriate/rational 
prescribing were included if (i) the correct antibiotic, (ii) correct dose, (iii) 
correct dosage form, (iv) correct frequency, (v) correct duration, (vi) 
explaining how to administer the antibiotic and (vii) correct treatment was 
prescribed (Table 3.2).    
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Table 3.2 Key parameters of the prescribing practices for mild/moderate CAP 
Parameters a  Definitions  
Prescribing an antibiotic After a correct classification/diagnosis, an 
antibiotic should be prescribed.  
Prescribing appropriate 
antibiotic 
Appropriate antibiotic was if it was recommended 
in the national, IMCI or other guidelines used widely 
in each country.   
Prescribing appropriate 
dose of an antibiotic 
Appropriate dose complying with guidelines  
Prescribing appropriate 
dosage form 
Appropriate dosage form complying with 
guidelines 
Prescribing appropriate 
frequency 
Appropriate frequency complying with guidelines  
Prescribing appropriate 
duration 
Appropriate treatment duration complying with 
guidelines  
Explaining how to 
administer the antibiotic 
Caregiver knows to explain to the patient how to 
take the medicine  
Prescribing an appropriate 
treatment  
A treatment was considered appropriate if a 
recommended medicine, dose, frequencyb and 
durationb were prescribed. In addition, explaining 
how to administer the antibiotic 
a Adopted from WHO/IMCI guidelines for treatment of CAP in children aged two 
to 59 months. 
b Some of the studies did not assess the frequency or duration  
Where publications included additional diagnoses along with CAP, it was 
decided where only aggregated data were provided at least 70% of the 
diagnoses would be for CAP (studies with limited relevance) unless data for 
CAP were isolated (relevant studies).  
All analyses were done using STATA version 10. The outcome measure was the 
odds ratio (OR) of the extent of prescription with a correct treatment 
performed by relevant health workers (HW). The ORs and associated 95% 
confidence intervals (CI) were tabulated by key parameters for appropriate 
drug use (Table 3.2), for example: a correct antibiotic prescribed and the HWs’ 
status of training. Heterogeneity was measured using the I2 statistic and the 
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null hypothesis of no heterogeneity was tested using the Q statistic generated 
from the χ2 test. A random effects model(172) was used to estimate the pooled 
OR.  
3.4 Results 
The database search yielded initially 36(37, 44, 78, 173-205) individual papers 
(Figure 3.1 and Table 3.3). After eliminating one duplicate study(197) and 
following a snowballing technique of those articles delivered another 78 
studies and 10 reports(30, 82, 85, 117, 167, 198, 206-286) 
Of 123 papers retrieved, 71(36, 37, 44, 76, 78, 85, 167, 173, 174, 177, 179, 181, 
184-190, 192-196, 198-202, 204, 205, 209, 214, 220-222, 224-227, 229, 231-233, 
237, 238, 240-251, 255, 258, 261, 264-266, 269-272, 278, 284, 285) were excluded 
because the information regarding the prescribing of antibiotics for CAP was 
not specific enough. Furthermore, 23 (175, 191, 197, 223, 228, 230, 234-236, 239, 
243, 252-254, 256, 257, 259, 260, 262, 263, 273, 282) articles were excluded 
because of the setting of the studies (hospital inpatient)(Figure 3.1).  
  
 
Figure 3.1 Data extraction  
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Table 3.3. Search results from databases 
 
Search terms 
 
Science 
Direct  
Web of 
Knowledge 
Pro Quest 
 
Embase 
(Ovid) 
 
Cochrane  
 
Medline 
(Ovid) 
Pneumonia 119, 470 156, 436 603, 042 118, 897 7604 54, 679 
AND (antibiotic OR 
antimicrobial) 
48, 505 26, 845 101, 686 25, 188 11  6, 692 
AND (“developing countries” 
OR “low-income countries” 
OR “transitional countries”) 
3, 743 298 4, 652 286    - 132 
 
 AND (appropriate OR 
rational OR inappropriate OR 
irrational)  
2, 513  
 
55 (14) 2, 652 34  - 26  
AND (prescribing OR 
prescription) 
658 10 1, 182 7  - 4  
  
AND community 1, 192 4  1062 2  1 
AND outpatient 619  1  659 2 -  1 
Total (36) 7(37, 44, 78, 
173-175, 179) 
1(181) 25(36, 37, 
176-178, 180, 
182-196, 200-
202, 204) 
2(197, 199) - 1(197) 
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3.5 Summary of the findings from relevant studies   
Studies were categorized into relevant if they included specific treatment 
criteria and patient treatment outcome. Consequently, nine studies were 
assessed as relevant. The SIGN levels were assigned for the assessment of the 
nine relevant studies, of which two belonged to SIGN level 2+(206, 218) and 
the remaining seven were assigned SIGN level 2- (Table 3.4).  
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Table 3.4 Relevant studies for the systematic review 
 
#  Paper  Methodology Sample Period or year  Country SIGN 
level 
1. Bryce, 2005(207)  Comparative non-
controlled study 
62(post) versus 
52 
(comparison) 
Aug, 2000 Tanzania 2- 
2. Kalyango, 2012(212) Comparative 
controlled study 
134 (post) 
versus 102 
(control)  
Jan-Feb, 2011 Uganda   
 
2- 
61 (CMD users) 
versus 174 
(non-CMD 
users)  
3. Rwanda, 2009(215)  Observational non-
controlled study 
14 (post) 11-16 May, 2009 Rwanda 2- 
73 (post) 
83 (post) 
30 (post) 
4. Kafle, 2009 (211) Comparative non-
controlled study  
177 (pre) 
versus 100 
(post) 
Mar-Jun, 2004 Nepal 2- 
5. Uzochukwu, 2007(219) Comparative non-
controlled  study 
9 (pre) versus 7 
(post) 
Three months, 
2005  
Nigeria  2-  
6. Osterholt, 2009(217) 
  
Comparative non-
controlled study 
34 (pre) versus 
31 (post) 
2001 Benin 2- 
55 (pre) versus 
33 (post) 
2002 
98 (pre) versus 
50 (post) 
2004 
7. Pariyo, 2005(218)  
 
Comparative non-
controlled  study 
154 (pre) 
versus 328 
(post) 
2000 Uganda 2+ 
148 (pre) 
versus 96 (post) 
2001 
352 (pre) 
versus 100 
(post) 
2002 
8. Odhacha, 1998(216) Comparative non-
controlled study 
115 (pre) 
versus 27 (post)  
1998 Kenya  2- 
9. Bang, 1994(206) Comparative non-
controlled study 
709 (post) 1988-1991 India 2+ 
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The reported studies were mainly from African(180, 182, 183, 207, 208, 212, 215, 
217, 218, 267, 274, 275, 277) and Asian countries.(178, 193, 206, 210, 211, 213, 
281) All studies, except one evaluating prescribing practice of antibiotics for 
adults,(117) assessed the prescribing practices of antibiotics used for the 
treatment of children aged less than five years diagnosed with pneumonia in 
developing countries.  
A majority of the extracted studies (85%) assessed the effect of IMCI case 
management training on the use of antimicrobials among community health 
workers (CHW) treating young children at first level health facilities. Only one 
study in the extracted nine relevant studies reported a control group of 102 
children with pneumonia (n=236, intervention=134).(212) Therefore, despite 
the possible confounding effects, the results from uncontrolled studies were 
pooled due to limited evidence. 
From the data provided in the relevant studies, the studies enrolled 3177 
patients. In addition the average extent of prescribing a correct antibiotic was 
56.7% and a correct treatment was 47%, respectively (Table 3.5).  
 
Table 3.5 Summary of prescribing practices for treatment of CAP in the 
relevant studies  
- Data were not provided  
3.5.1 Meta- analysis of the relevant studies 
As outlined in Table 3.6, correct dose was assessed in four of the selected 
studies(206, 212, 215, 217) and the frequency was evaluated in one study.(212) 
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46.9 
(0.5) 
92.2 
(0.1) 54 (0.2) 
59.7 
(0.2) 
19 
(0.01) 
58 
(0.3) - - 24 (0.1) 
29 
(0.01) 
16 
(0.1) 
47.8 
(0.4) 
36.3 
(0.4) 
74.4 
(0.04) 
26 
(0.12) 
59 
(0.3) 
74.1(0.36) 56.7 (0.17) 50 (0.34) - 26 (0.07) 35 (0.34) 55.4(0.3) 47(0.31) 
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The duration of prescribed antibiotic was measured in two studies.(206, 212) 
The assessment of appropriate advice regarding how to take the antibiotic 
was reported in two of the studies.(207, 219) The outcome of the antibiotic 
treatment was reported in five of the extracted studies.(207, 212) (11, 215) 
Dosage form of the prescribed antibiotic was not assessed in any of the 
reported studies.   
The meta- analysis with random effects model(172) of the relevant studies 
including post IMCI training data with pre as the comparative group was 
completed. The aim of the meta-analysis was to establish whether health 
workers’ training influenced an appropriate antibiotic selection. It indicated 
that overall IMCI training was associated with significantly better performance 
in regards to prescribing of correct antibiotic (OR= 1.91, CI= .82- 3.34, p < .001, 
Q= 22.8) and correct treatment (OR= 2.13, CI=1.21- 3.21, p < .01, Q= 15.3). The 
correct treatment was defined inconsistently in the studies. A study in Uganda 
considered it as correct if the child used the recommended drug, dose, 
frequency and duration.(212) In addition to these parameters, the study in 
Tanzania considered whether the  antibiotics administration was explained to 
children.(207) In contrast, a second study conducted in Uganda reported that 
correct treatment was defined as the child being prescribed the correct drug 
in the correct formulation and dosage.(218) A study in Rwanda reported only 
post IMCI training data(215); therefore it was not included in the meta-
analysis.     
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Table 3.6. Analysis of the relevant studies 
a The number of defined CAP patients out of the total ARIs 
b All studies located were intervention studies 
c  No comparison (pre IMCI training) data were provided  
- No data were provided 
# Study 
N/n (pneumonia 
patients) 
Prescribed AB n(%) Correct AB n(%) Correct dose  
n(%) 
Correct dosage 
form  n(%) 
Correct 
frequency  n(%) 
Correct duration  
n(%) 
Explain how to 
administer AB  n(%) 
Outcome 
(appropriate 
treatment)  n(%) 
Beforeb After Before After Before After Before After Before After Before After Before After Before After Before After 
1 
Bryce 
Tanzania a 
52 a 62 43 
(82.69%) 
49 
(79.03%) 
21 
(40.38%) 
45 
(72.58%) 
- - -  - - - - - 32 
(61.54%) 
48 
(77.41%) 
19 
(37%) 
45 (73%) 
2 
Kalyango, 
Uganda   
102 134 - - 38 (37%) 60 (45%) 20 
(20%) 
20 
(15%) 
-  - 16 
(16%) 
40 
(30%) 
11 
(11%) 
29 
(22%) 
- - 7 (7%) 16 (12%) 
Kalyango, 
Uganda  
CMD/nonCMD 
174 61 - - 78 (45%) 26 (42%) 31 
(18%) 
5 (9%) -  - 54 
(31%) 
17 
(28%) 
35 
(20%) 
16 
(26%) 
- - 23 
(13%) 
4 (7%) 
3 
Kafle, Nepal  177 100 - - 103 
(58.2%) 
72 (72%) - - -  - - - - - - - - - 
4 
Osterholt, 
Benin  
- 41 - 40/41 
(97.6%) 
- -  31/41 
(75.6%) 
-  - - - - - - - - 28/41 
(68.3%) 
5 
Uzochukwu, 
Nigeria 
9 7 1 
(11.1%) 
7 (100%) - - - - -  - - - - - 1 
(11.1%) 
5 
(71.4%) 
- - 
6 Pariyo, Uganda  
328 154 - - - - - - -  - - - - - - - 81 
(24.7%) 
62 
(40.3%) 
96 148 - - - - - - -  - - - - - - - 24 
(25.0%) 
53 
(35.8%) 
100 352 - - - - - - -  - - - - - - - 48 
(47.9%) 
181 
(51.4%) 
7 
Odhacha, 
Kenya  
131 40 - - 115/131 
(88%) 
27/40 
(67%) 
  -  - - - - - - - - - 
8 
Rwanda c 
Ruhango 
- 
14 - - - -  11 
(75%) 
-  - - - - - - - - 12 (84%) 
Rwanda 
Gisagara 
73 - - - -  62 
(85%) 
-  - - - - - - - - 62 (85%) 
Rwanda 
Nyamagabe 
83 - - - -  73 
(88%) 
-  - - - - - - - - 73 (88%) 
Rwanda 
Kirehe 
30 - - - -  9 (30%) -  - - - - - - - - 30 (99%) 
9 
Bang, India 709 - - - -  609 
(85.9%) 
-  - - - - 677 
(95.5%) 
- - - - 
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3.5.2 Practice of prescribing an antibiotic for patients with pneumonia 
Data extracted from the studies were incorporated into each of the identified 
criteria for appropriate prescribing. Prescribing an antibiotic for patients 
diagnosed with pneumonia is an essential step towards appropriate case-
management of the disease and three of the studies included information 
regarding whether an antibiotic was prescribed.(207, 217, 219)  Furthermore, 
information regarding the appropriate selection of antibiotic for treatment of 
CAP was assessed in four of the selected papers. (207, 211, 212, 216)  
Bryce et al. completed a comparative study of 114 children under five years 
of age in Tanzania who were treated by CHWs in intervention and comparison 
districts. The practice of prescribing an antibiotic was slightly lower in the 
intervention district (79%) compared to those in control district (82%).(207) 
Findings from Benin suggested that after complete assessment and correct 
diagnosis, almost all children were prescribed an antibiotic (97.5%).(217) Short-
term training of health workers in Nigeria was observed as helpful as the 
practice of prescribing or administering antibiotics for children was improved 
(100% versus 11%).(219)  
3.5.3 Prescribing a correct antibiotic for patients with pneumonia  
The pre and post intervention results with regards to appropriate selection of 
antibiotic was compared by Bryce,(207) Kalyango,(212) Kafle(211), 
Odhacha.(216) Overall, CHWs showed an improved practice of prescribing a 
correct antibiotic after the IMCI training. Bryce assessed the impact of IMCI 
with regards to quality of care received by children diagnosed with 
pneumonia in IMCI and non-IMCI districts of Tanzania and an improved 
prescribing practice of correct antibiotic, including correct amount, 
frequency, and duration was reported.(207) Approximately 42% of children 
with self-reported pneumonia symptoms received a correct antibiotic in a 
study reported from Uganda.(212) Kafle reported a statistically significant 
improved prescribing practice of cotrimoxazole or amoxicillin alone or with 
paracetamol as recommended in the STGs of Nepal (p < .001).(211) However, 
another assessment of CHWs’ prescribing practices after the training was 
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completed in Kenya and a slightly declined performance level of CHWs was 
reported after the first three months training for the treatment of pneumonia 
in children aged two to 59 months.(216) This study was included in the meta-
analysis despite the different intervention time line.   
Of the studies reporting the prescribing practice of correct antibiotic, four 
studies(207, 211, 212, 216) with one containing two separate analyses were of 
sufficient quality to be included in the meta-analysis. Estimates from these 
studies were grouped according to the pre and post intervention results and 
represented in a forest plot (Figure 3.2).   
 
* Pooled’ line means that the pooled estimate was obtained using the Random 
effects model. 
Figure 3.2 Meta-analysis of prescribing practice of selection of correct 
antibiotic for patients with mild/ moderate CAP in developing countries after 
IMCI intervention training 
This plot shows that IMCI trained CHWs performed significantly better when 
compared to no training group with regards to selection of correct antibiotic 
for patients with mild/moderate CAP. (OR= 1.91, CI= 1.09- 3.34, p < .001, Q= 
22.8). There was some heterogeneity between groups (Q=22.8, p = .01).   
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3.5.4 Prescribing a correct dose, frequency and duration for patients with 
pneumonia 
 A correct dose of prescribed antibiotic for patients with pneumonia given by 
birth attendants in India reported that 86% of children were prescribed a 
correct dose of sulfamethoxazole-trimethoprim. The correctness between age 
and treatment dose according to data from a patient record review was 70% 
for children in Rwanda.(215) A study from Uganda suggested that the extent 
of recommended drug and dose was higher in the control arm compared to 
the intervention group (20% versus 15%).(212) However, meta-analysis of these 
two studies comparing the extent of pneumonia patients using trained CHWs 
and non-trained CHWs suggested that the difference was not significant (OR= 
.62, CI= .35- 1.09, p = .36, Q= .83). The heterogeneity was tested and indicated 
that the studies were homogenous.  
In contrast, the extent of recommended drug and frequency was two-fold 
higher in an intervention group than in the control group (30% versus 
16%).(212) However, this was not significant (OR= 1.57, CI= .57- 4.37, p = .39, 
Q= 4.4). Again, the I2 test showed they were homogenous.  
Information regarding the duration of prescribed antibiotics was reported in 
two studies.(206, 212) A meta-analysis comparing CHWs prescribing practices 
in two areas (intervention and control), indicated that training was associated 
with a significantly better practice for both districts (OR= 1.81, CI=1.09- 2.99, p 
= .02, Q= .87). Birth attendants in India observed that most of the prescribed 
duration periods were correct (95.5%).(206)      
3.5.5 Advising how to administer antibiotics for patients with pneumonia 
The practice of providing explanations on how to administer antibiotics for 
children with pneumonia was reported in two studies and improved practice 
of providing information about how to administer antibiotics correctly after 
the training was observed by Bryce(207) (61.5% versus 77.4%), and 
Uzochukwu(219) (11.1% versus 71.4%).  
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3.5.6 Correct treatment/management of patients with pneumonia  
Of nine selected studies, five reported the correct management/ treatment 
of patients with pneumonia. These studies compared and presented results of 
the treatment outcomes before and after IMCI training(207, 212, 215, 217, 218) 
and CHWs demonstrated an improved management of pneumonia patients 
in three studies.(207, 212, 218) Outcome of appropriate treatment by CHWs 
was assessed in Tanzania and they observed an improved practice between 
IMCI trained CHWs and non-IMCI trained CHWs (70% versus 40%).(207) A study 
from Uganda reported that overall appropriate drug use tended to be slightly 
higher in the intervention arm (11%) when compared with the control arm 
(7%), however the difference was not statistically significant.(212)  
A meta-analysis with a random effects model using three studies(207, 212, 218) 
indicated a statistically significantly better antibiotic management of 
pneumonia patients by IMCI trained CHWs (OR= 2.13, CI=1.21- 3.21, p < .01, 
Q= 15.3)(Figure 3.3). 
 
* Pooled’ line means that the pooled estimate was obtained using the Random 
effects model. 
Figure 3.3 Comparison of administration of appropriate treatment outcome 
(relevant studies) 
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A study from Rwanda indicated that a majority of children with pneumonia 
received appropriate treatment by CHWs after IMCI training.(215) However, 
no data regarding the pre-intervention status of the patients were provided. 
Also, about 70% of patients received appropriate treatment in a study 
reported by Benin.(217)  
Findings from Kenya however indicated contrary results. Odhacha evaluated 
CHWs performance after the end of IMCI training and three months later. The 
results suggested that the level of performance had decreased after a three-
month period (67%) as compared to that at the end of training (88%).(216) 
Similarly, an evaluation of the management of sick children by CHWs in Kenya 
between 1997 and 2001 also reported a reduced level of recommended and 
adequate treatment at the third evaluation.(182) However, all these 
comparison studies, except one(212) had no control groups. 
3.6 Summary analysis of studies with limited relevance  
Studies with limited relevance included diagnosis of ARIs, including 
pneumonia. The criterion adopted was if pneumonia was the diagnosis for 
more than 70% of total ARIs related cases, the study would be included in the 
systematic review.  All studies except one(180) were assigned SIGN level 2- 
(Table 3.7).  
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Table 3.7 Selected studies with limited relevance 
 
#   Paper  Methodology Sample Period or year Country SIGN 
level 
1. Iqbal, 1997(210) Observational study 28 Jan-Mar, 1993 Pakistan 2- 
2. Fagbule, 1994(208) Observational study 63 1988-1999 Nigeria 2- 
3. Shrestha, 2006(117) Comparative study 8 versus 60  Jul/Aug, 2002  Nepal 2- 
4. IMCI Tanzania, 
2004(176)  
Comparative study 59 versus 52 Aug, 2000 Tanzania 2- 
5. Rowe, 2001(183) Comparative study  117 Jul.28, 
1999/11-
12.Oct.1999 
Benin  2- 
6. Kelly, 2001(182) Comparative study 48 Feb. 1998 Kenya 2- 
66 Nov. 1999 
92 Feb/Mar.2001 
7 Arifeen, 2005(178) Comparative study 70 Aug-Sep, 2000 Bangladesh  2- 
8 Gouws, 2004(180)  Comparative study  419 2000 Tanzania 2+ 
516 2000 Uganda 
653 2002 Brazil 
9 Keohavong, 
2006(213) 
Observational study 223 Apr-Jun, 2004 Lao 2- 
10 Ministry of Health, 
Ethiopia, 2003(275) 
Observational study 106 Oct, 2003 Ethiopia 2- 
11 Ministry of Health, 
Kenya, 2008(277) 
 
Observational study  10 Dec, 2008 Kenya,  public 2- 
 10 Kenya, FGHS 
12 Ministry of Health, 
Uganda, 2008(276) 
Observational study  10 Jul-Aug, 2008 Uganda 2- 
13 Ministry of Health, 
Jamaica, 2012(280) 
Observational study  114  Sep, 2012 Jamaica 2- 
14 Ministry of Health, 
Mongolia, 
2009(281) 
Observational study  10 Aug-Dec, 
2009 
Mongolia 2- 
15 Ministry of Health, 
Barbados, 
2011(279) 
Observational study  40 Feb, 2011 Barbados 2- 
16 Ministry of Health, 
Ghana, 2008(267) 
Observational study  10 May-Jun, 2008 Ghana 2- 
17 Ministry of Health, 
Syrian Republic, 
2009(283) 
Observational study  10 Jun, 2009 Syrian 
Republic 
2- 
18 Ministry of Health, 
Zambia, 2001(274) 
Observational study  489 2001 Zambia 2- 
19 Ministry of Health, 
Brazil, 2009(268) 
Observational study 123 Sep, 2009 Brazil 2- 
20 WHO, 2009(30) Review   1990-2006 Developing 
countries 
2- 
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A total of 20 studies were extracted of which six compared pre and post 
intervention results and only one study had a control group of eight.(117)  The 
remaining 14 observed prescribing practices for treatment of patients 
diagnosed with mild/moderate CAP (Table 3.8). Of those 14 studies observing 
prescribing practices, eleven studies reported an assessment of quality of care 
(adherence to standard treatment protocols) with regards to treatment of 
CAP by using the WHO Operational package.(287) These studies reported the 
level of prescribing of the first-line antibiotic for patients with mild/ moderate 
CAP at outpatient settings. 
The practice of whether an antibiotic was prescribed for patients with 
pneumonia was only reported  in one study,(208) 14 studies reported the 
prescribing practice of correct antibiotic(30, 180, 210, 213, 267, 268, 274-277, 
279-281, 283) and five studies evaluated the management of children with 
pneumonia (117, 178, 182, 183, 189) (Table 3.8).   
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Table 3.8 Analysis of studies with limited relevance 
# Study 
N/n (pneumonia 
patients) 
Prescribed AB n(%) Correct AB n(%) Correct dose n(%) Correct dosage 
form n(%) 
Correct 
frequency n(%) 
Correct duration 
n(%) 
Explain how to 
administer n(%) 
Correct treatment 
n(%) 
Before After Before After Before After Before After Before After Before After Before After Before After Before After 
1 
Iqbal, 
Pakistan(210) 
28 -  -   11 
(39%)a 
19 
(68%)b 
-  -  25 (89%) 
a 
23 (82%) 
b 
-  -  -  -  -  -  -  - 
2 
Fagbule, 
Nigeria(208) 
86/63 
(73.3%) 
- 73 
(84.9%) 
-  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
3 Shrestha, Nepal (117) 
2 6 -  -  -  -  -  -  -  -  -  -  -  -  -  - 
1.2 c 
 9 51 -  -  -  -  -  -  -  -  -  -  -  -  -  - 
4 
IMCI 
Tanzania(176) 
52 59 -  -  -  -  -  -  -  -  -  -  -  -  -  -  40%  
(28-52) 
75%  
(58-92) 
5 
Rowe, 
Benin(183)  
550/117 - -  -  -  -  -  -  -  -  -  -  -  -  33 
(28.2%) 
- 67 
(57.3%) 
 
6 Kelly, Kenya(182) f 
-  48  -  -  -  -  -  -  -  -  -  -  -  -  -  -  28/48 
(58.3%) 
28/48 
(58.3%), 
-  66 -  -  -  -  -  -  -  -  -  -  -  -  -  -  43/66 
(65.1%) 
38/66 
(57.6%) 
-  92 -  -  -  -  -  -  -  -  -  -  -  -  -  -  92 (50%) 92 
(39.4%) 
7 
Arifeen, 
Bangladesh(17
8) 
70 (25%)  -  -  -  -  -  -  -  -  -  -  -  -  -  -  8 
(12.5%) 
- 
8 
Gouws 
Tanzania(180)  
-  134/117 
(87%) 
-  -  58 (43%) 69 (77%) -  -  -  -  -  -  -  -  77 (18%) 73 
(98%) 
-  - 
Gouws 
Uganda(180) 
-  181/161 
(89%) 
-  -  83 (25%) 68 (41%) -  -  -  -  -  -  -  -  144 
(29%) 
80 
(31%) 
-  - 
Gouws  
Brazil(180) 
-  68/19 
(28%) 
-  -  35 (51%) 33 (67%) -  -  -  -  -  -  -  -  70 (9%) 41 
(54%) 
-  - 
9 
Keohavong, 
Lao(213) 
262 -  -  -  91% d -  - -  -  -  -  -  -  -  -  -  -  - 
10 
Ministry of 
Health, 
Ethiopia,(275) 
106 -  -  -  54% e -  - -  -  -  -  -  -  -  -  -  -  - 
11  
Ministry of 
Health, Kenya, 
public(277) 
10 -  -  -  95% e -  - -  -  -  -  -  -  -  -  -  -   
Ministry of 
Health Kenya, 
FGHS 268 
10 -  -  -  61% e -  - -  -  -  -  -  -  -  -  -  -  - 
12  
Ministry of 
Health, 
Uganda(276) 
10 -  -  -  70.0% e -  - -  -  -  -  -  -  -  -  -  -  - 
13 
Ministry of 
Health, 
Jamaica(280) 
114 
(50%) 
-  -  -  30.2% d  -  - -  -  -  -  -  -  -  -  -  -  - 
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14 
Ministry of 
Health, 
Mongolia(281) 
10 -  -  -  80.8% d -  - -  -  -  -  -  -  -  -  -  -  - 
15 
Ministry of 
Health, 
Barbados(279)  
40 -  -  -  32% e -  - -  -  -  -  -  -  -  -  -  -  - 
16 
Ministry of 
Health, 
Ghana(267) 
10 -  -  -  100% e   -  - -  -  -  -  -  -  -  -  -  -  - 
17. 
Ministry of 
Health, Syrian 
Republic(283) 
10 -  -  -  100% e -  - -  -  -  -  -  -  -  -  -  -  - 
18 
Ministry of 
Health, 
Zambia(274) 
489 -  -  -  13% d -  - -  -  -  -  -  -  -  -  -  -  - 
19 
Ministry of 
Health, 
Brazil(268) 
123 -  -  -  63.3% d -  - -  -  -  -  -  -  -  -  -  -  - 
20  
WHO - Africa 
(30) 
50 -  -  -  58,5% d -  -  -  -  -  -  -  -  -  -  -  -  - 
WHO- Sub-
Saharan 
Africa(30)  
50 -  -  -  58.5% d -  -  -  -  -  -  -  -  -  -  -  -  - 
WHO- Latin 
American and 
Caribbean(30) 
c 
21 -  -  -  70% d -  -  -  -  -  -  -  -  -  -  -  -  - 
WHO - Middle 
East and 
Central Asia 
(30) 
17 -  -  -  66.7% d -  -  -  -  -  -  -  -  -  -  -  -  - 
WHO- East Asia 
and Pacific 30 
16 -  -  -  74.3% d -  -  -  -  -  -  -  -  -  -  -  -  - 
WHO - South 
Asia(30) 
12 -  -  -  33.8% d -  -  -  -  -  -  -  -  -  -  -  -  - 
a The study results were obtained from the questionnaire 
b The data were obtained from the prescribing practice  
c OR was obtained from a logistic regression model  
d Mean value was provided   
e Median was provided  
f Only post training data were provided  
- No data were provided  
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Studies with limited relevance enrolled 2272 patients and the proportion of the 
patients receiving a correct antibiotic was reported to be 60% and a correct 
treatment was received by 51% of patients (Table 3.9).  
Table 3.9 Summary of prescribing practices in studies with relevance 
Prescribe 
AB 
Correct AB Correct 
dose 
Correct 
dosage 
form 
Correct 
frequency 
Correct 
duration 
Explain how 
to administer 
Correct 
treatment 
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84.9 - 60 (0.3) 
63 
(0.2) 
-  -  -  -  -  -  -  -  21 
(0.1) 
61 
(0.3) 
36.5 
(0.2) 
58 
(0.3) 
84.9 60 (0.2) - - - - 38.2 (0.3)  51(0.2)
- Data were not provided  
3.6.1 Practice of prescribing an antibiotic for patients with pneumonia 
The practice of prescribing an antibiotic for patients with pneumonia was 
reported in only one of the studies classified as of limited relevance.(208) 
Fagbule et al. observed a cohort of 63 children aged less than five years 
diagnosed with pneumonia in Nigeria and 85% of those children were 
prescribed an antibiotic.(208)  
3.6.2 Prescribing a correct antibiotic for patients with pneumonia  
The prescribing practice of a correct antibiotic for patients with pneumonia 
was reported in two studies and 12 reports.(30, 180, 210, 213, 267, 268, 274-277, 
279-281, 283) Iqbal compared the prescribing practice and interviewed the 
general doctors and fewer of doctors reported prescribing an oral antibiotic 
for patients with pneumonia (39%). However, this was lower when compared 
with observed prescribing practice (68%).(210) A study that assessed 
treatment of pneumonia in developing and transitional countries reported 
that about 80% of pneumonia cases were treated with appropriate antibiotics 
during 1990 and 2009.(30, 286) In a previous study completed by WHO, the 
extent of prescribing a correct antibiotic was 34% in South East Asia, 58.5% in 
African region and 74.3% in East Asia Pacific (Table 3.8).  
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3.6.3 Prescribing a correct dosage form  
Oral antibiotics are generally recommended for patients with mild/ moderate 
CAP. The prescribing of the correct dosage form was reported in only one 
study that observed the prescribing practice and interviewed doctors. The 
extent of prescribed injectable antibiotics was similar (82%) with reporting in 
the interview (89%).(210) 
3.6.4 Providing information on how to use antibiotic appropriately 
Data from multiple countries indicated that the practice of explaining how to 
use antibiotics appropriately to patients was statistically better achieved by 
IMCI trained CHWs when compared with those who did not receive any 
training.(180) 
3.6.5. Correct treatment/management of patients with pneumonia  
Of the extracted 22 studies five assessed the correct overall management of 
patients with CAP.(117, 178, 182, 183, 189) Practical Approach to Lung Health 
(PAL) is a WHO initiated generic clinical practice guideline that was designed 
to improve the management of respiratory diseases in adults. Impact of the 
PAL- intervention program was assessed in Nepal and it was a statistically 
significant improved adherence to treatment guidelines by the CHWs was 
observed (OR =1.2, p < .05).(117) However, the number of prescriptions in the 
control group was lower (8) compared to those in the intervention group (60) 
potentially biasing the result.(117) Data from Tanzania reported an improved 
management of pneumonia after the training, whereas a little over half of 
patients diagnosed with mild/ moderate CAP received an adequate 
treatment.(176) An assessment of the impact of IMCI training in three 
consecutive years indicated a declining performance of CHWs with relation 
to adequate treatment of pneumonia in children aged two to 59 months in 
one district of Kenya. The study observed a decline in both groups’ results 
ranging from 58% to 39.4% after the training. The management of pneumonia 
was considered to be adequate if the drug was selected correctly but the 
study did not assess the drug dosing.(182) A study from Bangladesh reported 
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that only 13% of children diagnosed with pneumonia were treated 
correctly.(178)  
3.7 Discussion 
Primary findings  
To the best knowledge of the candidate, this is the first systematic review that 
has investigated and evaluated data on the prescribing practice of 
antibiotics for outpatients with mild/moderate CAP in developing countries 
since January 1990. No random controlled trials were identified and for the 
comparative evaluation only two studies had control groups. Despite the 
WHO/IMCI developed guidelines for appropriate treatment of children 
diagnosed with CAP which includes information about the antibiotic 
selection, correct antibiotic, dose, dosage form, frequency, duration of an 
antibiotic in addition to explaining how to use the medicine appropriately, 
treatment outcome;(288) no study has provided data that has assessed all six 
key parameters when evaluating appropriate/ rational prescribing for 
patients with mild/moderate CAP separately. Notably, Bryce specified six of 
these parameters regarding the correct antibiotic.(207) A study from Uganda 
reported five key parameters including correct antibiotic, dose, frequency 
and duration(212) whereas Pariyo included correct drug, dose, frequency 
and duration.(218) In contrast, Odhacha specified correct treatment as only 
if antibiotic prescribed without providing any information about dosage of the 
antibiotic whereas a report from Rwanda compared only the dose of the 
prescribed antibiotic.(215) Furthermore, a study from Nepal assessed the pre 
and post intervention results using one key parameter (prescribing an 
antibiotic).(211) The remaining three studies assessed two parameters to 
assess the quality of care for treatment of CAP in children aged less than 
five.(206, 217, 219)      
The assessment of studies with limited relevance provided similar findings. Only 
one study assessed whether an antibiotic was prescribed for treatment of ARIs, 
including pneumonia(208) and one study reported prescribing practice of 
correct prescription (in terms of dose, frequency and formulation).(180) 
Studies from nine countries completed an assessment of the pharmaceutical 
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sector, including the assessment of quality of care for tracer conditions, such 
as pneumonia. The extent of prescribing practice of the recommended first-
line antibiotics for treatment of pneumonia in children was evaluated using 
outpatient records. However, the small number of samples (10) in each group 
should be considered when interpreting results. 
The results from the review indicated that the overall extent of patients with 
mild/moderate CAP receiving a correct antibiotic was 59% and a correct 
treatment was 48%, respectively. This is lower than a previous finding from 
developing and transitional countries, reporting about 80% of pneumonia 
cases were treated with appropriate antibiotics during 1990 and 2006.(30) 
More literature indicated that the treatment of pneumonia cases with 
appropriate antibiotics did not improve from 1992 to 2009 (varying over time 
in the range from 49% to 67%).(286, 289) 
Overall completeness and applicability of evidence 
The systematic review found important issues related with assessment of 
appropriate prescribing practices for treatment of mild/ moderate CAP in 
developing countries. But caution must be exercised when interpreting the 
results due to limited number of studies. Nine studies with relevance and 20 
studies with limited relevance were indentified including a good number of 
participants contributing to the results (5,449). In addition, the inclusion criteria 
for studies with limited relevance specified that the diagnosis of pneumonia 
specifically within the ARI group was more than 70%. 
Quality of evidence    
Despite WHO initiated health facility drug-use indicators being widely 
accepted as a ‘gold standard’,(290) inappropriate prescribing practice is not 
a rare issue in developing countries.(291) In the era of significantly increasing 
resistance of respiratory bacteria, for example S. Pneumoniae and H. 
Influenzae to antibiotics recommended for the treatment of mild/ moderate 
CAP,(232, 255, 285) the findings provide evidence to support the need for 
improvement of prescribing practices for treatment of mild/moderate CAP in 
developing countries. In addition, the results of the meta-analyses support the 
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effectiveness of IMCI training for CHWs with regards to prescribing practice of 
correct antibiotic, correct duration and overall management of patients with 
CAP. Therefore, due to limited number of studies more research is required to 
support this finding. 
Potential biases in the review process 
A systematic and thorough search of the literature identifying all studies 
meeting inclusion criteria was undertaken. The candidate and supervisor 
independently selected the studies and assigned the SIGN levels. 
Discrepancies were resolved by consensus.  
Agreements and disagreements with other studies or reviews 
Statistically significant differences were found in relation to the prescribing 
practice of the correct drug and correct treatment among IMCI trained and 
non-IMCI trained CHWs. In general, this was in line with systematic reviews that 
confirmed the effectiveness of case management with antibiotic treatment 
in reducing mortality from childhood pneumonia in developing countries.(232, 
255, 285) A review of prescribed antibiotics for treatment of pneumonia 
summarized findings from developing countries and it reported that the extent 
of practice of prescribing a correct antibiotic for children under five was under 
70%. In addition, the review concluded that the practice of prescribing a 
correct antibiotic did not improve over a period of more than 15 years.(36) 
However, there has been no previous attempt to assess the prescribing 
practice (including all parameters of appropriateness) for treatment of 
mild/moderate pneumonia in developing countries.    
3.8 Limitations 
There are limitations to be considered when interpreting and synthesizing 
results from the systematic review. First, the systematic review excluded any 
articles that were published in non-English languages. Moreover, the SIGN 
grading of the extracted papers is open to some interpretation because the 
SIGN grading system lacks precision in allocating the grading. Throughout the 
systematic review, it was notable there was a lack of high SIGN level quality 
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papers. This is of great concern with respect to the quality of studies over the 
past 23 years.   
Furthermore, there were some issues regarding reporting the IMCI studies, due 
to the different definition of the indicator “pneumonia cases managed 
correctly”.  In WHO/CHD studies it includes all aspects of case management 
whereas in WHO/IMCI studies it is interpreted as ʺ% pneumonia cases with 
appropriate antibioticsʺ because this indicator does not generally include 
other aspects of case management (such as dosing, referral and advice).(30) 
Additional issues include the quality of extracted studies. In particular, a 
majority of studies were uncontrolled (28/29), making it difficult to attribute 
observed changes to the intervention due to any secular trend or sudden 
change.(292) Also, interventions in uncontrolled before and after studies are 
often confounded by the Hawthorne effect which potentially could lead to 
an overestimate of the effectiveness of an intervention.(293) 
Heterogeneity between studies 
The observed differences between studies may reflect the difficulties of 
overlapping time periods and confounding, but could also reflect the 
differences in population studies, the definition of prescribing a correct 
antibiotic and correct management of pneumonia.       
3.9 Conclusion  
Considering the number and nature of studies that assessed the prescribing 
practices of antibiotics for patients diagnosed with mild/moderate 
pneumonia at outpatient settings in developing countries, the review 
concludes that a considerable amount of research needs to be completed 
into assessing the prescribing practice of antibiotics for mild/moderate 
pneumonia in developing countries. Moreover, the current WHO/IMCI 
guidelines consider only children aged two to 59 months. WHO/IMCI initiated 
studies should include evaluation of other recommended criteria of 
appropriateness of drug prescribing, for example dose, dosage form, duration 
of and explaining how to administer the prescribed antibiotic. The lack of 
reported studies in children over five years and adults in developing countries 
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is of great concern considering the prevalence of mild/moderate CAP in 
developing counties. Appropriate prescribing is poor and the patient 
adherence with prescribed medication adds an additional layer potentially 
resulting in poor patient outcomes.  
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Chapter	4 Methodology	
In addressing the overall aim of the project, two major studies were 
conducted. The first of these was a prescription study to evaluate the 
appropriateness of prescribing practices for mild/moderate CAP. Prescription 
data were collected from community pharmacies prospectively and 
sequentially. Secondly, questionnaire studies with community members, 
prescribers (doctors) and providers (pharmacists and pharmacy technicians) 
were completed in order to establish the level of and determinants that lead 
to inappropriate injection practices and to understand reasons for injectable 
antibiotics and other drugs being prescribed provided and preferred for 
treatment of mild/moderate CAP in Mongolia. 
4.1 Assurance of readability, validity of the studies  
A data collection form for the prescription study and questionnaire forms were 
developed and translated from English to Mongolian and back-translated 
into English, in order to assure the validity of data collection and minimise 
linguistic and cultural biases, known as decentering(294) (Appendix E and 
Appendix F ). These were carried out by experts as detailed in the relevant 
parts of the methodology.   
4.2 Evaluation of prescribing practices for CAP in Mongolia  
4.2.1 Data collection 
Prescriptions submitted to community pharmacies in Mongolia with a 
diagnosis of mild/moderate CAP written on a prescription by doctors were 
collected prospectively and sequentially. According to the standard for 
prescriptions,(295) all physicians must record the diagnosis on the prescription. 
Prescriptions with multiple diagnoses were not included due to the different 
assessment. All prescribed drugs, including their dosage, duration, route of 
administration and demographic information of patients were extracted from 
the prescriptions on to a data collection form that was developed for the 
study. The validity of data collection was assured by translating from English to 
Mongolian and back-translated into English as requested for ethics approval. 
The prescriptions were evaluated as received and prior to any amendments 
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made as a result of pharmacist intervention. Each drug was evaluated for 
rational prescribing based on the Standard Treatment Guidelines of Mongolia 
(2005, 2008),(6, 7) Australian Therapeutic Guidelines for Treatment of non-
severe pneumonia,(142) WHO/IMCI guidelines for pneumonia in children.(150) 
Appropriateness was assessed for each of the following indicators: drug 
selection, dosage form, prescribed dose, frequency of administration and 
prescribed duration.  A drug was classified as “inappropriate” if one or more 
indicators were inappropriate for each prescribed item. The assessment was 
based on a cascading effect, for example. If the first indicator was 
“inappropriate”, then the prescription item classification was “inappropriate” 
and this drug was excluded from further analysis and would not appear in the 
second indicator, etc. 
4.2.2 Site selection  
The site selection was based on the WHO Operational Package for assessing, 
monitoring and evaluating country pharmaceutical situations.(166) The 
principle of selecting private pharmacies in the urban areas and provinces 
was to select the closest private pharmacy to each public health facility 
surveyed where doctors were surveyed by questionnaire. However, branches 
and Revolving Drug Funds (RDF) were excluded in this study because 
branches of the pharmacies are legally restricted to only providing Over the 
Counter (OTC) drugs. RDFs have variable management structures, such as 
soum governor, nurse or pharmacy technician can be managers of RDFs. In 
addition, RDFs were not included in the study because of remote location and 
due to limited budget.       
A convenience selection method was applied for pharmacies in rural areas 
based on discussion with local professionals. The selection criteria were based 
on retail volume, operational activity and close location to hospital or health 
centres.  
Thirty pharmacies consisting of 20 in the Ulaanbaatar area and 10 in eight of 
the provinces were selected for inclusion in the study, of which 22 consented. 
This represented a response rate of 73%. All pharmacies that did not consent 
were in the urban area. The sites selected were privately owned community 
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pharmacies in towns in eight provinces (Bayankhongor, Bulgan, Govi-Altai, 
Khovsgol, Ovorkhangai, Sukhbaatar, Tuv, Uvs) and the remainder 12 
pharmacies in the capital city (Ulaanbaatar). 
4.3 Study definitions 
 An overdose was defined as a dose prescribed greater than 10% 
above that specified in the guidelines and an under dose greater than 
10% below that specified in the guidelines. The decision was based on 
the limits of dosage content of pharmaceutical products. (296) 
 Injections were determined as any medications, including 
contraceptives and vaccination that were injected either 
intravenously, intramuscularly or subcutaneously. Intravenous fluid 
medications with or without drug addition were defined as a 
continuous drip. 
 Prescriber of injections was defined as those who prescribed or 
recommended drugs, including injectables, irrespective of their 
position or qualification. These included doctors, specialists and 
traditional practitioners operating within their scope of practice. 
 Dispensers of injections are defined as those who provided injectables 
on a prescription irrespective of their position or qualification. These are 
pharmacists and pharmacy technicians. 
 Administrator of injections was defined as a person who administers 
injectables to community members, irrespective of their position or 
qualification. These included doctors, specialists, traditional 
practitioners and nurses. 
 It is noted that injections are often supplied outside of the law from 
various outlets in Mongolia.  
4.4. Questionnaire issued to community members  
4.4.1 Development of questionnaires issued to community members  
The development of a questionnaire relating to injection use among 
community members and to investigate knowledge, attitudes and other 
relevant factors was based on the WHO developed guide: Injection Practices: 
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Rapid Assessment and Response Guide(297) and other research findings.(70, 
76, 84, 85, 298, 299)  
A structured questionnaire included community members’ characteristics 
such as socio-demographics, experiences and views about their recent 
consultation and previous ones, self-diagnosis and self-request for injections, 
expectations for the consultation, satisfaction; compliance with oral 
medication; expectations of injections; attitude towards and knowledge 
about antibiotics.   
4.4.2 Validation of the questionnaires for community members 
Two actively working professional translators with more than 15 years of 
working experience and whose native language was Mongolian completed 
the English to Mongolian, and back translations to assure accuracy and 
minimize any possible bias. These translators were unknown to each 
other.(300) 
For readability and comprehensiveness of the questions, a pilot study was 
completed. Of forty distributed questionnaires, 15 were returned yielding a 
response rate of 37.5%. Modifications regarding some wording terms were 
made after the pilot study, in order to improve the completeness and clarity 
of questions (Appendix F ). No major omissions were identified. These 
responses were not used further in the study.     
4.4.3 Selection of community members  
As recommended in the guide,(298) a sample of community members, who 
appeared and were confirmed to be 18 years of age was selected by 
collecting at pre-determined locations to obtain a representative sample 
from different socio-economic groups. Questionnaires were administered at 
55 different locations. These included three public central hospitals in large 
district and five district hospitals in semi-rural districts; five FGPs located in large 
and 15 semi-rural and rural districts; three private hospitals in large and semi-
rural districts; one university in large and two in semi-rural districts; three 
supermarkets in the city centre and 19 small shops in the semi-rural and rural 
areas.  
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The researcher approached respondents and outlined the objectives of the 
study to them and asked for their permission to participate.  
4.4.4 Questionnaire administration to community members 
Patient information sheets, written in Mongolian, were distributed to the 
respondents and explained by the researcher. Prior to administering the 
questionnaire, a verbal consent was obtained.     
Most of the questionnaires were completed by participants. In some cases, 
however, the researcher administered the questionnaire to the participant 
and completed the questionnaire based on their responses. Questionnaires 
took between 10 to 20 minutes to complete, including the introduction, 
explanation and obtaining a verbal consent. 
The survey took place in a public quiet area, for example hallway of the 
hospitals, university or waiting area in supermarkets, whenever possible.  
The researcher made a clear statement that there were no right or wrong 
answers and explained the research objectives thoroughly.  
All questionnaires were administered during the winter period, January-March, 
2010 in Ulaanbaatar, Mongolia which is a period with a high prevalence of 
acute respiratory tract infections. 
4.5. Questionnaire issued to pharmacists and pharmacy technicians  
4.5.1 Development of questionnaires issued to pharmacists and pharmacy 
technicians 
A literature review was undertaken to establish previous findings related to the 
pharmacists’ role in dispensing, prescribing and administering injections in 
developing countries. Several studies were identified and used to inform this 
research.(85, 86) One previous study focusing on the role of doctors and 
nurses regarding therapeutic injections in Mongolia was also used.(301)  
A questionnaire was developed using a WHO/SIGN guide.(297, 298) This guide 
included information relevant to investigation of injection practices, their 
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determinants and their consequences. In addition, the questionnaire was 
developed after a range of discussions with pharmacy academics and 
practitioners from Australia and Mongolia, in order to explore pharmacists’ 
practice of dispensing and prescribing antibiotics for the treatment of CAP in 
Mongolia and to investigate the underlying factors that impact on dispensing, 
and prescribing practices and administering of therapeutic injections in 
Mongolia (Appendix F ).  
4.5.2 Validation of the questionnaire for pharmacists and pharmacy 
technicians  
Readability and validity of the preliminary questionnaires were evaluated by 
a team of local professionals, including an academic from the School of 
Pharmacy, Health Sciences University of Mongolia with more than twenty 
years work experience, one epidemiologist with more than seven years of 
working experience, one pharmacist who is registered and a community 
pharmacist who has worked for more than twenty years in Mongolia. Based 
on the comments of local professionals, another two antibiotics were added 
to the number of medicines prescribed for mild/moderate CAP.  
The questionnaire was piloted to ensure that the questions were clear, and 
considering the average pharmacists and pharmacy technicians’ busy 
workload, that the instrument could be completed in a reasonable amount 
of time. The pilot study included two pharmacists and two pharmacy 
technicians and the response rate was 100%. After the pilot study, a few further 
modifications in wording and order of the questions were made (Appendix F 
).  
4.5.3 Selection of pharmacists and pharmacy technicians  
For the selection of community pharmacies and health facilities, three large 
districts in urban areas and one semi-rural were chosen to represent the 
average conditions in the country. In addition, one rural district of 
Ulaanbaatar was chosen based on population size that were thought to be 
representative of all socioeconomic areas in Mongolia.(287) Forty community 
pharmacies were conveniently selected from these chosen five districts that 
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represented a range of pharmacies regarding size, accessibility and distance 
from clinics, based on discussions with local professionals, ensuring that no 
particular type of pharmacies was excluded. These included pharmacies 
selected for the prescription study (12) and another 28 pharmacies. In respect 
to their location, 25 community pharmacies were located in three large 
districts, twelve were in semi-rural districts and the remaining three were 
located in rural districts.  
Pharmacists and pharmacy technicians who did not consent (19) were 
working in pharmacies located in the large districts. The refusal was due to 
busy workload and unwillingness to participate.       
The study aimed to involve at least one pharmacist, and/or pharmacy 
technician from each pharmacy and accordingly they were contacted in 
their working area. Where the two were at the same pharmacy, they 
completed the questionnaire separately.   
4.5.4 Questionnaire administration to pharmacists and pharmacy technicians 
After obtaining verbal consent, a self-administered questionnaire with 33 items 
was distributed to qualified pharmacists, pharmacy technicians working in 
community pharmacies in urban and rural districts of Ulaanbaatar, Mongolia.  
In order to improve the response rate, the survey was completed in the early 
mornings or when the participants were able to focus on the survey. No more 
than two respondents were selected from the same pharmacy and where 
there were two, they were a pharmacist and a pharmacy technician. The 
respondents filled out the questionnaire independently from each other if 
there were more than one respondent at the same pharmacy.  
4.6 Questionnaire issued to doctors  
4.6.1. Development of the questionnaires issued to doctors   
Development of the 24-item questionnaire was also informed by the 
WHO/SIGN guide(297, 298) and additional relevant questions were included. 
As recommended, self-administered questionnaires were used to elicit 
prescribing practice for tracer conditions (mild/moderate CAP), including 
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prescribing reported antibiotics and non-antibiotic medicines and 
administering injections. Also, the questions were focused on doctors’ views 
on current treatment guidelines for CAP, their experience with prescribing 
treatment with injectable medicines, attitudes and knowledge about 
injectables, patients’ expectations and demands, and the prevalence of 
counterfeit and substandard medicines in Mongolia.  
Literature that related to factors influencing injection prescribing was 
evaluated.(84, 85, 302)  Those studies highlighted the importance of 
investigating the underlying factors. Published data on prescriber’s 
perceptions about injections from other countries were conducted and a 
small study regarding doctors’ attitude toward prescribing of injections in 
Mongolia were reviewed.(301)  
4.6.2 Validation of the questionnaires for doctors 
Preliminary questionnaires were assessed in terms of readability and validity, 
by an epidemiologist with more than seven years of working experience and 
two medical experts of more than 15 years working experience. They all 
practised in Mongolia.  
Final questionnaires were piloted with three family group practitioners and two 
specialists. Following their feedback and discussion with local professionals, 
the wording and order of some the questions were modified (Appendix F ).  
4.6.3 Selection of doctors 
As recommended in the WHO guide,(298) three large districts (based on 
population size), one semi-rural district to represent the average conditions in 
the country and one rural district of Ulaanbaatar thought to be representative 
of all socioeconomic areas in Mongolia were selected.  
There are three  public central hospitals,  eight specialized centres, nine district 
hospitals, six private hospitals and 126 FGPs located in Ulaanbaatar.(303) 
Selection of health facilities was based on their location and accessibility. For 
the study, three public central hospitals in large districts, five district hospitals 
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in semi-rural districts, three private hospitals in semi-rural districts and 20 FGPs 
located in both large and semi-rural districts were selected.  
The study aimed to select at least two doctors; one general doctor and one 
specialist form each setting. Similar to the questionnaire study with 
pharmacists and pharmacy technicians, where there were two at the same 
hospital, they completed the questionnaire independently from each other.  
4.6.4 Questionnaire administration to doctors  
Doctors were randomly selected from the list of actively working employees, 
provided by human resource offices in the selected sites. 
4.7 Data analysis  
The statistical analysis was completed using the Statistical Package for Social 
Sciences (SPSS Version 21.0). Standard descriptive statistics were used to 
summarize demographic data and responses to the questionnaires 
(frequencies for categorical variables, means and standard deviations for 
variables measured on a continuous scale).  
The drugs prescribed for the diagnosis of mild/moderate CAP were analysed 
against requirements in the Standard Treatment Guidelines for mild/ 
moderate CAP (2005, 2008), the National Guidelines for Good Prescribing 
Practice of Mongolia, Australian therapeutic guidelines and WHO/IMCI 
recommendations for treatment of pneumonia in children aged less than five. 
Decisions regarding appropriateness were made separately by the 
candidate and validated by one supervisor. Differences were resolved by 
consensus. Differences in prescribing practices between adults and children 
and urban and rural areas were tested for statistical significance using the Chi-
square statistic and Fisher’s Exact’s test.   
Questions regarding the frequency of dispensed/prescribed medicines for 
treatment of CAP were identified using a five-point Likert scale ranging from 
never to always. The responses were condensed into three categories 
(never/rarely, sometimes, and often/always).  Those responses gauged using 
Likert scales ranged from strongly agree to strongly disagree were formed into 
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two groups, strongly agree/agree, and disagree/strongly disagree. The Likert 
scale responses were coded from one to five. For the Likert scales, the mean 
values were used to compare the differences between the groups. Other 
questions were coded as 1- Yes, 2- Sometimes, 3 – No.  
The mean values of responses measured on a Likert scale can be assumed as 
normally distributed, as the number of samples were large (>30) in each group 
(community members-474, pharmacy and pharmacy technicians-61, 
doctors-71) (Central Limit Theorem).(304) In addition, appropriate frequencies 
were provided for each category on the response forms.  
Logistic regression analysis was applied in order to perform comparisons of 
binary dependent variables (for example: yes/no) across different groups, 
whereas dependant variables with more than two categories were 
compared by one-way analysis of variance, ANOVA or Kruskal-Wallis test for 
independence. The differences between individual groups were identified 
performing a Tukey’s HSD (honestly significant difference) Post Hoc Test or 
Pairwise comparisons. A p value of < .05 was considered to be statistically 
significant.   
Cronbach’s coefficient alpha was used for internal consistency of the 
questions regarding community members’ reasons to refuse injections, 
influencing factors of injections issued to doctors and pharmacists.   
4.8 Ethical considerations and confidentiality 
The study protocol was approved by the Human Research Ethics Committee, 
Curtin University, Western Australia (PH-11-2010). As advised by the Human 
Ethics Committee, MoH of Mongolia, a local ethical approval was not 
required in addition to the Curtin approval.  
All participants were informed on the nature of the study, its length and their 
right to withdraw (Appendix D ). Informed consent was sought for 
participation (Appendix D ). Personal details were removed from the data 
collection forms upon the completion of the data collection and were 
replaced with an appropriate numeric code. In accordance with NHMRC 
(National Health & Medical Research Committee) requirements on “data 
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storage and retention”, only de-identified data were stored in a locked 
cupboard in the School of Pharmacy; the electronic version of data was 
stored in a password protected computer where only the researcher had 
access to. No individual patient data were published. At the completion of 
the study all data will be archived for a minimum of five years.  
No monetary incentives or prizes were offered or distributed throughout the 
study.         
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Chapter	5 Results	of	an	evaluation	of	prescribing	practices	for	
mild/moderate	CAP	in	Mongolia		
This section provides results from the prescription study. Prescriptions submitted 
to community pharmacies in Mongolia with a diagnosis of mild/moderate 
CAP written on the prescription by doctors were collected prospectively and 
sequentially.  
Firstly, the chapter describes the selection and characteristics of participants 
and continues with the prescribing pattern of doctors. Thereafter, the 
frequency analysis of inappropriate prescribing using the Mongolian Standard 
Treatment Guidelines (STG) for mild/moderate CAP and the results from 
analysis of prescribing level of injections are presented. In addition, a 
comparative analysis using the Australian therapeutic guidelines and 
WHO/IMCI guidelines for treatment of non-severe pneumonia is presented. 
Finally, the overall results from the prescription study are summarized.   
5.1. Selection and characteristics of participants 
The study enrolled 394 (193 adults and 201 children) participants who were 
diagnosed with mild/moderate CAP. The prescriptions represented the 
prescribing practices of 118 doctors.  
Table 5.1 shows the demographic characteristics of participants. Adults 
(48.9%) and children (51.0%) were almost equally represented, with a median 
age for children of 2.0 years (range: 0.03-12) and adults of 33.0 years (range: 
13-92). The proportions of adults (48.9%) and children (51.0%) were almost 
equally represented.  
Table 5.1 Demographic characteristics of participants 
Characteristics Number 
n (%) 
Gender 
(male) 
n (%) 
Median 
age (years) 
Median 
weight (kg) 
Location 
n (%) 
Adults 193 
(48.9) 
97 (50.3) 33.0 - Urban=124 (64.2) 
Rural=69 (35.8) 
Children 201 
(51.)) 
98 (48.8) 2.0 13.7 Urban=111 (55.2) 
Rural=90 (44.8) 
Total 394 (100) 
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5.2 Prescribing pattern of doctors  
A total of 1100 drugs were prescribed for the 394 participants, with the most 
commonly prescribed being aminopenicillins (10.4% for adults and 18.3% for 
children), followed by vitamins, mucolytics (bromhexine), ciprofloxacin and 
paracetamol (Table 5.2).  
Table 5.2 Most commonly prescribed drugs for patients with mild/moderate 
CAP 
Drug name 
Prescribed frequency 
(N=1100) 
Percentage 
(%) 
ATC Code 
Aminopenicillins 163 16.0 J01CA 
Vitamin C 67 8.8 A11GA01 
Bromhexine (Mucolyitic) 62 5.6 R05CB02 
Paracetamol 57 3.5 N02BE01 
Ciprofloxacin 52 4.7 J01MA02 
Salbutamol 37 3.4 R03CC02 
Erythromycin 36 3.3 J01FA01 
Cotrimoxazole 34 2.7 J01EE01 
Ketotifen (Antihistamine) 33 3.0 R06AX17 
Calcium gluconate 32 2.9 A12AA03 
Cefazoline 31 2.8 J01DB04 
Sodium chloride 31 2.8 A12CA01 
Chlorpheniramine 29 2.6 R06AB04 
Chitamona 23 2.1 Herbal 
Vitamin B Complex 17 1.6 A11EA 
a Local product containing Glycyrrhiza uralensis Fisch, Thermopsis dahurica Czefr.  
There was a low level of poly-pharmacy with the median number of drugs 
being three per prescription. There was no significant difference in the number 
of drugs prescribed for adults and children χ2[(1, n=749) =0.24 p = .63] or in 
urban and rural locations,  χ2[(1, n=745) =0.001, p = .98] (Table 5.3). 
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Table 5.3 Number of drugs prescribed per prescription 
Category 
Adults Children 
Urban Rural Urban Rural 
No. of patients 124 69 111 90 
No. of prescribed drugs 368 188 301 243 
Min 1.00 1.00 1.00 1.00 
Median 3.00 3.00 3.00 3.00 
Max 7.00 6.00 7.00 6.00 
Mean 2.99 2.72 2.71 2.73 
Std Dev 1.20 0.87 1.12 0.91 
p valuea  = .63 = .98 
a p-value was calculated based on number of adults and children and number of 
drugs in urban or rural.  
 
The number of antibiotics prescribed per prescription ranged from zero to 
three and most prescriptions included at least one antibiotic (93.4%). Doctors 
tended to prescribe more than one antibiotic for adults in urban areas. More 
detailed results by urban and rural areas are presented in Table 5.4. 
Table 5.4 Number of antibiotics prescribed for children and adults 
Number of 
antibiotics per 
prescription  
Adults Children 
Urban 
n (%) 
Rural 
n (%) 
Urban 
n (%) 
Rural 
n (%) 
0 3 (6.5) 3 (4.3) 15 (13.5) 5 (5.6) 
1 24 (52.2) 57 (82.6) 92 (82.9) 73 (82.0) 
2 16 (34.8) 8 (11.6) 4 (3.6) 10 (11.2) 
3 3 (6.5) 1 (1.5) - 1 (1.2) 
 
5.3 Frequency of inappropriate prescribing, using Mongolian standard 
treatment guidelines for mild/moderate CAP   
The overall level of inappropriate prescribing for all patients based upon the 
Mongolian STGs was 845 (84.0%) (Figure 5.1). A total of 95 were not assessable 
because of a lack of information about drug selection, dosage form, dose, 
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frequency and duration in the current guidelines for children aged between 
6 to 15 years.  
 
 
  
Figure 5.1 Appropriateness level of prescribing for patients with mild/moderate 
CAP 
The evaluation of prescribing practices of antibiotics and non-antibiotics for 
children and adults with mild/ moderate CAP indicated that 54.7% of all 
prescribed antibiotics were appropriately prescribed for children under five 
years (86/157) and 53.1% for adults (35/66).  
Table 5.5 Appropriateness of antibiotic use prescribed for children and adults  
Variables  Children, n (%) Adults, n (%)  
Appropriate 86 (54.5)  35 (53.1) 
Not appropriate 71 (45.5) 31 (46.9) 
 
The assessment of non-antibiotics revealed similar findings, with only 33.2% of 
prescribed items for children and 47.1% for adults being appropriate. (Table 
5.6).    
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Table 5.6 Appropriateness of non-antibiotic medicines prescribed for 
children and adults  
Variables  Children, n(%) Adults, n(%) 
Appropriate 97 (33.2) 231(47.1) 
Not appropriate 195 (66.8) 259(52.9) 
 
The assessment was carried out by sequential elimination of selection dosage 
form, dose and frequency of administration in the order shown in Table 5.7 
and Table 5.8.  The duration of an antibiotic course could not be included due 
to lacking information in the Mongolian guidelines. A drug was classified as 
“inappropriate” if one or more indicators were inappropriate for each 
prescribed item. The assessment was based on a cascading effect, for 
example. If the first indicator was “inappropriate”, then the prescription item 
classification was “inappropriate” and this drug was excluded from further 
analysis and would not appear in the second indicator. 
A chi-squared analysis showed a statistically significant difference between 
inappropriate prescribing for adults and children, χ2[(1, n=1100) =22.8, p = 
<.001]. Relatively more adults were prescribed inappropriate drugs, largely as 
a result of the dosage frequency prescribed. 
Table 5.7 Assessment of prescriptions for children with mild/moderate CAP* 
Category 
Drug 
selection  
n (%) 
Dosage form  
n (%) 
Dose  
n (%) 
Frequency  
n (%) 
Final result  
n (%) 
A 195 (43.4) 171 (87.7) 102 (59.6) 99 (97.1) 99 (22.1) 
IA 254 (56.6) 24 (12.3)a (see below) 3 (2.9) 350 (78.0) 
OPD - - 1 (0.6) - - 
UPD - - 68 (39.8) - - 
NAI 95 95 95 95 95 
Total 
assessable 
449 195 171 102 449 
Total  544 290 266 197 544 
A- Appropriate, IA- Inappropriate, NAI- No assessable guideline information,  
OPD- Overprescribed dose, UPD- Under prescribed dose  
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a Includes the number of appropriately selected drugs from the previous column.  
* If the first indicator was “inappropriate”, then the prescription item classification was 
“inappropriate” and this drug was excluded from further analysis and would not 
appear in the second indicator.  
 
Table 5.8 Assessment of the prescriptions for adults with mild/moderate CAP 
Category 
Drug selection  
n (%) 
Dosage form  
n (%) 
Dose  
n (%) 
Frequency  
n (%) 
Final 
result  
n (%) 
A 235 (42.3) 192 (81.7) 120 (62.5) 61 (50.8) 61 (11.0) 
IA 321 (57.7) 43 (18.3)a (see below) 59 (49.2) 
495 
(89.0) 
OPD - - 18 (9.4) - - 
UPD - - 54 (28.1) - - 
Total 556 235 192 120 556 
A- Appropriate, IA- Inappropriate,  OPD- Overprescribed dose, UPD- Under 
prescribed dose  
a Includes the number of appropriately selected drugs in inappropriate dosage 
forms only.  
Inappropriate drug selection was the major reason for inappropriate 
prescribing for patients with CAP, with the extent of inappropriate drug 
selection similar for children (56.6%) and adults (57.7%). Doctors in urban areas 
prescribed a higher frequency of inappropriate drugs than those in rural areas 
for the population studied, χ2 [(1, n=575) =10.25, p =.0014] (Figure 5.2).  
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Figure 5.2 Inappropriate levels of drug selection for adults and children with 
mild/moderate CAP in urban and rural areas 
5.4 Prescribing level of injectables  
The proportion of drugs prescribed as injections was 28.4% for adults (n=556) 
and 9.0% for children (n=544). The proportion of encounters with at least one 
injection prescribed was 29.3%, and it was greater for adults (42.7%) than for 
children (16.5%).  
Prescribing of injectables was significantly higher for adults in urban areas 
compared with rural areas χ2[(1, n=556)=21.7, p = <.001], but the difference 
between urban and rural prescribing of injectables was not significant for 
children (Table 5.9). In the case of antibiotics, the proportion of injectables 
prescribed was 34.7% in the urban (83/239) and 18.5% in rural areas (31/168). 
Since the guideline for ambulatory care does not allow any use of injectables 
for outpatients with moderate/mild CAP,(305) this finding for injectables is non-
compliant with the prescribing standards in Mongolia.(295) Moreover, it is 
noted that gentamicin is recommended for the treatment of mild/moderate 
CAP for children and it was prescribed for outpatients with mild/moderate 
CAP. However, this is available only as injectable, so the guideline of 
ambulatory care is non-compliant with the Mongolian prescribing standard.   
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Table 5.9 Proportion of prescribed injectables for participants with 
mild/moderate CAP 
Category No. of injectables  
n (%) 
No. of non-
injectables n (%) 
Total p 
Value  
Urban adults 128 (23.0) 240 (43.2) 368 
< .001 
Rural adults 30 (5.4) 158 (28.4) 188 
Urban children 32 (5.9) 269 (49.4) 301 
.141 
Rural children 17 (3.1) 226 (41.5) 243 
 
5.5 Frequency of inappropriate prescribing based upon Australian therapeutic 
guidelines for treatment of mild/moderate CAP   
The results of the assessment of prescription categories for patients with 
mild/moderate CAP based on an application of Australian therapeutic 
guidelines(142) are shown for children and adults, respectively (Table 5.9 and 
Table 5.11).   
Table 5.10 Assessment of the prescriptions for children with mild/moderate 
CAP, compared against Australian therapeutic guidelines* 
Category Drug 
selection  
n (%) 
Dosage 
form  
n (%) 
Dose  
n (%) 
Frequency  
n (%) 
Prescribed 
duration 
n(%) 
Final 
result  
n (%) 
A 141 
(25.9) 
125  
(88.7) 
64  
(51.2) 
49  
(76.6) 
48  
(98.0) 
48 
(8.82) 
IA 403  
(74.1) 
16  
(11.3)a 
- 15  
(23.4) 
1  
(2.0) 
496 
(91.2) 
OPD - - 24 (19.2) - - - 
UPD - - 37 (29.6) - - - 
Total  544 141 125 64 49 544 
A- Appropriate, IA- Inappropriate, OPD- Overprescribed dose, UPD- Under 
prescribed dose  
a  Includes the number of appropriately selected drugs with inappropriate dosage 
form 
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* If the first indicator was “inappropriate”, then the prescription item classification was 
“inappropriate” and this drug was excluded from further analysis and would not 
appear in the second indicator.  
 
A chi-squared analysis showed a statistically non-significant difference 
between inappropriate prescribing for adults and children, χ2[(1, n=1100,) 
=0.012, p = .91] (with Yates correction). Similar scores were obtained for 
inappropriate prescribing for both adults and children.  
Inappropriate drug selection was the major reason for inappropriate 
prescribing for patients with CAP, with the extent of inappropriate drug 
selection being lower for children (74.1%) compared to adults (82.2%).  
Table 5.11 Assessment of the prescriptions for adults with mild/moderate CAP, 
compared against Australian guidelines* 
Category Drug 
selection  
n (%) 
Dosage 
form  
n (%) 
Dose  
n (%) 
Frequency  
n (%) 
Prescribed 
duration    
n (%) 
Final 
result  
n (%) 
A 99  
(17.8) 
75  
(75.8) 
65 (86.7) 55  
(84.6) 
47 
(85.5) 
47 
(8.5) 
IA 457  
(82.2) 
24  
(24.2) 
- 10  
(15.4) 
8  
(14.5) 
509 
(91.5) 
OPD - - 5 (6.7) - - - 
UPD - - 5 (6.7) - - - 
Total  556 99 75 66 56 556 
A- Appropriate, IA- Inappropriate, OPD- Overprescribed dose, UPD- Under prescribed 
dose  
*If the first indicator was “inappropriate”, then the prescription item classification was 
“inappropriate” and this drug was excluded from further analysis and would not 
appear in the second indicator.  
Doctors in urban areas prescribed more inappropriate drugs than those in rural 
areas for the population studied, χ2 [(1, n=860) =10.77, p = .001] (Figure 5.3).  
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Figure 5.3 Inappropriateness level of drug selection for patients with CAP in 
urban and rural areas compared against Australian guidelines 
5.6. Frequency of inappropriate prescribing by comparing against Integrated 
Management of Childhood Illness (IMCI) guidelines for pneumonia in 
children   
The assessment using IMCI guidelines(150) included a total of 544 drugs, 
prescribed for children. Of all of these, one hundred were not assessable due 
to a lack of information in the guideline regarding the children aged 6 to 15 
years. Therefore, these drugs were excluded from the final analysis. The overall 
inappropriateness level of assessable drugs prescribed for children was 90.3% 
(Figure 5.4). 
 
  
Figure 5.4 Appropriateness level of prescribing for children with 
mild/moderate CAP, compared against IMCI guidelines 
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Inappropriate drug selection was the major reason (77.9%) for inappropriate 
prescribing for children with CAP compared against IMCI guidelines (Table 
5.12).   
Table 5.12 Assessment of the prescriptions for children with mild/moderate 
CAP, compared against IMCI guidelines 
Category Drug 
selection  
n (%) 
Dosage 
form  
n (%) 
Dose  
n (%) 
Frequency  
n (%) 
Prescribed 
duration 
n (%) 
Final 
result  
n (%) 
A 98 (22.1) 97 (21.8) 56 (12.6) 46 (10.4) 43 (9.7) 43 
(9.7) 
IA 346 (77.9) 1 (0.2) - 10 (2.3) 3 (0.7) 401 
(90.3) 
OPD - - 13 (2.9) - - - 
UPD - - 28 (6.3) - - - 
NAI 100     100 
(18.4) 
Total 
assessable 
444 98 97 56 46 444 
Total  544 98 97 56 46 544 
A- Appropriate, IA- Inappropriate, NAI- No assessable guideline information, OPD- 
Overprescribed dose, UPD- Under prescribed dose  
* If the first indicator was “inappropriate”, then the prescription item classification was 
“inappropriate” and this drug was excluded from further analysis and would not 
appear in the second indicator.  
 
In terms of the extent of inappropriate drug selection, it was greater for 
patients (85.7%) in urban areas compared to rural areas (67.7%). Doctors in 
urban areas prescribed more inappropriate drugs than those in rural areas 
studied applying IMCI guidelines, χ2 [(1, n=444) =19.51, p < .001] (Figure 5.5).  
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Figure 5.5 Inappropriateness levels of drug selection for children with 
mild/moderate CAP in urban and rural areas, compared against IMCI 
guidelines 
5.7 Summary of the results of the evaluation of prescribing practices for 
mild/moderate CAP in Mongolia  
The prescription analysis indicated that a wide range of antibiotics and non-
antibiotic medicines were prescribed for the treatment of mild/moderate 
pneumonia in Mongolia. The most commonly prescribed drugs were 
aminopenicillins, vitamins, and mucolytics, with the median number of drugs 
being three per prescription. When the evaluation was compared against 
Mongolian standards the level of inappropriate drug selection was similar for 
adults (57.7%) and children (56.6%), and was the major reason for the overall 
frequency of inappropriate prescribing for adults (89.0%) and children (78.0%). 
Doctors in urban areas prescribed more inappropriate drugs than those in rural 
areas for both children and adults χ2 [(1, n=575) =10.25, p =.0014].  
Moreover, a non-compliance with Mongolian guidelines was found in relation 
to the prescribing practice of injections for non-hospitalized patients. The 
proportion of prescribed injections was 28.4% for adults and 9.0% for children, 
and for adults, it was significantly higher in urban areas. The prescribing 
standard for non-hospitalized patients in Mongolia states that injections should 
not be prescribed. This is at variance with current guidelines.   
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The assessment of prescriptions for adults with mild/moderate CAP, compared 
against Australian guidelines revealed that a similar extent of inappropriate 
medicines was prescribed for adults (91.5%) when compared with results of 
the assessment of prescriptions using Mongolian standards (89.0%). Also, the 
prescribing practice of inappropriate drugs for children was higher using 
Australian guidelines (91.2%) than Mongolian standards (78.0%). Similar to the 
results using the Mongolian standards, doctors in urban areas selected more 
inappropriate drugs compared to their counterparts in rural areas χ2 [(1, 
n=860) =10.77, p = .001].   
A higher extent of inappropriateness was found in the evaluation of 
prescribing practices for treatment of CAP in children aged two months to 59 
months using the WHO/IMCI guidelines. The total inappropriateness level of 
assessable drugs prescribed for children was 90.3%. 
Overall, the main reason for inappropriate prescribing was inappropriate drug 
selection when a comparison made against three guidelines.  
Again a similar result was obtained from the evaluation using the Mongolian 
standards in relation to different prescribing practices between doctors in 
urban and rural areas of Mongolia. Doctors in urban areas prescribed more 
inappropriate drugs when compared to their counterparts in rural areas when 
WHO/IMCI guidelines were applied χ2 [(1, n=444) =19.51, p < .001].   
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Chapter	6 Results	of	the	questionnaire	studies	with	community	
members,	doctors,	pharmacists,	including	pharmacy	
technicians			
An important finding from the prescription study was the high level of 
prescribing of injectable medicines for the treatment of CAP. The prescribing 
of injections for ambulatory outpatients at family group practices is not 
allowed under the Mongolian regulation. This chapter investigates this 
question of prescribing injectables further by reporting the results of  
questionnaires administered to community members, pharmacists, including 
pharmacy technicians and doctors that investigated treatment practices 
and experiences and the extent of and factors influencing injection practices 
in Mongolia.  
6.1 Results of a questionnaire issued to community members  
Section 6.1 provides information about community members’ characteristics, 
their experiences and views about their recent consultation and previous 
ones; self-care practices; for example self-diagnosis and self-request for 
medications, expectations for the consultation, satisfaction, injections, 
attitude towards and knowledge about antibiotics in Mongolia.  
6.1.1 Demographic characteristics of respondents  
Six hundred community members aged over 18 years were contacted at 
various locations (pharmacies, shopping centres, hospitals and universities) in 
Ulaanbaatar, Mongolia. The response rate of usable questionnaires was 79%. 
Non-respondents included people who refused to participate when asked 
and those who agreed but were unable to complete the questionnaire. 
Almost half of respondents were aged between 31 and 50 (n=228, 48.1%), 
40.9% of respondents were male (n=194), and the average income was 
US$154-230 (range: 201,000-300,000 MNT) per month (n=99, 20.9%). The details 
of the respondents are provided in Table 6.1. In addition, for comparison 
purposes, census data are provided for Mongolia.      
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Table 6.1 Demographic characteristics of respondents 
Variables Study 
N=474, n (%) 
Census data of  
Mongolia, 2011  
p Value  
 
Age (years) 
 20-30 
 31-50 
 ≥51 
 
198 (41.8) 
228 (48.1) 
48 (10.1%) 
 
586,302 (35.6) 
746,834 (45.3) 
315,188 (19.1) 
< .0001 
Gender:  
 Male 
 Female 
 
194 (40.9) 
280 (59.1) 
 
937,271 (49.2) 
968,698 (50.8) 
.0003 
Marital status:  
Single 
Married 
Divorced 
Separated 
Widowed 
 
148 (31.2) 
250 (52.7) 
30 (6.3) 
25 (5.3) 
21 (4.4) 
  
344,679 (20.9) 
1,140,111(69.2) 
35,329 (2.1) 
23,576 (1.4) 
104,629 (6.3) 
< .0001 
Education:  
Higher 
Secondary 
Primary 
Other 
       
       116 (24.5) 
238 (50.2) 
98 (20.7) 
22 (4.6) 
     
392,572 (20.6) 
869,240 (45.6) 
562,485 (29.5) 
81,672 (4.3) 
.0004 
Occupation:  
Employed 
Unemployed 
Civil servant 
Student a 
Military servant 
 
247 (52.1) 
58 (12.2) 
66 (13.9) 
74 (15.6) 
29 (6.1) 
 
911,664 (84.7) 
164,116 (15.3) 
- 
300,494 (36.2) 
- 
.0994 
Income (MNT) c:  
<90,000 
91,000-200,000  
201,000-300,000 
301,000-400,000 
401,000-500,000 
>501,000 
 
83 (17.5) 
77 (16.2) 
99 (20.9) 
90 (19.0) 
68 (14.3) 
57 (12.0) 
379.400 b 
 
 
 
- 
a Economically non active population  
b Average income in 2011 in Mongolia 2 
c MNT- Mongolian National Tugrug  
- No data were available  
 
 
A comparison of the sample of community members with population data 
indicated statistically significant differences with respondents being younger 
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and the sample comprising more females, more singles and separated 
people and having higher education levels than the Mongolian population.    
6.1.2 Demographic characteristics of respondents by location 
The distribution of respondents according to location is outlined in Table 6.2. 
Most respondents were from the Ulaanbaatar city region (n=407, 85.7%) where 
the survey was administered, Respondents from Ulaanbaatar city region, 
when compared with those from rural areas, tended to be older, more were 
female, fewer were employed, more were students, and incomes were 
higher.  
A comparison with the Mongolian population showed statistically significant 
differences in the demographic characteristics of respondents for both 
Ulaanbaatar city region and rural areas. Respondents from Ulaanbaatar city 
region tended to be younger than their counterparts in the general 
population, relatively more were female, and more were divorced or 
separated. Respondents from rural areas also tended to be younger than their 
counterparts but relatively more were male, had higher education levels, and 
were single, separated or divorced.  
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Table 6.2 Demographic characteristics of respondents, by location 
Variable Ulaanbaatar Rural 
Study 
n (%) 
Census^ 
n (%) 
p-value Study 
 n (%) 
Census 
n (%) 
p-value 
Age (years) 
 20-30 
 31-50 
 ≥51 
 
156 (38.3) 
209 (51.4) 
42 (10.3) 
 
424,856 (37.2) 
503,368 (44.0) 
215.121 (18.8) 
< .0001 
 
42 (62.7) 
19 (28.4) 
6 (10.0) 
 
161,446 (31.9) 
243,433 (48.2) 
100.067 (19.8) 
< .0001 
Gender 
 Male 
 Female 
 
152 (37.3) 
255 (62.7) 
 
636,955 (47.8) 
694,724 (52.2) 
< .0001 
 
42 (62.7) 
25 (37.3) 
 
300,316 (52.3) 
273,974 (47.7) 
.0885 
Marital status  
Single  
Married 
Divorced 
Separated  
Widowed  
 
124 (30.5) 
216 (53.1) 
28 (6.9) 
20 (4.9) 
19 (4.7) 
 
436,974 (33.0) 
774,705(58.2) 
18,517 (1.4) 
28, 896 (2.2) 
69,587 (5.2) 
< .0001 
 
24 (35.8) 
34 (50.7) 
2 (3.0) 
5 (7.5) 
2 (3.0) 
 
156,111 (27.2) 
371,533 (64.7) 
5,143 (0.9) 
6,451 (1.1) 
35,052 (6.1) 
< .0001 
Education 
Higher 
Secondary 
Primary 
Other 
 
104 (25.6) 
196 (48.6) 
85 (20.9) 
20 (4.9) 
 
345,655 (25.9) 
687,547 (51.6) 
271,231 (20.4) 
27,246 (2.0) 
.0006 
 
13 (19.4) 
40 (49.7) 
12 (17.9) 
2 (3.0) 
 
46,917 (8.2) 
181,693(31.6) 
291,254 (50.7) 
54,426 (9.5) 
< .0001 
Occupation 
Employed 
Unemployed 
Civil servant 
Student* 
Military servant 
 
205 (50.4) 
49 (12.0) 
59 (14.5) 
70 (17.2) 
24 (5.9) 
 
556,602 (61.0) 
108,171 (11.9) 
- 
247,017 (27.1) 
- 
 
.034 
 
42 ( 62.7) 
9 (13.4) 
7 (10.4) 
4 (6.0) 
5 (7.5) 
 
355,062 (76.4) 
55,945 (12.0) 
- 
53,477 (11.5) 
- 
0.4251 
Income (MNT):  
<90,000 
91,000-200,000 
201,000-300,000 
301,000-400,000 
401,000-500,000 
>501,000 
 
74 (18.2) 
60 (14.7) 
78 (19.2) 
80 (19.7) 
64 (15.7) 
51 (12.5) 
 
 
 
379,400 a - 
 
9 (13.4) 
17 (25.5) 
21 (31.3) 
10 (14.9) 
4 (6.0) 
6 (9.0) 
 
 
 
379,400 a - 
a Average income in 2011 
- No data were available  
6.1.3 Injection exposure  
Data on the nature and prevalence of injection use were collected from 
community members as a part of the questionnaire. Questions regarding the 
extent of injection use revealed that all respondents had received at least one 
injection in the past and 56.6% had received an injection in the past twelve 
months (Table 6.3).  
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Table 6.3 Time since respondents had received an injection 
Period Number of respondents, n (%) 
<1 month 97 (20.5) 
1-6 months 91 (19.2) 
6-12 months 80 (16.9) 
>1 year 206 (43.5) 
Total 474 (100) 
 
The most common reason for having an injection was reported to be for 
treatment of a disease (n=358, 61%), for administration of vitamins (n=166, 
26%), and some had injections for vaccinations and contraception (Figure 
6.1). 
 
 
Figure 6.1 Patients’ stated reasons for being given an injection 
To further explore the extent of received injections, the respondents were 
asked to indicate the number of injections they had for their last treatment. Of 
the 358 participants, who had injections for  treatment of a disease, almost 
80% had between one and four injections and almost 14% reported more than 
five injections. A single injection was usually given for immunization and always 
for contraception (Table 6.4).   
 
358( 61%)
69 (11%)
12 (2%)
166 (26%)
Disease
Vaccination
Contraception (female
only)
Others: vitamin etc.
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Table 6.4 Reason and number of injections received for that treatment 
Reason of injection/ Number of 
injectionsa 
One 
(%) 
2-4 
n (%) 
5-8 
n (%) 
>8 
n (%) 
Disease (N=358) 36.3 47.7 9.2 6.7 
Vaccination (N=69) 86.9 11.6 0 1.4 
Contraception (N=12) 12 - - - 
Others: vitamins, etc. (N=165) 32.1 54.5 9.7 3.6 
a Respondents could select more than one option  
6.1.4 Quality of care  
Questions concerning the reasons for receiving an injection were proffered 
and results are summarized with regards to major illnesses and the type of 
parenteral administration. The frequency analysis of injections indicated that 
the administration of contraception and vaccinations were appropriately 
administered with a single injection (Table 6.5). 
Table 6.5 Reasons and type of injections received 
Reason for injection a Single injection(s) 
n (%) 
Continuous drip  
n (%) 
Disease 301 (59.4) 206 (40.6) 
Vaccination 67 (95.7) 3 (4.3) 
Contraception (females only) 12 (100) - 
Others: vitamins, etc. 113 (50.2) 112 (49.8) 
a Respondents could choose more than one option 
Injections were commonly reported for management of symptoms of 
weakness, respiratory symptoms, which included cough, sore throat or 
pneumonia. A little less than half of respondents (46%) had multiple single 
injections for their last treatment. Of these 196 (41.4%) were continued on oral 
medicines that were similar to the injection medication.   
In terms of using new clean needles and syringes, a majority was aware of 
these requirements and only 39 respondents (8.2%) said they did not know.  
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Questions regarding unwanted effects of injections were presented and 
about 20% had one of the proffered side effects after previous injections.  
Similar proportions experienced a swollen or hard lump under the skin (n=26, 
28.6%) and a warm feeling under the skin (n=23, 25.2%). Less common were 
extravasation and an experience of fainting after having an injection (Table 
6.6).  
Table 6.6 Distribution of side effects experienced after getting an injection  
Description  Proportion of respondents,  
N=91(%) 
Swollen or hard lump under skin 26 (28.6) 
Warm feeling under the skin 23 (25.2) 
Persistent pain under injected area 12 (13.2) 
Weak feeling after the injection 11 (12.1) 
Fever caused by injection 9 (9.9) 
Persistent redness 4 (4.4) 
Extravasation  3 (3.3) 
Fainted   3 (3.3)  
 
When presented with reasons regarding side effects, several possible 
explanations were put forward in the questionnaire. About one-third (34.1%) 
did not know that these effects could occur whereas others attributed them 
to the injection or the injection techniques employed (Figure 6.2).  
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Figure 6.2 Possible reasons for side effects occurring after getting an injection 
Regarding the actions undertaken after experiencing side effects (Figure 6.3), 
some respondents consulted a doctor (n=30, 32.9%) and others went to 
hospital (n=15, 16.7%) or consulted a pharmacist (n=6, 6.3%). However, almost 
one-half respondents did not do anything (n=40, 44.0%), which may be due 
to respondents not recognizing that those symptoms were side effects related 
to an injection or considering them minor.  
 
Figure 6.3 Actions undertaken after experiencing a side effect to an injection 
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6.1.5 Characteristics of prescribers, providers and administrators of 
injectables  
6.1.5.1 Injection prescribers  
Participants were asked about prescribers and providers of therapeutic 
injections to gain an insight to this practice. The main prescribers were doctors 
(75%), who are formal prescribers which was compliant with the current 
guidelines(305) (Table 6.7). Other practitioners were less frequently sought for 
prescribing of injections.  
Table 6.7 Prescribers of injections 
Category a Yes  
n (%) 
Sometimes 
n(%) 
Doctor 353 (74.9) 75 (15.9) 
Pharmacist 24 (5.1) 79 (16.7) 
Nurse 30 (6.4) 66 (14.0) 
Traditional practitioner 35 (7.4) 64 (13.6) 
a Some responses were missing for each category 
 
6.1.5.2 Injection providers 
Of the 474 respondents, most obtained their injections on prescription or 
received over-the-counter injectables from pharmacists (60%). Detailed 
results are summarized in Table 6.8.  
Table 6.8 Practitioners who supplied or dispensed injections for community 
respondents  
Category a Yes  
n (%) 
Sometimes 
n (%) 
Doctor 118 (25.0) 69 (14.6) 
Pharmacist 283 (59.7) 71 (15.0) 
Nurse 21 (4.4) 54 (11.4) 
Traditional practitioner 31 (6.5) 50 (10.6) 
a Some responses were missing for each category 
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Demographic differences were found among the respondents agreeing with 
pharmacists dispensing or providing injections. There was a significant 
difference between respondents with different educational level,  [Kruskal-
Wallis test, H = 9.51, df=3, p =.023]. In particular respondents with tertiary 
education (Group 3: M =1.53, SD = 0.82) were more likely to respond that 
injections were dispensed or provided with or without a prescription by 
pharmacists than those respondents with primary education (Group 1: [M = 
1.86, SD =  0.93], p = .006).  
Additionally, about 25% of respondents indicated doctors as dispensers or 
suppliers of injections (this includes people who were severely ill and received 
an injection from a doctor at inpatient settings). Respondents from urban 
compared with those from rural areas did not support doctors providing 
injections [Kruskal-Wallis test, H=14.4, df=1, p < .001]. Pairwise comparisons 
indicated a significant difference between doctors providing injections across 
respondents with different marital status [H=10.3, df=4, p = .036] and pairwise 
comparisons indicated single respondents (Group 1: [M = 2.16, SD = .93] were 
more likely to accept injections provided from doctors than married people 
(Group 2: [M = 2.46, SD = .79]), p = .002.  
As shown in Table 6.8, seventy-five respondents stated that injections were 
provided by nurses. In this case, widowed people (Group 5: [M = 2.47, SD = .75 
] were more likely to accept injectables from nurses than single (Group 1: [M 
= 2.82, SD = .46], p = .004, or married people (Group 2: [M = 2.83, SD = .45]) p 
= .003.    
6.1.5.3 Administration of therapeutic injections  
In compliance with guidelines,(305) most respondents chose nurses as the 
main health professional for the administration of injections, followed by 
doctors. When comparing responses across different groups, administration of 
injections by nurses were more likely to have been to the older age group 
(more than 51 years) (Group 3: [M = 1.35, SD = .67]) than younger ones (range: 
20-30 years) (Group 1: [M = 1.8, SD = 0.9]) and Tukey’s HSD demonstrated a 
significant result (p = .003).  
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Of all respondents, about seventeen people stated traditional practitioners as 
the administrators of injections and one-way ANOVA showed significant 
difference across respondents with different marital status [F (4, 467) = 3.6, p = 
.006]. Similar to injection providers, widowed people (Group 5: [M = 2.47, SD = 
0.6]) tended to agree with traditional practitioners being an administrator of 
injections compared with single (Group 1: [M = 2.88, SD = .42]) or married 
respondents (Group 2: [M = 2.79, SD = 0.49]) (p = .003, p = .028).    
About 15% of respondents reported that injections were administered by 
friends or relatives (Figure 6.4).  
 
 
Figure 6.4 Distribution of individuals who administer injections 
6.1.6 Respondents’ attitude towards therapeutic injectable medicines 
When presented with questions regarding their attitude towards injections, 
only seventy-seven respondents had the likelihood of receiving injections in 
their mind when they visited a doctor (16.2%). A significant difference was 
found using Kruskal-Wallis test of expecting an injection across respondents in 
different age groups [H=6.1, df=2, p = .048], with respondents aged over 51 
(Group 3; [M = 2.08, SD = 0.85]) being more supportive of the statement than 
younger ones (range: 20-30 years) (Group 1: [M = 2.39, SD = 0.69]), p  =0.018 
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Respondents indicated their perception that doctors prescribed (n=137, 
29.0%) injections. However, about 9% of respondents desired an injection 
being prescribed (n=41, 8.7%). Statistically significant differences were found 
between desiring an injection across respondents’ age groups, with younger 
respondents being more likely to reject the statement (Table 6.9).  
Table 6.9 Relationship between desiring an injection from a doctor across 
different age groups 
Category Age level with significant difference  
Kruskal-
Wallis 
Sig. Pairwise comparison between 
groups 
M (SD) a M (SD) 
Desire for an 
injection   
≥51 years versus 20-30 years 
2.4 (0.8) 
2.7 (0.6) .008 
≥51 years versus 31-50 years 2.7 (0.6) .02 
a Answers were coded from 1 to 3, with ‘Yes’  being 1 and ‘No’ being 3.   
 
When asked their opinion about therapeutic injectables, 40% of all 
respondents agreed that injections were a better medicine (n=190) than oral 
medications, with significantly more older respondents tending to agree with 
this [F (2, 471) = 9.13, p < .001].   
Moreover, when participants were asked for their opinions regarding 
treatment with injectable medicines, a number of aspects were proffered and 
detailed results are summarized in Table 6.10.  
An important perception regarding injections was that they hasten the 
recovery process (n=269, 56.8%). Older respondents (over 51 years) agreed 
with this statement relatively more when compared with respondents aged 
less than 51 years [F (2, 471) = 7.87, p < .001]. Similarly, widowed respondents 
agreed more with this statement [F (4, 471) = 6.93, p < .001] (Group 5: [M = 
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1.09, SD = 0.3]) when compared to single (Group 1: [M= 1.76, SD = .74]) or 
separated respondents (Group 4: [M = 1.72, SD = .84]).      
Table 6.10 Reasons to prefer injection 
Explanations a Yes 
 n (%) 
Sometimes 
n (%) 
No 
n (%) 
An injection helps to recover  faster       269 (56.8) 143 (30.2) 62 (13.1) 
An injection costs less  72 (15.2) 111 (23.4) 291 (61.4) 
I prefer having an injection, because 
I forget to take medicine   
126 (26.6) 108 (22.8) 240 (50.6) 
When doctor prescribes tablets/ 
capsules, the treatment is more 
effective  
79 (16.7) 201 (42.4) 194 (40.9) 
My friends, relatives recommend me 
to have an injection  
106 (22.4) 129 (27.2) 239 (50.4) 
Medical companies advertise 
injections                                 
103 (21.7) 118 (24.9) 253 (53.4) 
Having an injection is a personal 
preference 
22 (4.6) 60 (12.7) 392 (82.7) 
a Some responses were missing for each category 
However, less than half of respondents disagreed that the treatment with oral 
medication was more effective than injectables (n=194, 40.9%). In general, 
most respondents did not support the statement that treatment cost was less 
with injections (61.4%) with younger respondents significantly stronger in their 
disagreement than respondents older than 51 years [F (2, 471) = 7.43, p = .001].  
Having an injection was not a personal preference for most respondents 
(82.7%). When comparing responses, respondents with other or no formal 
education were more likely to agree with having an injection as a personal 
preference when compared with respondents with primary or secondary 
education, however this was not statistically significant [Kruskal-Wallis test, 
H=6.1, df=3, p  = .107] (Table 6.11).  
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Table 6.11 Relationship between likelihood of having an injection as a 
personal preference across respondents with different education levels 
Variable  Yes/Sometimes  
n (%) 
p value a  
Primary 3 (13.6)/10 (16.7) 
.107 
Secondary 6 (27.3)/33 (55.0) 
Tertiary  9 (40.9)/14 (23.3) 
Other 4 (18.2)/3 (5.0) 
a p value is estimated by performing Kruskal-Wallis test   
Purchasing injections 
When purchasing injections several key matters were identified. The price of 
the injection and whether it was imported or a local product was of a less 
importance when getting an injection. On the other hand, people were more 
concerned about the importance of complete package (61.9%) and the 
expiry date of the injection (85.2%) (Figure 6.5).  
 
Figure 6.5 Important matters identified by a majority of respondents when 
purchasing an injection 
If an injection was not prescribed, only 69 respondents (14.6%) said they would 
be disappointed and statistical differences were found using Kruskal-Wallis test 
across different groups (Table 6.12).  
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Table 6.12 Relationship between being disappointed if injection was not 
prescribed by age and income group 
Variable  Yes/Sometimes  
n (%) 
p a   
Age 
20-30 
31-50 
≥51 
 
20 (10.1)/37 (18.7) 
35 (15.4)/38 (16.7) 
14 (29.2)/16 (33.3) 
< .001  
Income (MNT) 
≤90,000 
91,000-200,000 
201,000-300,000 
301,000-400,000 
401,000-500,000 
≥501,000 
 
13 (15.7)/13(15.7) 
21 (27.3)/15 (19.5) 
13 (13.1)/19 (19.2) 
12 (13.3)/17 (18.9) 
7 (10.3)/14 (20.6) 
3 (5.3)/13 (22.8) 
 
.071 
a p values are estimated by performing Kruskal-Wallis test   
Pairwise comparisons showed older respondents (Group 3: [M = 2.08, SD = .82]) 
were more likely to be disappointed if an injection was not received (Kruskal-
Wallis test, H=20.8, df=2, p < .001).  
The questionnaire also asked about respondents’ practice of refusing 
therapeutic injections and 39.4% respondents answered they would refuse an 
injection. Several reasons were proffered for refusing or rejecting injectable 
medicines (Table 6.13). A reliability analysis showed that all items for refusing 
an injectable appeared to have good internal consistency, Cronbach’s 
α=0.78.  
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Table 6.13 Reasons for refusal if injection was prescribed/ supplied 
Reasons a Yes 
n (%) 
Sometimes 
n (%) 
No 
n (%) 
I am scared of pain  138 (29.2) 82 (17.4) 252 (53.4) 
I am scared of needle and injection    180 (38.1) 86 (18.2) 206 (43.6) 
I do not trust the doctors and 
pharmacists   
46 (9.7) 141 (29.9) 285 (60.4) 
It is possible to recover without any kind 
of injection 
119 (25.2) 151 (32.0) 202 (42.8) 
There are lots of dosage forms, e.g. 
tablets, capsules are available for 
many diseases 
129 (27.3) 126 (26.7) 217 (46.0) 
After sometime disease cures by itself    
48 (10.2) 124 (26.3) 300 (63.6) 
There was no clean needle and syringe 21 (4.4) 29 (6.1) 422 (89.4) 
Others 126 (26.8) 52 (11.0) 293 (62.2) 
a Some responses were missing for each category 
Of the participants, 22 men (11.3% of male cohort) and 19 women (6.8% of 
female cohort) had refused injections in the past. As data in Table 6.13 
demonstrate, the main reason for refusal was being scared of needles and 
injections (n=180, 38.1%) and acknowledging the availability of other dosage 
forms than injections.  
In particular, respondents aged between 20 and 30 years stated being scared 
(Group 1: [M = 2.14, SD= .89], p = .013) compared with those aged ≥51 (Group 
3: [M = 2.54, SD = .74]). Similarly, younger respondents were likely to accept 
that other dosage forms, including tablets, capsules etc. were available 
[Kruskal-Wallis test, H=12.1, df=2, p = .002].  
In general, most respondents did not have trust issues with their doctors and 
pharmacists. In addition, most did not support that after a period of time a 
disease would be cured by itself (63.6%).  
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6.1.7 Cost of injections  
The cost of injections was estimated from the payment during their last visit at 
the doctor and whether they paid any fees for the purchase and 
administration of an injection. The respondents paid approximately 
US$14.3(median US$13.8) for visiting a doctor, US$12.6(median US$11.5) for 
purchasing an injection, and US$4.6 (median US$3.3) for the administration of 
injection. Comparing these fees with the average income in Mongolia at that 
time (US$291 per month), these are high prices to pay, however, most 
respondents reported the fees paid for visiting the doctor, for purchasing 
medicine from pharmacy and for the administration of injections was 
affordable. 
6.1.8 Counterfeit medicines in Mongolia  
When asked about knowledge about counterfeit medicines in Mongolia, the 
majority of respondents reported that they were aware about its existence 
(66.5%). Comparing the type of counterfeit medicines, counterfeit/ 
substandard antibiotics were slightly more prevalent (59.4%), than non-
antibiotic medicines (49.2%).  
6.1.9 Summary of findings of the questionnaire study with community 
members  
The questionnaire study with community members in Mongolia investigated 
their experiences, views and attitudes towards injection practices relevant to 
the treatment of CAP.  
The results showed that all respondents had received at least one injection in 
past years and 56.6% had received an injection in the past twelve months. The 
most common reason for having an injection was reported to be for treatment 
of a disease (61%) or for administration of vitamins (26%). 
In terms of injection prescribers and providers, participants indicated that the 
main prescribers were doctors (75%), who are formal prescribers which was 
compliant with the current guidelines. Other practitioners were rarely sought 
for prescribing of injections. Of the 474 respondents, most obtained on 
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prescription or received OTC injectables from pharmacists (60%). In 
compliance with guidelines, most respondents chose nurses as the main 
health professional for the administration of injections, followed by doctors. A 
small number of respondents chose informal injection administers, such as 
friends or relatives for administration of injections (15%).  
Attitude towards injections was assessed and a minority respondents had the 
likelihood of receiving injections in their mind when they visited a doctor 
(16.2%), in particular a statistically significant difference was observed for older 
respondents when compared with those aged less than 51 years. 
Respondents indicated their perception that doctors prescribed injections 
(29.0%). At the same time, about 9% of respondents did not desire an injection 
being prescribed. Also, statistically significant differences were found 
between desiring an injection across respondents’ age groups, with younger 
respondents being more likely to reject the statement. Similarly, of those who 
would be disappointed if an injection was not prescribed or provided, older 
respondents were more likely to be disappointed if an injection was not 
received. When asked about their opinion about therapeutic injectables, 40% 
of all respondents agreed that injections were a better medicine than oral 
medications. And significantly, older respondents tended to agree with this. 
Moreover, when participants were asked for their opinions regarding the 
effect and quality of injectable medicines and the main belief in injections 
was explained by the reason that it hastens the recovery process (56.8%). 
Older respondents tended to agree more with a faster recovery from 
injections. However, less than one-half disagreed that the treatment with oral 
medication was more effective than injectables (n=194, 40.9%). Having an 
injection was not a personal preference to most respondents (82.7%). The 
study indicated that most respondents did not have trust issues with their 
doctors and pharmacists.  
Assessment of safe injection practice indicated positive findings: a majority 
was aware of using new syringe and needles for every injection administration.  
The majority was aware about the existence of counterfeit and substandard 
medicines (66.5%) and respondents indicated that the prevalence of 
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counterfeit/substandard antibiotics was slightly more (59.4%) than non-
antibiotic medicines (49.2%) in Mongolia.  
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6. 2 Results of a questionnaire issued to pharmacists and pharmacy 
technicians 
This section provides results of the questionnaire study with pharmacists and 
pharmacy technicians with regards to their practice of dispensing and 
prescribing antibiotics for the treatment of CAP in Mongolia and to investigate 
the underlying factors that impact on dispensing, and prescribing practices 
and administering of therapeutic injections in Mongolia.  
6.2.1 Respondents’ characteristics  
Of eighty distributed questionnaires, 61 were returned yielding a usable 
response rate of 76.3%. The majority of respondents were females (77.0%), and 
most of the respondents were aged between 31 and 50 years. This indicates 
the current gender distribution of Mongolia with most pharmacists being 
female (92.9%).(4) A little over half of the respondents were pharmacists 
(55.7%), and most respondents had been working for one to five years (65.6%) 
(Table 6.14).  
Table 6.14 Demographic characteristics of respondents 
Variable (N=61)a Category n (%) 
Age (years) 20-30 
31-50 
≥51 
22 (36.1) 
23 (37.7) 
16 (26.2) 
Gender Male  
Female  
14 (23.0) 
47 (77.0) 
Pharmacy ownership  Owner 
Employee  
12 (19.7) 
49 (80.3) 
Professional level Pharmacist 
Pharmacy technician  
34 (55.7) 
27 (44.3) 
Years of working experience 1-5 
6-10 
≥11 
40 (65.6) 
11 (18.0) 
10 (16.4) 
Income (MNT) 90.000-200.000 
201.000-300.000 
301.000-400.000 
≥401.000 
9 (15.0) 
13 (21.7) 
23 (38.3) 
15 (25.0) 
a Some responses were missing for each category 
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6.2.2 Dispensing practice with prescriptions for CAP  
Participants were asked about their dispensing practice in relation to 
prescribed medicines for treatment of CAP. The dispensing practices of more 
than one antibiotic prescribed by physicians was examined using a five-point 
Likert scale which ranged from never to always and the responses were 
reduced to three categories, never/rarely, sometimes and often/always. As 
shown in Table 6.15, 80% of respondents reported they dispensed more than 
one antibiotic sometimes with almost one-quarter reporting they do so 
frequently.  
Table 6.15 Frequency of dispensing practice of more than one antibiotic 
prescribed for treatment of CAP 
Never/Rarely a 
n (%) 
Sometimes 
n (%) 
Often/Always 
n (%) 
12 (20.0) 34 (56.7) 14 (23.3) 
a Likert scale answers were coded from 1 to 5, with ‘Never’ being 1 and           
‘Always’ being 
6.2.3 Factors influencing dispensing practice of prescribed medicines  
When presented with questions regarding the respondents’ dispensing 
practice of prescribed medicines, a number of contexts were identified, such 
as pharmacist’s opinion on the importance of treatment guidelines, 
government control on dispensing practice, patient’s condition and the price 
of medication.  
Characteristics that influenced respondents’ practices in dispensing 
prescriptions for CAP included reimbursable drugs from the Essential Drug List 
of Mongolia (EDLM) which are subsidized and usually generic medicines, 
making it cheaper to patients, patient’s severity, children and adults’ 
treatment, dosage form, duration and cost of prescribed medicines. These 
data together with other characteristics are presented in Table 6.16. 
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Table 6.16 Characteristics influencing practices of respondents dispensing 
prescribed medicines for patients with CAP 
Characteristic a 
SA/A 
n (%) 
D/SD/N 
n (%) 
Selection of reimbursable generic drugs via EDLM 
(concession rates)        
43 (71.7) 17 (28.3) 
Appropriate children’s treatment (dosage adjustment) 50 (84.7) 9 (15.3) 
Appropriate adults treatment (dosage adjustment) 43 (72.9) 16 (27.1) 
Patient’s severity  45 (76.3) 14 (23.7) 
Duration of treatment of medicines in the prescription 46 (78.0) 13 (22.0) 
Knowledge of adverse effects of drugs (e.g. drug allergies) 40 (65.6) 19 (32.2) 
Legislative documents, such as standard on prescribing 
and dispensing practice of Mongolia  
31 (52.5) 28 (47.5) 
Guidelines for treatment of CAP  34 (58.6) 24 (41.4) 
Patient’s compliance with treatment  39 (66.1) 20 (33.9) 
Patient is not satisfied with the treatment if injection is not 
prescribed 
35 (59.3) 24 (40.7) 
Ability of patient to buy prescription medicines without 
prescription 
39 (66.1) 20 (33.9) 
The price is important when dispensing generic and brand 
medicines   
45 (76.3) 14 (23.7) 
Expiry date of medicine  38 (64.4) 21 (35.6) 
Practice to re-use medicines  29 (49.2) 30 (50.8) 
SA- Strongly agree, A-Agree, D- Disagree, SD- Strongly disagree, N-Neutral  
a Some responses were missing for each category 
 
Most respondents agreed that patient’s severity had an influence on their 
dispensing practice (76.3%).  
Logistic regression was performed to assess the impact of a number of factors 
on the likelihood that respondents would agree that patient’s ability to buy 
medicines without a prescription had an influence on their dispensing 
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practice for CAP. The model contained five independent variables (age, 
gender, pharmacy ownership, and pharmacist versus pharmacy technician 
and working years). The full model containing all predictors was statistically 
significant χ2 (5, N=59)=19.05. p = .004, indicating that the model was able to 
distinguish between respondents who supported and did not support the 
statement. The model as a whole explained between 27.6% (Cox and Shell R 
square) and 38.2% (Nagelkerke R square) of the variance in the statement, 
and correctly classified 78% of cases. As shown in Table 6.16, only three of the 
independent variables made a unique statistically significant contribution to 
the model (gender, pharmacists versus pharmacy technicians and working 
years). Males were less likely than females to agree that patient’s ability to buy 
medicines had an influence on their dispensing practice and it was just 
significant (p= .044). Similarly, pharmacy technicians were less likely than 
pharmacists to agree with the statement (p = .008), as were respondents with 
more than 11 years of working experience (p = .019) (Table 6.17). 
Table 6.17 Logistic regression predicting likelihood of agreeing that patient’s 
ability to buy medicines influenced the dispensing practice 
Independent 
variables a 
n/N (,%) 
A/SA  
p Odds ratio (OR) 95.0% CI for OR 
Lower Upper 
Age - .14 .53 .22 1.24 
Gender 
Male 
Female  
 
8/14 (57.1) 
31/45 (68.9) 
.044 6.6 1.05 40.74 
Ownership  
Owner  
Employee 
 
7/11 (63.6) 
32/48 (66.7) 
.16 .22 .03 1.82 
Profession 
Pharmacist Pharmacy 
technician 
 
27/33 (81.8) 
12/26 (46.2) 
.008 .14 .03 .59 
Working years 
1-5 
6-10 
≥11 
 
29/39 (74.4) 
6/10 (60.0) 
4/10 (40.0) 
 
- 
.06 
.019 
 
- 
.15 
.09 
 
- 
.02 
.01 
 
- 
1.04 
.67 
Constant - .024 162.27 - - 
A-Agree, SA- Strongly agree 
a Some responses were missing for each category 
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The likelihood of agreeing that the practice to re-use medicines was an 
important factor when dispensing was also tested by performing a logistic 
regression model with the five independent variables and found to be 
statistically significant χ2 (5, N=59)=18.64. p = .002. Pharmacy technicians were 
less likely to agree with the practice of re-using medicines than pharmacists 
(p = .001) and female respondents were six times more likely to agree with this 
practice when compared with males (p = .039) (Table 6.18).   
Table 6.18 Logistic regression predicting likelihood of agree with the practice 
to re-use medicines 
Independent 
variables a 
n/N (,%) 
A/SA  
p Odds ratio 
(OR) 
95.0% CI for OR 
Lower Upper 
Age - .42 1.39 .62 3.16 
Gender 
Male 
Female  
 
4/14 (28.6) 
25/45 (55.6) 
.039 6.19 1.09 35.02 
Ownership  
Owner  
Employee 
 
4/11 (36.4) 
25/48 (52.1) 
.65 .66 .11 4.02 
Profession 
Pharmacist 
Pharmacy 
technician 
 
23/33 (69.7) 
6/26 (23.1) 
.001 .09 .02 .35 
Working years - .63 .81 .35 .189 
Constant - .98 1.05 - - 
A-Agree, SA- Strongly agree 
a Some responses were missing for each category 
 
6.2.4 Changing the prescribed treatment for mild/ moderate CAP 
Of sixty one respondents, 70% had to change the prescription for treatment of 
CAP sometimes or always because the prescribed treatment was 
inappropriate. Distribution of responses is presented in  Table 6.19.     
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Table 6.19 Frequency of respondents’ practice of changing prescribed 
treatment for CAP 
Never/Rarely 
n (%) 
Sometimes 
n (%) 
Often/Always 
n (%) 
 18 (30.0) 33 (55.0) 9 (15.0) 
 
Pharmacists were significantly more likely to change prescriptions for CAP 
when compared with pharmacy technicians [t (59) = 2.55, p = .013](Figure 
6.6). 
 
Figure 6.6 Frequency of prescriptions that were changed by a pharmacist/ 
pharmacy technicians 
6.2.5 Duration of prescribed drugs for treatment of CAP  
To assess the knowledge of respondents with regards to the duration of 
prescribed medicines, including an injectable, respondents were asked to 
identify the extent to which they agreed with the proposed extent of duration. 
The extent of duration started from less than three days to more than five days 
for duration of both oral and injectable medicines prescribed for the 
treatment of CAP. Regarding the conversion time from parenteral to oral 
antibiotic after commencing the treatment, four options were proposed, 
starting from within 24 hours to more than five days.  
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Of 61 respondents, 60.7% reported that the duration of treatment with 
prescribed injections was more than five days. Also, most respondents 
reported the same duration for oral antibiotics (68.9%). A majority of 
respondents indicated that the conversion from parenteral to oral antibiotic 
strongly depended on a patient’s improvement and the highest proportion 
(44.3%) answered more than five days after commencing treatment (27/61), 
followed by three days 37.7% (23/61).  
6.2.6 Types of dispensed antibiotics for CAP with prescription 
The dispensed frequencies of prescribed antibiotics and other drugs were 
identified using 5-point Likert scales ranging from never, sometimes to always. 
Subsequently, the responses were collapsed into three categories and the 
details are shown in the Table 6.20 and Table 6.21. Commonly dispensed 
antibiotics with prescriptions were oral and injectable penicillins with 
extended spectrum and oral sulfonamides. Oral macrolides were dispensed 
more frequently than injetactables whereas in contrast, injectable quinolones 
and injectable cephalosporins were more frequently dispensed than oral 
forms (Table 6.20).   
Table 6.20 Antibiotics dispensed with prescription for treatment of CAP 
ATC classification a  
 
Never/Rarely 
n(%) 
Sometimes 
n(%) 
Often/Always 
n(%) 
Penicillin, oral 48 (78.7) 8 (13.1) 5 (8.2) 
Penicillin, injection 35 (57.4) 17 (27.9) 9 (14.8) 
Penicillin with extended spectrum, oral 22 (18.0) 36 (29.5) 64 (52.5) 
Penicillin with extended spectrum, injection  20 (16.4) 34 (27.9) 68 (55.7) 
Combination of penicillin, oral 7 (11.5) 26 (42.6) 28 (45.9) 
Quinolone, oral 53 (43.4) 28 (23.0) 41 (33.6) 
Quinolone, injection 13 (21.3) 14 (23.0) 34 (55.7) 
Cefalosporin, oral 16 (26.2) 15 (24.6) 30 (49.2) 
Cefalosporin, injection 7 (1.5) 8 (13.1) 46 (75.4) 
Macrolides, oral 40 (21.9) 50 (27.3) 93 (50.8) 
Macrolides, injection 131 (71.6) 26 (14.2) 26 (14.2) 
Tetracycline, oral 103 (84.4) 16 (13.1) 3 (2.5) 
Sulfonamid, oral 18 (29.5) 19 (31.1) 24 (39.3) 
a Some responses were missing for each category 
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Other medicines dispensed with a prescription for treatment of CAP included 
mucolytics, vitamins and antihistamines (Table 6.21). Additionally, injectable 
corticosteroids and injectable xanthines were frequently dispensed non-
antibiotics.  
Table 6.21 Non-antibiotic medicines dispensed with prescription for treatment 
of CAP 
Other medicines a   Never/Rarely 
n(%) 
Sometimes  
n(%) 
Often/Always 
n(%) 
Corticosteroid, oral 31 (50.8) 19 (31.1) 11 (18.0) 
Corticosteroid, injection 19 (31.1) 24 (39.3) 18 (29.5) 
Mucolytics, oral 4 (6.6) 26 (42.6) 31 (50.8) 
Vitamin, oral 31 (26.1) 42 (35.3) 46 (38.7) 
Vitamin, injection 88 (49.4) 56 (31.5) 34 (19.1) 
Antihistamin, oral 58 (48.7) 36 (30.3) 25 (21.0) 
Antihistamin, injection  37 (62.7) 15 (25.4) 7 (11.9) 
Xanthin, oral 18 (30.0) 25 (41.7) 17 (28.3) 
Xanthin, injection 27 (45.8) 19 (32.2) 13 (22.0) 
Pyrazolone, oral 45 (76.3) 7 (11.9) 7 (11.9) 
Pyrazolone, injection 44 (75.9) 9 (15.5) 5 (8.6) 
a Some responses were missing for each category 
6.2.7 Dispensing practice of drugs issued without prescription for patients with 
CAP  
6.2.7.1 Influencing factors of dispensing practice of non- prescribed drugs for 
treatment of CAP 
According to the current regulation, only qualified medical doctors can 
prescribe medicines to patients.(305) However, the practice of providing non-
prescribed medicines, including injections  is commonly observed in 
Mongolian pharmacies.(35, 301) Therefore, respondents were asked to 
indicate the extent to which they agreed with issues that influenced their 
 122 
 
dispensing practice of medicines without prescriptions (Table 6.22) and all 
their responses had a good internal consistency (Cronbach’s α=0.76).  
The questionnaire raised issues related to providing non-prescribed injectable 
medicines and it was commonly reported that injectables were provided if 
patients had severe CAP (79.3%) and to achieve better patient’s compliance 
with treatment (68.4%).    
Amongst respondents, a fairly high proportion (69%) specified that the clinical 
effect of injections was more than oral medicines (40/61), however no 
significant relationship was observed between pharmacists and pharmacy 
technicians [t (56) = .52, p = .603].  Additionally, the proportion of pharmacists 
supporting the idea that medication outcome from injections was better than 
tablets or capsules tended to be greater (62.5%) than pharmacy technicians 
(53.8%), yet, it was not statistically significant: [t (56)= .66, p = .514]   
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Table 6.22 Characteristics that influence practice of providing drugs without 
prescriptions 
Characteristic a SA/A 
n (%) 
D/SD/N 
n (%) 
The clinical effect of injections is more potent than oral 
medicines’  
40 (69.0) 18 (31.0) 
The quality of injections better than tablets/ capsules   34 (58.6) 24 (41.4) 
The adverse events occur with oral drugs more than with 
injections  
16 (27.6) 42 (72.4) 
The dosage form of injection is chosen for better compliance 
of a patient  
39 (68.4) 18 (31.6) 
The injection requires new syringes and needles  48 (82.8) 10 (17.2) 
There is no benefit for the transfer of patient with pneumonia 
from injection to oral medicines   
22 (37.9) 36 (62.1) 
Training promotes more about treatment with an injection 
than oral medicines     
12 (20.7) 46 (79.3) 
There is lot of advertisement about injection by drug 
companies   
11 (19.0) 47 (81.0) 
Prefer to dispense newly distributed medicines in the market  39 (67.2) 19 (32.8) 
Cost of treatment by oral medicines is more than the 
treatment cost with injections (including cost of syringes and 
needles) 
21 (36.2) 37 (63.8) 
If patients are prescribed an injection, they are required to 
visit a pharmacy several times  
23 (39.7) 35 (60.3) 
Better patient compliance is achieved by choosing an 
injection  
32 (55.2) 26 (44.8) 
Patient prefer to use tablets rather than injection  17 (29.3) 41 (70.7) 
When dispensing injection, patient’s age, gender are 
important  
44 (75.9) 14 (24.1) 
Injection is chosen if patient had severe CAP 46 (79.3)  12 (20.7) 
SA- Strongly agree, A-Agree, D- Disagree, SD- Strongly disagree, N-Neutral  
a Some responses were missing for each category 
Moreover, a majority of respondents did not support that there were frequent 
advertisements about injectables by drug companies (47[81.0%]). The impact 
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of factors on the likelihood that respondents disagreed with the statement 
that there is a lot advertisements about injections by pharmaceutical 
companies more than oral medicines was tested using logistic regression. The 
model contained two independent variables (pharmacy owners or 
employees; pharmacists or pharmacy technicians). The model was 
statistically significant [χ2 (2, N=58)=6.3. p = .043], indicating that the model 
was able to distinguish between respondents who supported and did not 
support the statement (Table 6.22). Employees were less supportive of the 
statement regarding advertisements than owners who are pharmacists only 
(p = .034) (Table 6.23).  Pharmacists in comparison to pharmacy technicians 
were also less supportive of the statement that there were lots of injections 
advertised by the companies; however it was not statistically significant.  
Table 6.23 Logistic regression predicting the likelihood of agreeing that there 
are a lot of advertisements about injections by pharmaceutical companies 
Independent 
variables a 
n/N (,%) 
A/SA  
P Odds ratio 
(OR) 
95.0% CI for OR 
Lower Upper 
Ownership  
Owner  
Employee 
 
5/11 (45.5) 
6/47 (12.8) 
.034 .2 .05 .89 
Profession 
Pharmacist 
Pharmacy 
technician 
 
4/32 (12.5) 
7/26 (26.9) 
.32 2.08 0.49 8.68 
Constant - .31 .25 - - 
A-Agree, SA- Strongly agree 
a Some responses were missing for each category 
Of 61 respondents, 36 (62.1%) disagreed that there was no benefit for the 
patient with CAP to transfer from injection to oral medicines. Logistic 
regression analysis was performed and a model containing three 
independent variables (pharmacy ownership, pharmacist or pharmacy 
technician and working years) was able to distinguish statistically significant 
differences, [χ2 (3, N=58)=9.17, p = .027]. The only variable that had a 
statistically significant independent effect was ownership, with employees 
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being less likely to agree that the cost of treatment by oral medication was 
more than with injections (p = .029).  
Table 6.24 Logistic regression predicting the likelihood of agreeing with the 
cost of oral medicines being higher than cost of injections 
Independent 
variables a 
n/N (,%) 
A/SA 
P Odds ratio 
(OR) 
95.0% CI for OR 
Lower Upper 
Ownership  
Owner  
Employee 
 
7/11 (63.6) 
14 (29.8) 
.029 .173 .036 .839 
Profession 
Pharmacist 
Pharmacy 
technician 
 
10/32 (31.2) 
11/26 (42.3) 
 
.48 1.54 .47 5.03 
Working years 
1-5 
6-10 
>11  
 
29/39 (74.4) 
3/9 (33.3) 
7/10 (70.0) 
.053 .39 .15 1.01 
Constant - .372 5.7 - - 
A-Agree, SA- Strongly agree 
a Some responses were missing for each category 
A practice of providing newly marketed medicines without prescription was 
preferred by most respondents (67.2%) and about 70% did not support that 
adverse effects occurred more with oral medications than with therapeutic 
injectables. Most respondents supported that an injection requires new 
syringes and new needles (82.8%).  
6.2.7.2 Dispensing practice of antibiotics without prescription 
Respondents were asked about their practice of providing antibiotics without 
a prescription. Most never or rarely dispensed medicines without a prescription 
(65.0%); on the other hand 13 (21.7%) respondents dispensed non-prescribed 
antibiotics sometimes. Differences between the practice of providing non-
prescribed antibiotics and various groups are summarized in Table 6.25. 
Pharmacists provided more than one antibiotic to patients more frequently 
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than pharmacy technicians [t (58) = 2.26, p = .027]. However, pharmacy 
ownership did not influence this finding.  
Table 6.25 Relationship between the practices of providing non-prescribed 
antibiotics across respondents in various demographic groups 
Variable a  Never/Rarely 
n (%) 
Sometimes 
n (%) 
Often/Always 
n (%) 
p Value 
Age  
20-30 
31-50 
≥51 
 
12 (57.1) 
15 (65.2) 
12 (75.0) 
 
7 (33.3) 
4 (17.4) 
2 (12.5) 
 
2 (9.5) 
4 (17.4) 
2 (12.5) 
.847b 
Gender 
Male 
Female 
 
11 (78.6) 
28 (60.9) 
 
1 (7.1) 
12 (26.1) 
 
2 (14.3) 
6 (13.0) 
.631 
Pharmacy ownership 
Owner 
Employee 
 
10 (83.3) 
29 (60.4) 
 
- 
13 (27.1) 
 
2 (16.7) 
6 (12.5) 
.664 
Professional level 
Pharmacist  
Pharmacy technician  
 
18 (54.5) 
21 (77.8) 
 
8 (24.2) 
5 (18.5) 
 
7 (21.2) 
1 (3.7) 
.027 
Year of working 
experience 
1-5 
6-10 
>11 
 
25 (64.1) 
7 (63.6) 
7 (70.0) 
 
9 (23.1) 
2 (18.2) 
2 (20.0) 
 
5 (12.8) 
2 (18.2) 
1 (10.0) 
.883b 
Income 
91-200.000 
201.000-300.000 
301,000-400,000 
>401,000 
 
6 (66.7) 
8 (61.5) 
13 (59.1) 
11 (73.3) 
 
3 (33.3) 
3 (23.1) 
4 (18.2) 
3 (20.0) 
 
- 
2 (15.4) 
5 (22.7) 
1 (6.7) 
.456 b 
a Some responses were missing for each category 
b p value was calculated using one-way ANOVA 
6.2.7.3 Duration of non-prescribed drugs for treatment of CAP  
Further analysis regarding respondents’ practice of dispensing without 
prescription focused on the duration of oral and injectable antibiotics for CAP. 
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Most respondents indicated that the duration of dispensed non-prescribed 
antibiotics by injection was more than five days (58%), as well as the duration 
of dispensed medicine orally (70.0%).  
In contrast to the result (60.7%) regarding the conversion time from parenteral 
to oral antibiotics with prescription (more than five days), 43.3% reported that 
it was three days after commencing the treatment without prescription 
(26/61).  
6.2.7.4 Types of dispensed medicines for CAP without prescription 
The most commonly dispensed antibiotics without prescription were similar to 
those dispensed with prescription: oral and injectable penicillins with 
extended spectrum and oral sulfonamides. Additionally, non-prescribed oral 
and injectable cefalosporins were frequently dispensed. In contrast, 
tetracyclines and injectable macrolides were less frequently dispensed.  
Table 6.26 Antibiotics dispensed without prescription for treatment of CAP 
ATC classification a Never/Rarely 
n (%) 
Sometimes 
n (%) 
Often/Always 
n (%) 
Penicillin, oral 28 (45.9) 16 (26.2) 17 (27.9) 
Penicillin, injection 30 (49.2) 13 (21.3) 18 (29.5) 
Penicillin with extended spectrum, oral 31 (25.4) 34 (27.9) 57 (46.7) 
Penicillin with extended spectrum, injection  47 (38.5) 31 (25.4) 44 (36.1) 
Combination of penicillin, oral 20 (32.8) 23 (37.7) 18 (29.5) 
Quinolone, oral 67 (54.9) 30 (24.6) 25 (20.5) 
Quinolone, injection 30 (49.2) 13 (21.3) 18 (29.5) 
Cefalospin, oral 28 (45.9) 14 (23.0) 19 (31.1) 
Cefalosporin, injection 28 (45.9) 10 (16.4) 23 (37.7) 
Macrolides, oral 77 (42.1) 53 (29.0) 53 (29.0) 
Macrolides, injection 134 (73.2) 29 (15.8) 20 (10.9) 
Tetracycline, oral 91 (74.6) 19 (15.6) 12 (9.8) 
Sulfonamid, oral 17 (27.9) 18 (29.5) 26 (42.6) 
a Some responses were missing for each category 
There was no hesitancy to dispense oral or injectable non-antibiotic medicines 
without a prescription with regards to corticosteroids, pyrazolones and 
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xanthines. The most common medicines dispensed without prescription for 
treatment of CAP were oral mucolytics, vitamins and xanthines (Table 6.27).  
Table 6.27 Non-antibiotic medicines dispensed without prescription for 
treatment of CAP 
ATC classification a   Never/Rarely 
n (%) 
Sometimes  
n (%) 
Often/Always 
n (%) 
Corticosteroid, oral 35 (59.3) 16 (27.1) 8 (13.6) 
Corticosteroid, injection 28 (48.3) 24 (41.4) 6 (10.3) 
Mucolytics, oral 6 (10.0) 19 (31.7) 35 (58.3) 
Vitamin, oral 28 (23.7) 30 (25.4) 60 (50.8) 
Vitamin, injection 97 (55.1) 42 (23.9) 37 (21.0) 
Antihistamine, oral 63 (53.4) 24 (20.3) 31 (26.3) 
Antihistamine, injection 41 (70.7) 11 (19.0) 6 (10.3) 
Xanthin, oral 21 (35.0) 15 (25.0) 24 (40.0) 
Xanthin, injection 34 (57.6) 12 (20.3) 13 (22.0) 
Pyrazolone, oral 35 (60.3) 13 (22.4) 10 (17.2) 
Pyrazolone, injection 37 (63.8) 13 (22.4) 8 (13.8) 
a Some responses were missing for each category 
6.2.8 Antimicrobial resistance  
Knowledge and up-to-date information about antimicrobial resistance is 
essential to perform appropriate treatment for CAP patients. Therefore, 
questions were asked about the government’s effort to manage the use of 
antimicrobials with regards to surveillance, implementation and update of 
antibiotic policies in Mongolia.  
The results showed that the government did not frequently distribute 
antimicrobial resistance data to relevant health professionals with about one-
half of respondents (53.3%) answering that they received government 
information about antibiotic resistance only once a year (Figure 6.7).  
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Figure 6.7 Frequency of information about antimicrobial resistance from 
government 
6.2.9 Appropriateness of treatment guidelines 
Treatment guidelines are crucial for an evidence-based treatment outcome. 
The role of pharmacists and pharmacy technicians is of high importance in 
providing quality health-care services for those in need. 
In order to gain an insight into respondents’ attitudes on the current standard 
treatment guidelines for CAP in Mongolia, participants were asked to indicate 
the extent to which they agreed with their appropriateness. As the results 
showed, a majority of respondents considered that the current treatment 
guidelines for CAP were not appropriate (80%). In addition, it was common 
that they referred the patients with CAP to hospitals (73.3%).  
6.2.10 Treatment cost of CAP 
To examine the respondents’ view on the financial benefits from prescribing 
and providing injectable medicines to patients, questions were asked about 
this practice.  
As Table 6.28 shows, the views of respondents was that the people who had 
the most financial benefit from treatment with an injection were often or 
always the patients (52.5%), followed by nurses and doctors.  
8, 13.3% 5, 8.3% 4, 6.7%
11, 18.3%
32, 53.3%
never
weekly
monthly
3 times a year
once a year
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Table 6.28 Person who financially benefits from injections 
Category  Never/Rarely 
n (%) 
Sometimes 
n (%) 
Often/Always 
n (%) 
Doctor 35 (59.3) 9 (15.3) 15 (25.4) 
Pharmacist 36 (60.0) 19 (31.7) 5 (8.3) 
Patient 22 (37.3) 6 (10.2) 31 (52.5) 
Nurse 33 (54.1) 8 (13.3) 19 (31.7) 
 
Kruskal-Wallis test was performed to demonstrate variances among 
respondents. A significant relationship was found across respondents with 
different income in regards to their opinion on the various individuals who 
financially benefited most from injections. Respondents were divided into 4 
groups according to their income level (1: ≤200.000, 2: 201-300.000, 3:301-
400.000, 4:≥ 401.000 MNT) and pairwaise comparisons was employed to locate 
the differences. Respondents with lower income compared with higher 
earners reported that doctors benefited most often from prescribing injections 
(Table 6.29).   
Similarly, respondents with lower income compared with higher wage earners 
identified themselves or pharmacists as another individual benefitting from 
injections (Table 6.29).   
 
 
 
 
 
 
 131 
 
Table 6.29 Differences between income level and person who financially 
benefits from injection 
Category Income levels with significant difference Kruskal-
Wallis 
Sig. 
Pairwise comparison 
between groups 
M (SD) M (SD) M (SD) 
Doctors Group 1 versus 3 
4.1 (1.4) 
2.5 (1.1)  .003 
Group 1 versus 4  2.7 (1.0) .002 
Pharmacists Group 1 versus 2 
3.3 (1.3) 
2.4 (0.9)  .002 
Group 1 versus 3  2.3 (0.5) .012 
6.2.11 Administration of therapeutic injections for treatment of CAP  
When presented with questions regarding their practice of administering 
injections to patients, a high proportion of respondents reported they did not 
administer injections. The administration of injections is only allowed in hospital 
settings and only by qualified health personnel. This does not include 
pharmacists or pharmacy technicians.(305) However, some of the dispensers 
said that they would administer an injection if it was purchased from their 
pharmacy. Forty-four respondents (73.3%) did not charge anything for 
administering injections to patients.  
Participants were asked for their opinions about affordability of administration 
fees for the patient. Less than one-half thought that the fee of dispensed and 
administered injection was affordable to the patient.  
6.2.12 Dispensing of injectables  
When presented with questions regarding factors that have an impact on 
their dispensing practice of injectables to patients (Table 6.29), the majority of 
respondents considered obtaining their medicines from wholesaling 
companies with authorization from the Ministry of Health and use of new sterile 
syringe and needles as major factors.  
On the other hand, self-diagnosis by the patient was another noteworthy 
matter, as a majority [33 (55.9%)] of respondents indicated, it was common for 
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patients to come to the pharmacy and request injections for their self-
diagnosed symptoms. More detailed results are summarized in Table 6.30.  
Table 6.30 Characteristics influencing dispensing of injectables  
Characteristic a Never/Rarely 
n (%) 
Sometimes 
n (%) 
Often/Always 
n (%) 
Supply of injectables from 
registered and wholesaling 
companies with authorization 
2 (3.4) 4 (6.8) 53 (89.8) 
Use of sterile syringes and needles  4 (6.8) 1 (1.7) 54 (91.5) 
Completeness of injection’s 
package  
7 (11.9) 14 (23.7) 38 (64.4) 
Self-diagnosis of patient and his/her 
wishes to buy injection   
16 (27.1) 10 (16.9) 33 (55.9) 
Re-use of antibiotic 19 (32.2) 24 (40.7) 16 (27.1) 
Expired date of re-used product  17 (28.8) 8 (13.6) 34 (57.6) 
a Some responses were missing for each category 
6.2.13 Overuse of antibiotics  
Misusing or overusing antibiotics can have a number of disadvantages such 
as increased antimicrobial resistance, increased treatment cost.(306) 
Therefore, it is essential an appropriate treatment duration of antibiotics is 
prescribed to the patient.  
A majority of respondents supported that antibiotics were overused in 
Mongolia (41, 69.5%). The main reported reason for overusing antibiotics was 
the ability to purchase antibiotics from pharmacies (35, 59.3%), a significant 
difference was obtained performing a logistic regression analysis containing 
two predictors (gender, pharmacist versus pharmacy technician), [χ2 (2, 
N=59)=6.82, p = .033]. As Table 6.31 shows, only one variable made a 
statistically significant contribution to the model (pharmacist and pharmacy 
technician). This indicated that pharmacy technicians were less likely to agree 
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with patients being able to easily buy injectable antibiotics, when compared 
with pharmacists (p = .02).  
Table 6.31 Logistic regression predicting the likelihood of agreeing with 
patients being able to easily buy injectable antibiotics from pharmacies 
Independent 
variables a 
n/N (,%) 
A/SA  
P Odds ratio 
(OR) 
95.0% CI for OR 
Lower Upper 
Gender 
Male 
Female 
 
10/14 (71.4) 
25/45 (55.6) 
.287 .48 .12 1.86 
Profession 
Pharmacist 
Pharmacy 
technician 
 
24/33 (72.7) 
22/26 (42.3) 
 
.02 .27 .09 .82 
Constant - .08 10.01 - - 
A-Agree, SA- Strongly agree 
a Some responses were missing for each category 
Additionally, respondents tended to agree that the overuse of antibiotics was 
related to a strong public desire for therapeutic injectables including 
antibiotic injections (36, 61.0%). On the other hand, most respondents were 
reluctant to support that there was insufficient government control for retail 
sales of antibiotics (34, 57.6%). 
6.2.14 Injection safety  
Most of the surveyed participants were aware of safe practices relating to 
injections and similar scores were provided for never keeping the syringes for 
reuse (93.2%) and never reusing the needle and syringe after sterilization 
(89.8%) and always using it once and destroyed it (80.0%). After administering 
an intravenous drip, respondents rarely kept the remaining volume of injection 
for the next use (90.0%), or used the remaining powder for the next patient 
(81.7%). Instead, most of them used the intravenous drip once and discarded 
everything (68.3%).  
Regarding the supply of injectable medicines, they were always obtained 
either from a drug wholesaler (70%) or a pharmacy (65.0%), while they were 
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rarely purchased from an agent/seller or from elsewhere, for example: 
personal importation. 
6.2.15 Counterfeit medicines in Mongolia 
According to WHO, counterfeit medicines are defined as “a medicine which 
is deliberately and fraudulently mislabeled with respect to identity and/or 
source. Counterfeiting can apply to both branded and generic products and 
counterfeit products may include products with the correct ingredients or with 
the wrong ingredients, without active ingredients, with insufficient active 
ingredients or with fake packaging”.(307)  
At the present time, about 75% of all required medications are imported in 
Mongolia and the pharmaceutical procurement sector is 100% 
privatized.(281) Respondents were concerned about counterfeit and 
substandard medicines in Mongolia (93.4%). As reported by most participants, 
counterfeit medicines were those without or with little effect, or faulty looking 
products. As shown in Figure 6.8, respondents were more concerned about 
antibiotics than other medicines.    
 
Figure 6.8 Prevalence of counterfeit and substandard medicines in Mongolia 
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It was commonly reported that respondents only purchased their medicines 
from well-known wholesaling companies because they were mainly 
concerned about the prevalent counterfeit/substandard medicines from 
unreliable providers.  
6.2.16 Summary of findings of the questionnaire study with pharmacists and 
pharmacy technicians  
This is the first study that explored pharmacists’ and pharmacy technicians’ 
practice of dispensing and prescribing medicines for the treatment of CAP 
and investigated the underlying factors that impact on dispensing, prescribing 
practices and administering of therapeutic injections in Mongolia.  
Respondents indicated that a wide range of antibiotics and non-antibiotics 
were dispensed with prescription. A similar wide range were issued without 
prescription.  
Attitude and knowledge of STGs for CAP was assessed and a majority 
considered that the STGs for CAP were not appropriate (80%). In addition, it 
was common that they referred the patients with CAP to hospitals (73.3%).  
Moreover, respondents commonly reported that injectables were provided if 
patients had severe CAP (79.3%) and to achieve better patient compliance 
with treatment (68.4%). Amongst respondents, a fairly high proportion (69%) 
specified that the clinical effect of injections was more than oral medicines. 
On the other hand, self-diagnosis by the patient was another noteworthy 
matter, as a majority (55.9%) of respondents indicated that it was common for 
patients to come to the pharmacy and request injections for their self-
diagnosed symptoms. Additionally, about 70% of respondents agreed that 
patients preferred having an injection rather than tablets or capsules.   
Despite administration of injections by pharmacists or pharmacy technicians 
not being consistent with the guidelines in Mongolia, some respondents said 
that they would administer an injection if it was purchased from their 
pharmacy. Safe injection practice was observed in the study, most 
respondents never keep the syringes for reuse (93.2%) even after sterilization 
(89.8%) and they always used it once and destroyed it (80.0%). 
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A majority of respondents agreed that antibiotics were overused in Mongolia 
(69.5%). The main reported reason of overusing antibiotics was the ability to 
purchase antibiotics from pharmacies (59.3%). Pharmacy technicians were 
less likely to agree with patients being able to easily buy injectable antibiotics, 
when compared with pharmacists (p = .02). Additionally, a strong public need 
for therapeutic injections including antibiotic injections was also evident from 
the questionnaire (61.0%). On the other hand, most respondents were 
reluctant to support that there was insufficient government control for retail 
sales of antibiotics (57.6%). Respondents were concerned about counterfeit 
and substandard medicines, in particular counterfeit antibiotics in Mongolia.  
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6.3 Results of a questionnaire issued to doctors  
This section presents data from the questionnaire study with doctors regarding 
their prescribing practice for treatment of mild/moderate CAP. This included 
prescribing antibiotics and non-antibiotic medicines and administering 
injections. Also, the questions focused on doctors’ views on current treatment 
guidelines for CAP, their experience with prescribing treatment with injectable 
medicines, attitudes and knowledge about injectables, patients’ 
expectations and demands from patients and prevalence of counterfeit and 
substandard medicines in Mongolia. 
6.3.1 Respondents’ characteristics  
The study enrolled 71 participants and the response rate was 88.8%. Of 
seventy-one participants, 83.1% were female doctors, which is comparable to 
the gender distribution of Mongolian doctors (79.1%)(4). Most respondents 
were working in public hospitals and about 70% of respondents were 
specialists. A majority was over 30 years (63.4%). Most respondents had a 
monthly income of over 300.000 MNT per month. More details are provided in 
Table 6.32.    
Table 6.32 Demographic characteristics of respondents (N=71) 
Variable a Category n (%) 
Gender Male  
Female  
12 (16.9) 
59 (83.1) 
Age (years) 20-30 
≥31 
26 (36.6) 
45 (63.4) 
Practice setting 
  
Public hospital 
Private setting (including FGPs and others) 
54 (76.1) 
17 (23.9) 
Profession General doctor  
Specialist 
22 (31.0) 
49 (69.0) 
Years of work 
experience 
1-5 
6-10 
≥11 
34 (47.9) 
12 (16.9) 
25 (35.2) 
Income (MNT) b ≤90.000-200.000 
201.000-300.000 
≥301.000-400.000 
12 (17.1) 
28 (40.0) 
30 (42.9) 
a Some responses were missing for each category 
b Mongolian National Tugrug, currency, equivalent to 1300 USD at the time of study 
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6.3.2 Prescribing characteristics for treatment of CAP 
The participants were asked to identify the factors that influence their 
prescribing practice for patients with CAP. Factors included their own 
experience (67.6%), the STGs (57.7%), information on previously used 
antibiotics bought from a pharmacy by a patient (52.1%), the availability of 
medicines (50.7%) and that the best choice is an effective antibiotic with 
proven low resistance (54.9%). Information and knowledge gained though 
continuous medical training and seminars were less likely to be considered 
(38.0%) (Table 6.33). STGs tended to be considered more by younger 
respondents than those aged over 30 years, [t (69) = 2.69, p = 0.09]. A 
significant relationship was found using a t-test, with females more frequently 
supporting the STG as an influencing factor on their prescribing practice for 
mild/moderate CAP [t (69) = -2.09, p = .039].  
Moreover, information about local antibiotic resistance (18.3%), and patient’s 
antimicrobial sensitivity data (28.2%) had a low importance when prescribing 
medicines for patients with CAP. Specialists were more concerned about 
patient antimicrobial sensitivity data when prescribing for patients with CAP 
than general doctors, and it was just significant [t (69) =-2.07, p = .042].  
On the other hand, patient demand and expectation played a minor role 
(16.9%) and reimbursable drugs from the essential drug list of Mongolia were 
also weakly highlighted (16.9%).  
Preference was given to newly marketed and broad spectrum antibiotics 
(47.9%) and information from specialists (39.4%). Medicine’s availability and 
patient’s ability to afford medicines were also taken into account when 
prescribing medicines (49.3%).  
Participants confirmed that they often had visits from pharmaceutical 
company representatives; however most of them stated that these visits did 
not have any influence on their practice. A similar number of respondents said 
they never or rarely considered benefits from drug companies. In particular, 
less female respondents were likely to accept incentives from pharmaceutical 
companies when compared with males [t (69) =-2.42, p = .018].  
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Generally, doctors tended to rely on previous experience whether it was their 
own or the patient’s (who previously had purchased and used antibiotics).  
Participants did not recognize governmental control on prescribing practice 
as a worthy consideration (22.5%) and they explained that this was mainly 
because they did not prescribe anything prohibited. Specialists were more 
likely to acknowledge governmental control as an influence on their 
prescribing practice compared with general doctors, however it was just 
statistically significant [t (69) =-2.0, (p = .049).  
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Table 6.33 Characteristics that have influenced prescribing practice for 
mild/moderate CAP 
Characteristics a Never/ 
Rarely  
n(%)  
Sometimes  
n(%) 
Often/ 
Always 
n(%) 
Patient expectation/ need  41 (57.7) 18 (25.4) 12 (16.9) 
Patient’s ability to buy medicine  11 (15.5) 25 (35.2) 35 (49.3) 
Likelihood of side effects 26 (36.6) 28 (39.4) 17 (23.9) 
Local antibiotic resistance data 40 (56.3) 18 (15.4) 13 (18.3) 
Information about patient’s antibiotic 
sensitivity   
28 (39.4) 23 (32.4) 20 (28.2) 
Information on previously used antibiotics 
bought from pharmacy by a patient   
17 (23.9) 17 (23.9) 37 (52.1) 
Reimbursable drugs of EDL         36 (50.7) 23 (32.4) 12 (16.9) 
Medicine’s availability   14 (19.7) 21 (29.6) 36 (50.7) 
The best choice is effective antibiotic 
with proven low resistance 
10 (14.1) 22 (31.0) 39 (54.9) 
Standard treatment guidelines  15 (21.1) 15 (21.1) 41 (57.7) 
Intensive training and text information 
  
23 (32.4) 21 (29.6) 27 (38.0) 
Journals, books and professional 
publications   
27 (38.0) 18 (25.4) 26 (36.6) 
Influence from co-workers, doctors and 
directors 
29 (40.8) 24 (33.8) 18 (25.4) 
Influence from specialists  19 (26.8) 24 (33.8) 28 (39.4) 
Own experience  10 (14.1) 13 (18.3) 48 (67.6) 
Government control on prescribing   35 (49.3) 20 (28.2) 16 (22.5) 
Pharmaceutical company information   26 (36.6) 30 (42.3) 15 (21.1) 
Pharmaceutical company 
representatives visit    
48 (67.6) 17 (23.9) 6 (8.5) 
Prefer to choose newly distributed brands 
in the market   
12 (16.9) 25 (35.2) 34 (47.9) 
Incentive from drug  companies  59 (83.1) 9 (12.7) 3 (4.2) 
a Some responses were missing for each category 
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6.3.3 Attitude and perception of injectable medicines for treatment of CAP   
When presented with questions regarding their choice of an injectable 
dosage form when prescribing for patients with pneumonia, key items were 
identified and results are summarized in Table 6.34.  
A similar proportion of respondents stated that injections had often or always 
better effects than oral medicines and that the quality of injections was better 
than oral medicines (43.7% and 40.8% respectively). Respondents did not 
agree that the prevalence of side effects was higher with injections than with 
oral medicines, and the cost of treatment with injections was higher than with 
oral medicines.  
Most respondents acknowledged the importance of patient characteristics 
and severity of pneumonia when choosing a medicine for them. Only eleven 
respondents indicated a frequent practice of choosing an injection to 
improve patient compliance with treatment and male respondents tended 
to agree more than females with injections improving patient compliance 
with a treatment [t (69) = 2.53, p = .014].   
Furthermore, most recognized the benefit and importance of switching from 
injections to oral treatment once the patient’s condition had improved. In 
addition, most doctors supported the statement that patients never or rarely 
preferred oral medicines than injections (42.3%) (Table 6.34).       
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Table 6.34 Important factors when choosing medicines for patients with CAP 
Factors a Never/ Rarely  
n(%) 
Sometimes 
n(%) 
Often/ Always 
n(%) 
Injection has a better effect than oral 
medicine  
16 (22.5) 24 (33.8) 31 (43.7) 
Patients prefer oral medicine than 
injection  
30 (42.3) 24 (33.8) 17 (23.9) 
The pharmaceutical quality of injection is 
better than oral medicine  
15 (21.1) 27 (38.0) 29 (40.8) 
Oral medicines have more side effects   39 (54.9) 22 (31.0) 10 (14.1) 
Cost of treatment by  injection (incl. 
syringes and needles) is more than cost of 
treatment by oral medicines 
45 (63.4) 11 (15.5) 15 (21.1) 
If patient has an injection, he/she is 
required to visit a hospital several times  
7 (9.9) 19 (26.8) 44 (62.0) 
The injection requires new sterile syringes 
and needles  
2 (2.8) 7 (9.9) 62 (87.3) 
When treating patient with pneumonia it 
is better to shift injection treatment to oral 
medicine treatment once the patient’s 
condition has improved  
9 (12.7) 23 (32.4) 39 (54.9) 
Medicine companies advertise more 
about injection treatment 
35 (49.3) 27 (38.0) 9 (12.7) 
In order to follow treatment more 
effectively by patient, injection was 
chosen     
34 (47.9) 26 (36.6) 11 (15.5) 
Trainings teach the usage of injections 
more than usage of tablets/capsules   
52 (73.2) 15 (21.1) 4 (5.6) 
The severity of pneumonia influences the 
prescribing of injection   
16 (22.5) 21 (29.6) 34 (47.9) 
Patient’s characteristics, such as age, 
gender and severity have influence on 
prescribing   
8 (11.3) 16 (22.5) 47 (66.2) 
a Some responses were missing for each category 
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6.3.4 Appropriateness of standard treatment guidelines (STG) for CAP   
Doctors were asked their opinion regarding the appropriateness of STGs of 
pneumonia in Mongolia and only twenty two (31%) respondents supported 
the appropriateness of the current treatment guidelines of pneumonia. 
Furthermore, about one-half of respondents reported that they sometimes 
have prescribed more than one antibiotic to patients with pneumonia at the 
same time (n=38, 53.5%).  
Forty-two doctors (59.2%) reported they had to change the prescribed 
antibiotic sometimes because the first chosen one showed no effect (Table 
6.35). Respondents with one to five years of working experience were less likely 
to change antibiotics for mild/ moderate CAP compared with respondents 
with more than 11 or more years of working experience, however this was not 
significant [F (2, 68) =2.56, p = .09].  
Table 6.35 Frequency of respondents’ practice of changing prescribed 
antibiotic for patients with mild/moderate CAP 
Never/Rarely 
n (%) 
Sometimes 
n (%) 
Often/ Always 
n (%) 
17 (23.9) 42 (59.2) 12 (16.9) 
 
6.3.5 Treatment practice of patients with CAP  
Respondents were asked about the duration of treatment of CAP with 
injectables and oral medicines and most agreed that treatment was more 
than five days for treatment both injections and oral medicines (56.3%, 74.6%). 
Whilst most respondents agreed that the duration to switch from treatment 
with injection to oral medicine was subject to patient’s illness characteristics 
(Table 6.36), a small proportion indicated it was less than two days (15.5%), 
whereas about 49% reported between three to five days after initial 
treatment. When presented with questions regarding their treatment practice, 
most respondents stated that they often or always send their patients 
diagnosed with CAP to hospitals (57.7%). There was no significant relationship 
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between respondents in different practice settings [t (69) =-1.03, p = .31] and 
years of working experience [F (2, 68) = .22, p = .8] with regards to referring 
patients with CAP to hospitals.  
Table 6.36 Duration of prescribed treatment for patients with mild/moderate 
CAP 
Duration Treatment with 
injection,  
n (%) 
Treatment with oral 
antibiotic,  
n (%) 
Switch from injection to 
oral antibiotic,  
n (%) 
≤ 24 hours - - 5 (7.0) 
≤3 days 5/71 (7.0) - 2 days: 6 (8.5) 
4-5 days 26 (36.6) 18 (25.4) 3-5 days: 35 (49.3) 
>5 days  40 (56.3) 53 (74.6) 25 (35.2) 
 
6.3.6 Commonly prescribed medicines for patients with CAP  
Participants were asked to identify the most commonly prescribed medicines 
for the treatment of CAP (Table 6.37 and Table 6.38).  
The most common were antibiotics such as cefalosporins, oral combination of 
penicillin, penicillins with extended spectrum, oral macrolides and oral 
sulfonamides. Injectable macrolides were not frequently prescribed nor were 
oral quinolones when compared to their injectable counterparts.  
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Table 6.37 Antibiotics prescribed for treatment of CAP 
ATC classification Never/Rarely 
n(%) 
Sometime
s n(%) 
Often/Alway
s n(%) 
Penicillin, oral 64 (90.1) 3 (4.2) 4 (5.6) 
Penicillin, injection 51 (71.8) 14 (19.7) 6 (8.5) 
Penicillin with extended spectrum, 
oral 
52 (36.6) 49 (34.5) 41 (28.9) 
Penicillin with extended spectrum, 
injection  
43 (30.3) 43 (30.3) 56 (39.4) 
Combination of penicillin, oral 12 (16.9) 28 (39.4) 31 (43.7) 
Quinolone, oral 74 (52.1) 37 (26.1) 31 (21.8) 
Quinolone, injection 18 (25.4) 26 (36.6) 27 (38.0) 
Cefalosporin, oral 22 (31.0) 22 (31.0) 27 (38.0) 
Cefalosporin, injection 6 (8.5) 20 (28.2) 45 (63.4) 
Macrolides, oral 66 (31.0) 58 (27.2) 89 (41.8) 
Macrolides, injection 145 (68.1) 42 (19.7) 26 (12.2) 
Tetracycline, oral 132 (93.0) 6 (4.2) 4 (2.8) 
Sulfonamid, oral 32 (45.1) 15 (21.1) 24 (33.8) 
 
In addition to antibiotics, other common medicines prescribed were vitamins, 
mucolytics, antihistamines and corticosteroids. On the other hand, xanthins 
and pyrazolones were never or rarely prescribed. When comparing the 
frequency of prescribing of oral medicines and injections, doctors were more 
likely to report that they prescribed more oral medicines than injectables for 
patients with CAP, for example a little less than half of respondents prescribed 
oral vitamins often or always, whereas only 26% prescribed vitamin injection 
(Table 6.38). 
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Table 6.38 Non-antibiotic medicines prescribed for treatment of CAP 
Other medicines Never/Rarely 
n(%) 
Sometimes 
n(%) 
Often/Always 
n(%) 
Corticosteroid, oral 44 (62.0) 16 (22.5) 11 (15.5) 
Corticosteroid, injection 40 (56.3) 17 (23.9) 14 (19.7) 
Mucolytics, oral 15 (21.1) 19 (26.8) 37 (52.1) 
Vitamin, oral 30 (21.1) 54 (38.0) 58 (40.8) 
Vitamin, injection 80 (37.6) 78 (36.6) 55 (25.8) 
Antihistamin, oral 74 (52.1) 43 (30.3) 25 (17.6) 
Antihistamin, injection  49 (69.0) 17 (23.9) 5 (7.0) 
Xanthin, oral 30 (42.3) 27 (38.0) 14 (19.7) 
Xanthin, injection 34 (47.9) 23 (32.4) 14 (19.7) 
Pyrazolone, oral 59 (83.1) 11 (15.5) 1 (1.4) 
Pyrazolone, injection 51 (71.8) 17 (23.9) 3 (4.2) 
 
6.3.7 Patients’ history prior to consulting a doctor 
Respondents were asked where patients obtained or bought antibiotics from 
prior to consulting with them (Figure 6.9). The main source of antibiotics without 
a prescription was from a pharmacy (n=61, 87.1%) and only a small proportion 
were obtained from other sources such as their relatives or friends (n=8, 11.3%).   
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Figure 6.9 Source of obtaining antibiotics prior visiting doctor 
Respondents were asked their opinions regarding the use of antibiotics in 
Mongolia and to suggest possible explanations. Fifty-nine respondents agreed 
that antibiotics were overused in Mongolia (83.1%). Older respondents were 
more likely to disagree that antibiotics were overused, however this 
relationship was not significant [t (69) =2.24, p = .82].  
The majority of respondents agreed that governmental control of medicines 
was insufficient (76.1%). A statistically significant difference was found using 
binary logistic regression with a model containing three independent 
variables (gender, general doctors versus specialists and working years), χ2(3, 
N=64)=10.5, p = .015. The model as a whole explained between 15.2% (Cox 
and Shell R square) and 26.1% (Nagelkerke R square) of the variance in the 
statement, and correctly classified 84.4% of cases. Female respondents 
compared with males were more likely to agree with insufficient government 
regulation (p = .008) (Table 6.39).  
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Table 6.39 Logistic regression analysis for likelihood of agreeing with 
insufficient control for medicines across different variables 
Independent variables a n/N (,%) 
A/SA  
p Odds ratio 
(OR) 
95.0% CI for OR 
Lower Upper 
Gender  
Male  
Female 
  
6/12 (50.0) 
48/59 (81.4) 
.008  
12.1 
1.9 76.2 
General doctor 
Specialist 
18 (94.7) 
36 (80.0) 
.12 .14 .01 1.64 
Working years 
1-5 
6-10 
≥11 
 
28 (90.3) 
8 (72.7) 
18 (81.8) 
.46 1.46 .54 3.96 
Constant - .22 15.9 - - 
a Some responses were missing for each category 
Moreover, doctors agreed that purchasing medicines from pharmacies was 
easy (n=60, 84.5%). They also indicated that public need and demand for 
antibiotics was one of the main reasons for overusing antibiotics in Mongolia 
(n=39, 54.3%).   
6.3.8 Generic prescribing  
The issue of generic prescribing was examined and twenty eight respondents 
(39.4%) stated that they often or always prescribed generic medicines. 
However, a smaller proportion (12.7%) did not know what generic medicines 
were and requested more information.   
Statistical analysis showed a significant relationship between generic 
prescribing across professional levels, with general doctors stating more 
frequent practice of generic prescribing compared with specialists [t (69) 
=2.47, p = .016]. Additionally, more frequent extent of this practice was 
observed among doctors in private settings than respondents working in 
public hospitals [t (69) =3.92, p < .0001].  
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6.3.9 Antimicrobial sensitivity information  
When presented with questions regarding the source of antimicrobial 
sensitivity data, respondents stated it was obtained from the packaging 
information of the medicines (39.4%).  General doctors were more likely to 
extract antimicrobial sensitivity data from the packages of the medicines than 
specialists [t (69) =-2.7, p = .009].   
Frequent sources to obtain information about antimicrobial sensitivity were 
from package of antibiotics and professional books. Other sources such as the 
internet and patient samples were less frequently cited as place to get 
information about antimicrobial sensitivity. Respondents indicated information 
from government and co-workers in a similar frequency. In addition, less 
frequent responses scores were obtained for obtaining information from cured 
patients and peers (12.7%). Only two respondents reported that they find out 
about antimicrobial sensitivity after the prescribed antibiotic was not 
effective. Further details regarding different sources to obtain information are 
shown in Table 6.40.  
Table 6.40 Sources to acquire information about antibiotic sensitivity 
Source  Never/ rarely  
n(%) 
Sometimes 
n(%) 
Often/ Always  
n(%) 
Government information  34 (47.9) 23 (32.4) 14 (19.7) 
Professional books, journals   26 (36.6) 22 (31.0) 23 (32.4) 
Package of antibiotic 25 (35.2) 18 (25.4) 28 (39.4) 
Patient samples 33 (46.5) 21 (29.6) 17 (23.9) 
Cured patient  42 (59.2) 20 (28.2) 9 (12.7) 
Co-workers, colleagues  32 (45.1) 30 (42.3) 9 (12.7) 
No effect of antibiotic 50 (70.4) 19 (26.8) 2 (2.8) 
Internet source 30 (42.3) 22 (31.0) 19 (26.8) 
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Only nine people referred to co-workers or colleagues as a source of 
information about antibiotic sensitivity (12.7%). A significant relationship 
between obtaining information from colleagues and years of working 
experience was found in Kruskal-Wallis test [H=8.6, df=2, p = .013] (Table 6.41).  
Table 6.41 Statistical differences between obtaining information from                 
co-workers with regards to working years of experience 
Category Working years with significant difference  Kruskal- 
Wallis 
Sig. 
Pairwise comparison 
between groups 
M (SD) M (SD) 
Co-workers   1-5 years versus ≥11 years 2.5 (0.8) 3.2 (1.0) .004 
 
Correspondingly, younger respondents aged between 20 to 30 years were 
unlikely to get antimicrobial sensitivity information than older ones and this was 
just significant [t (69) =-2.01, (p = .044)].  
The frequency of government distribution regarding antimicrobial resistance 
revealed that almost one-third of respondents received information from the 
government once a year (n=20, 28.2%). Only two people (2.8%) stated that 
they received information about antimicrobial resistance from government 
every week (Figure 6.10).  
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6.3.10 Counterfeit and substandard medicines in Mongolia  
Respondents were predominantly aware of counterfeit and substandard 
medicines in Mongolia (n=65, 91.5%). As the frequency analysis showed, 
respondents did not separate the type of medicines, reporting a similar 
proportion for both antibiotics and non-antibiotic medicines (Figure 6.11).   
 
Figure 6.11 Prevalence of counterfeit/substandard medicines in Mongolia 
6.3.11 Summary of findings from the questionnaire study with doctors 
The questionnaire study examined the prescribing practice of doctors for 
treatment of mild/moderate CAP, in particular the prescribing of antibiotics 
and non-antibiotic medicines and administering injections in Mongolia. 
Factors influencing the prescribing of a treatment for patients with mild/ 
moderate CAP were identified and STGs were often or always considered, 
however only twenty two (31%) respondents supported the appropriateness 
of the STGs for pneumonia. Younger respondents compared with those aged 
over 30 years tended to consider STGs [t (69) = 2.69, p = 0.09]. Furthermore, 
about one-half of respondents reported that they sometimes have prescribed 
more than one antibiotic to patients with pneumonia at the same time 
(53.5%).  
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Confirming results obtained from the prescription and questionnaire study with 
providers (pharmacists and pharmacy technicians), a wide range of 
antibiotics and non-antibiotics were identified for the treatment of mild/ 
moderate CAP.  
Similar to pharmacists and pharmacy technicians, preference was given to 
newly marketed and broad spectrum antibiotics (47.9%) when prescribing a 
treatment for patients with CAP. On the other hand, patient demand and 
expectation played a minor role (16.9%) and reimbursable drugs from the EDL 
were also not strongly highlighted (16.9%). Moreover, participants did not 
recognize governmental control on prescribing practice as a worthy 
consideration (22.5%).  
Factors influenced the prescribing practice of an injection for patients with 
pneumonia were the importance of patient characteristics and severity of 
pneumonia. In addition, most doctors supported the statement that patients 
never or rarely preferred oral medicines than injections (42.3%). A little less than 
half of respondents reported that injections had often or always better effects 
and quality than oral medicines (43.7%, 40.8%).  
Information regarding the local antibiotic resistance (18.3%) and patient’s 
antimicrobial sensitivity data (28.2%) had a low status when prescribing 
medicines for patients with CAP.  
A majority of respondents agreed that antibiotics were overused in Mongolia 
(83.1%). The main reasons were the governmental control of medicines was 
insufficient (76.1%), purchasing medicines from pharmacies was easy (84.5%) 
and public demand for antibiotics (54.3%). Furthermore, respondents were 
predominantly aware of existing counterfeit and substandard medicines in 
Mongolia (91.5%). 
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Chapter	7 Discussion	
This Chapter discussion of the main findings from the study. It starts with 
discussion of the primary findings from the prescription analysis, followed by 
findings from questionnaire studies regarding the prescribing and dispensing 
practices of antibiotic and non-antibiotic medicines for treatment of 
mild/moderate CAP. Thereafter, the discussion of different prescribing 
practices in urban and rural areas is presented. In addition, findings regarding 
the parenteral therapy, attitude towards treatment guidelines for CAP and 
safe injection practice are discussed in the next section.  Finally, 
methodological aspects and limitations are discussed.   
7.1 Prescription analysis  
This is the first study to explore prescribing practices for mild/moderate CAP in 
Mongolia and involved evaluating drug prescribing by doctors with respect 
to government initiated treatment guidelines. It was found that the prescribing 
practice for the treatment of mild/moderate CAP at outpatient settings was 
highly inappropriate with respect to these guidelines. It was also highly 
variable regarding antibiotic selection and dosage form selection.  
WHO has recommended the indicators to measure appropriate use of 
medicines including the average number of drugs per prescription to be less 
than two and the proportion of antibiotics per prescription to be less than 30%, 
but these may vary from country to country and also may need to be 
modified over time.(287) Moreover, the WHO indicators are measured on 
randomly selected prescription samples whereas this study was a purposeful 
sample of prescriptions for CAP hence these indicators would not be relevant. 
This study has revealed low levels of poly-pharmacy with the average number 
of drugs prescribed being three per patient. This was consistent with previous 
findings of two drugs per encounter in public health facilities and three in 
private dispensaries in Mongolia in 2009.(281) In addition, other studies based 
on randomly selected outpatient records from developing countries have 
indicated the average number of drugs per prescription was similar (2 to 3), 
showing that poly-pharmacy was not a major problem in the treatment of 
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CAP in the surveyed health facilities.(308-311) In accordance with guidelines 
an antibiotic would be appropriate for patients diagnosed with CAP.  
The systematic review on appropriate prescribing of antibiotics for the 
treatment of mild/ moderate CAP in developing countries indicated that 
despite the existing guidelines, no study published between 1990 and 2013 has 
assessed all eight parameters (antibiotic selection, correct antibiotic, dose, 
dosage form, frequency, duration of an antibiotic, to explaining how to use 
the medicine appropriately and treatment outcome) of appropriate 
prescribing. From the extracted 29 studies only one was located that included 
six parameters. The overall treatment of patients with mild/moderate CAP was 
poor, in particular the frequency of patients receiving a correct antibiotic was 
below 60% and only about one half of patients received a correct treatment 
(48%).  
In this study of pharmacy-based prescriptions high levels of inappropriate 
prescribing were found with 84% of all drugs being inappropriately prescribed. 
Since each prescription included the diagnosis written by the prescriber, it was 
clear there was no doubt regarding the diagnosis for which the prescribing 
occurred. The major reason causing inappropriate prescribing for both adults 
and children was inappropriate drug selection (about 60%). However, 54.7% 
of all prescribed antibiotics were appropriately selected for children aged less 
than five (86/157). A study from Uganda reported a lower finding with  
approximately 42% of children aged less than five with self-reported 
pneumonia symptoms received a correct antibiotic.(212)  
The correct dose of a correctly selected antibiotic was given to 59% of 
children and 62.5% of adults in this study. A study from Africa observed a better 
prescribing result with 87% of correct doses of an antibiotic for children under 
five with pneumonia at outpatient settings.(215) A lower result was obtained 
in a comparison study; only 20% of children with self-reported pneumonia 
received a recommended antibiotic and dose.(212) A study from India also 
indicated a similar finding of 14% of pneumonia cases with a wrong dose of 
sulfamethoxazole-trimethoprim.(206)   
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The findings of this study showed that the inappropriate dosing frequency of 
antibiotic prescribing also contributed to the inappropriate prescribing 
practice for patients with mild/moderate CAP. Particularly, inappropriate 
frequency was greater for adults (49%) when compared with children (2.9%). 
In contrast, a higher extent of inappropriate prescribing for children aged less 
than five (16%) was reported from Uganda.(212) No data were located 
regarding the dosing frequency of antibiotics prescribed for adult patients 
with mild/moderate CAP in developing countries.    
According to the WHO, the target for indicators measuring the proportion of 
prescribed medicines dispensed and adherence to treatment guidelines is 
ideally to be 100%.(287) However, the evaluation of prescriptions indicated 
diverse prescribing practices for patients with mild/moderate CAP. Moreover, 
in this study approximately 10% of children and 3% of adults were prescribed 
no antibiotic, adding to the poor prescribing practice for CAP. Literature 
evidence indicates that prompt and appropriate antibiotic therapy is crucial 
for patients with even mild CAP caused by bacteria, because of a risk of 
deterioration of the disease within a very short time period.(312) A meta-
analysis has suggested that interventions mainly performed in settings where 
a control group had no access to antibiotics showed a significant reduction 
in the mortality by 42%, 36% and 36% among neonates, infants and children 
aged up to four with pneumonia in developing countries.(233)   
This study also found about 13% of encounters were prescribed more than one 
antibiotic, with 7.5% of children aged less than five receiving more than one 
antibiotic for treatment of mild pneumonia. This was lower than a previous 
finding in 2009 for Mongolia, where about 80% of children under five with 
mild/moderate CAP received ampicillin (first-line antibiotic) and 21% received 
more than one antibiotic.(281) Prescribing more than one antibiotic for 
children with CAP is recommended in some guidelines depending on several 
factors including patient’s characteristics or existence of any treatment 
failure.(142) The appropriateness of this practice of prescribing more than one 
antibiotic should be therefore further investigated from a patient outcome 
perspective and antibiotic resistance implications.  
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In a South-African study examining adherence to treatment guidelines for 
CAP, empirical antibiotic treatment for severe CAP accorded with local 
guidelines for 14 patients (8%) only. The remaining 168 patients (92%) were 
given treatment that was inconsistent with the guidelines.(313) Poor 
adherence to treatment guidelines for mild/moderate pneumonia was also 
observed in Nigeria, with only 40% of children aged less than five receiving 
first-line antibiotics and a similar proportion of children were prescribed more 
than one antibiotic.(314) A Jamaican study reported a low adherence of 
prescribing to recommended guidelines, only 30.2% of children with mild 
pneumonia received first-line antibiotics and about 2.2% received more than 
one antibiotic.(280) The results observed in Kenya were notably better with 
95% of patients receiving first-line antibiotics in public facilities and 61.3% in 
faith based health services. But the median proportion of children receiving 
more than one antibiotic was higher in both surveyed health facilities (20% 
and 34%) in Kenya.(277) A study from Ghana reported a better result, most 
children (90.5%) and adults (87.5%) received first-line antibiotics, 
recommended in STGs.(315) However, the appropriateness of multiple 
prescribing of antimicrobials for CAP was not assessed in these studies.  
7.2. Prescribing and providing antibiotics for patients with mild/moderate 
CAP  
The prescription analysis carried out in this study showed that at least one 
antibiotic was prescribed in most encounters (93.4%). Examining the range of 
antibiotics, aminopenicillins (40.9%), macrolides (14.5%) cephalosporins 
(14.3%) and quinolones (14%) were commonly prescribed. Similarly, doctors, 
pharmacists and pharmacy technicians in the questionnaire studies indicated 
that amoxicillin or ampicillin were commonly prescribed and dispensed for 
CAP. This practice was in compliance with the guidelines.(7) However, the 
guidelines allow for only oral aminopenicillins and 25% were injectables. No 
significant difference was observed between the frequency of prescribing 
practice of oral and injection aminopenicillins among doctors and this was 
supported by the questionnaire result with dispensers. Also, pharmacists and 
pharmacy technicians indicated a similar likelihood of supplying oral or 
injectable aminopenicillins without prescription (53% versus 56%). 
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Cephalosporins were prescribed for patients with mild pneumonia and 
doctors tended to prescribe injectable cephalosporins (cefazolin) rather than 
oral, and this was supported by the questionnaire study with pharmacists and 
pharmacy technicians. Providing cefazolin without prescription was also 
reported in the questionnaire study, but the pharmacists and pharmacy 
technicians did not indicate any preference for either of the dosage forms.       
The prescription analysis showed that prescribing of ciprofloxacin occurred, 
with an estimated prevalence of 12.6% based on the total number of 
prescribed antibiotics. In the questionnaire studies, most pharmacists and 
pharmacy technicians indicated oral ciprofloxacin as a frequently prescribed 
(33.6%) and dispensed antibiotic on prescription for CAP. Fewer doctors 
reported that they prescribed oral ciprofloxacin (22%). Notably, a 
comparable proportion of pharmacists and pharmacy technicians (21%) 
indicated oral ciprofloxacin was a frequently provided antibiotic without 
prescription for patients with CAP.  
The prescription analysis showed the proportion of injectable ciprofloxacin 
was 7.7% (4/52). In terms of the questionnaire results, a greater proportion of 
pharmacists and pharmacy technicians indicated it was a frequently 
dispensed dosage form with prescription (55.7%) whereas fewer doctors 
confirmed this practice (38%). The prescription analysis however did not 
support this level of prescribing. It is possible the questionnaire data may have 
been contaminated from the pharmacists reporting the general level of 
prescribing rather than just for CAP. Additionally, pharmacists and pharmacy 
technicians reported the practice of providing injectable ciprofloxacin 
without prescription (30%). The prescription analysis however did not support 
this level of prescribing. It is possible the questionnaire data may have been 
contaminated from the pharmacists reporting the general level of prescribing 
rather than just for CAP.       
In addition, the prescription analysis showed that about 14.5% of macrolides 
were prescribed in this study (60/413). When comparing this result with reports 
from the questionnaire studies with doctors and pharmacists, including 
pharmacy technicians, about 42% of doctors indicated that oral macrolides 
were a frequently prescribed antibiotic, and a comparable percentage of 
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pharmacist and pharmacy technicians confirmed this practice (51%). On the 
other hand, 29% of pharmacist and pharmacy technicians reported the 
practice of providing oral macrolides without a prescription from a doctor.   
Injectable macrolides were not found in the prescription analysis and only 
approximately 10% of both doctors and providers reported the prescribing 
and dispensing practice of injectable macrolides for patients with 
mild/moderate CAP. Similarly, about 11% of pharmacists and pharmacy 
technicians confirmed the practice of providing non-prescribed injectable 
macrolides for patients with CAP.   
Concerning the widespread resistance of older antibiotics, macrolides are 
usually promoted by the pharmaceutical industry as better or ‘stronger’ 
antibiotics.(316) However, macrolides should only be used with caution for the 
elderly, because of drug interactions and adverse effects.(312)    
7.3. Prescribing and providing non-antibiotic medicines for patients with CAP  
The range of non-antibiotic medicines prescribed for patients with 
mild/moderate CAP included vitamins, mucolytics, corticosteroids and 
antihistamines. According to the frequency results of the prescription analysis, 
vitamins were commonly prescribed (10.3%).  
In the questionnaire study, a similar percentage of doctors and providers 
indicated that oral vitamins were also frequently prescribed and dispensed 
with prescription (about 40%). A higher proportion of pharmacists and 
pharmacy technicians indicated oral vitamins as a frequently provided non-
antibiotic medicine for patients with CAP without prescription (51%). 
According to the current regulations, the OTC sale of oral vitamins is legal in 
Mongolia. Prescription results showed that only three injectable vitamins were 
prescribed. 
Questionnaire studies with doctors indicated that about 26% of prescribed 
injectable vitamins often/always for patients with mild CAP, this result was 
confirmed by pharmacists and pharmacy technicians. The practice of selling 
by pharmacies of non-prescribed injectable vitamins was also found to be at 
a similar level (21%). The practice of providing vitamin injections without a 
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prescription is not consistent with current regulations. Detailed results from the 
prescription analysis and questionnaire studies showed that vitamins A and C 
were frequently prescribed and dispensed for the treatment of 
mild/moderate CAP. This could reflect a low fresh food intake containing 
necessary vitamins in Mongolia. A previous research study reported low levels 
of vitamin D among children in Ulaanbaatar indicating that this deficiency 
was prevalent among children who were not exposed to the sunlight due to 
the long winter period of six to eight months.(317) A later study revealed that 
78% of 243 children aged six to 36 months were at risk of more than two 
coexisting micronutrient deficiencies.(318) Vitamin A supplementation was 
confirmed to be an effective treatment for only pneumonia complicated with 
measles and it contributed to a significant reduction of pneumonia and case 
fatality.(319) However, for children with non-measles pneumonia, the value 
from intake of vitamin A should be further investigated.(320) A Cochrane 
review of five trials suggested vitamin C was beneficial in both prevention and 
treatment of pneumonia. However, caution must be exercised with 
generalisations made from trials owing to the conditions in which the trials 
were conducted. But for those patients who have low plasma vitamin C levels, 
intake of vitamin C could be beneficial.(321)  
The prescription study showed that 15 (1.4%) prescribed items were 
corticosteroids (dexamethasone) of which 66.7% were injections. In the 
questionnaire study with doctors, a greater extent of injectable rather than 
oral corticosteroids (20% versus 16%) was reported. This practice was also 
confirmed by the questionnaire result regarding dispensing practice with 
prescriptions amongst surveyed pharmacists and pharmacy technicians 
(29.5% versus 18%). This could be related to prescribers’ perception about the 
severity of CAP and preference for corticosteroid injections. According to a 
recent review of randomised clinical trials, corticosteroids are generally 
beneficial for accelerating the time to resolution of symptoms; however this 
area needs further investigation.(322)  
Another commonly prescribed non-antibiotic medicine was a mucolytic 
(bromhexine) and this was confirmed by doctors. Pharmacists and pharmacy 
technicians also reported the practice of dispensing mucolytics on 
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prescription and providing them without a prescription for patients with 
mild/moderate CAP.   
Adjunctive therapies for CAP were compared in a previous review but this 
analysis was unable to find any clinical trials assessing the effectiveness of 
over-the-counter preparations for cough.(323) Intake of OTC medications, 
including mucolytics and antitussives was reviewed by an Australian team 
and they concluded that there was insufficient evidence to support the 
effectiveness of any OTC taken as an adjunct for cough associated with 
pneumonia in children or adults.(323) In addition, a review to assess clinical 
trials of medications, including antitussives, expectorants, mucolytics, 
antihistamine–decongestant combinations and histamine H1 receptor 
antagonists, in adults with acute cough due to upper respiratory infection 
concluded that insufficient evidence existed to recommend OTC cough 
medicines in the treatment of CAP.(324) This conclusion was supported by 
another review in 2006 confirming a low efficacy of OTC medicines may be 
applied to patients with LRIs, including CAP.(323)  
7.4 Prescribing practices in urban and rural settings   
The prescription study showed that the median number of drugs per patient 
was three in both urban and rural areas. In terms of prescribed antibiotics, 
doctors prescribed a comparable extent of antibiotics in both settings (36% 
versus 39%).  
There were differences in prescribing practices between rural and urban 
areas. Generally, the prescription analysis showed that Mongolian doctors in 
rural areas performed better with respect to the guidelines compared with 
urban prescribers. In particular, the selection of appropriate drugs was 
significantly higher in rural areas compared with their counterparts in urban 
areas. Prescribing of injectables was significantly higher for adults in urban 
areas compared with rural areas; however the difference between urban and 
rural prescribing of injectables was not significant for children in this study. Also, 
a different prescribing practice of antibiotic injections was recorded where 
the prescribed proportion estimated from the total number of prescribed 
drugs in each area was 15.9% in the urban and 8.4% in rural areas, 
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respectively. Findings regarding different prescribing practices for the 
treatment of CAP can be found in the literature. A study from the U.S reported 
that a significantly better treatment practice for inpatient pneumonia was 
observed in rural hospitals than those in urban areas. The possible explanations 
included a lower patient load in comparison to their urban counterparts, 
resulting in a better performance of medical staff regarding evaluating and 
treating patients.(325) Knowledge and practical competence in a 
’pneumonia scenario’ in children under five years was measured among 
health care practitioners in Vietnam and a significantly better result was 
observed for those who were in highland and mountainous areas than those 
in the lowland area.(269) Data have also suggested that appropriate use of 
antibiotics for pneumonia was somewhat higher among children less than five 
years in urban areas (24%) compared to children in rural regions (17%). A study 
from China reported a contrary finding, where inappropriate use of antibiotics 
for ARIs including pneumonia by health care workers was higher in villages 
than in the county and township areas combined, however the difference 
was not statistically significant (.005 < p < .1).(209) The appropriate prescribing 
practice of antibiotics for ARIs, including pneumonia was slightly higher in 
urban clinics in Bangladesh, compared to rural health complexes (19% versus 
10%), reporting that urban clinics performed relatively better when prescribing 
antibiotics.(177) 
 In the case of Mongolia, prescribing for CAP in rural areas showed improved 
conformity with the guidelines compared with the metropolitan area but both 
areas need marked improvement.   
7.5 Parenteral therapy for patients with CAP  
Parenteral therapy for outpatients is considered appropriate only when one 
of the following three factors exist: impaired gastrointestinal absorption, non-
availability of oral antibiotics or severity of the disease.(326) In general, 
intravenous antibiotics (and to a lesser extent intramuscular antibiotics) are 
considered to guarantee prompt and high serum levels, which the oral route 
cannot always ensure.(326) In this study, the prescribing level of injectables 
based on total medicines for the treatment of mild/moderate CAP was 
approximately 18% of all drugs and the proportion of patients prescribed at 
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least one injection was 29.3%. Also, the proportion of antibiotic injectables 
prescribed compared to the total number of antibiotics was 34.7% in urban 
and 18.5% in rural areas, respectively. A study from China analysed randomly 
selected outpatient records from township health centres and a high 
proportion of prescriptions with a diagnosis of pneumonia contained at least 
one injection (74%).(188) Previous research by Kundi reported that 100% of 
unlicensed practitioners and 60% of qualified doctors gave injections for 
pneumonia regardless of the severity of the disease.(327)  
Inconsistency is evident in the Mongolian guidelines. Gentamicin is 
recommended in the current treatment guidelines for children with CAP.(7) 
However, it is available only as injectable and this recommendation does not 
comply with the standard prescription requirement (MNS 5376:2008) of 
Mongolia.(295)  
The questionnaire studies with doctors and pharmacists including pharmacy 
technicians indicated that they chose an injection if the patient was severe. 
This perspective is consistent with guidelines and several findings from other 
countries.(328-330) Likewise, considering the period of study (cold winter) and 
risk of deterioration of the patient, this practice may reflect clinical concern. 
However, choosing an injection for patients with mild/moderate CAP is non-
compliant with current guidelines.(7) (295) 
Additionally, one of the factors that has contributed to inappropriate use of 
injections in developing countries has been the prescriber’s perception that 
patients preferred them.(76, 82, 299, 329, 330). In the questionnaire study 
conducted as a part of this research, only 24% of doctors and 29% of 
pharmacists, plus pharmacy technicians in the questionnaire study strongly 
supported the notion that patients often/always preferred oral medications. 
This contrasted with a finding from this study that only 16% of community 
members always/often expected injections to be prescribed. A previous 
research study that investigated maternal perception of mild pneumonia in 
an outpatient clinic found that 40% of mothers stated doctors should give their 
child at least one injection. However, the generalisation of this study to a larger 
population might be questionable, due to a small number and poorer 
understanding of the participants (n=50).(327) From those who expected 
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injections, older people in this study tended to expect injections for common 
medical conditions and this was similar to other findings.(328, 331, 332)Also a 
finding by Raglow, indicated that attitudes of patients towards injections was 
rather balanced and open. Although, patients stated they paid higher prices 
for injections and thought they were more powerful, they disagreed that 
injections lasted longer than tablets, one in five patients would prefer oral 
medications, if they were told oral medicines were equally effective.(84, 301) 
However, the number of patients should be considered when interpreting 
these results (one in five). Other literature has confirmed that injections were 
often not preferred by patients, when they were advised about the clinical 
efficacy and potential risks associated with unsafe injection practices.(299) 
Health workers in developing countries believed that patient’s compliance 
was better with injections than with oral medication(70, 85) and similarly, 
doctors and providers in the questionnaire study indicated choosing an 
injection was to avoid non-compliance problems.  
Financial considerations are another important reason why injections are 
preferred by prescribers and providers. The questionnaire study with 
pharmacists and pharmacy technicians indicated that 27% charged fees for 
administering an injection to a patient. Administration of an injection is not 
permitted in community pharmacies and this finding was inconsistent with the 
current Mongolian guidelines.(305) Also, questionnaire data from pharmacists 
and pharmacy technicians indicated that apart from patients, doctors (25%) 
had a financial benefit from prescribing and administering injections. Even 
though, nurses are not allowed to prescribe or dispense medications in 
Mongolia, about one third of providers (pharmacists and pharmacy 
technicians) indicated nurses often/always had financially benefitted from 
prescribing and administering injections. Economic incentives from 
prescribing an injection were reported in a previous study where 19% of high 
rate injection prescribers admitted having economic incentives for prescribing 
injections in Iran.(82) Correspondingly, in addition to the formal administrators 
(for example: nurses, doctors and traditional practitioners), pharmacists and 
friends/relatives were indicated by community members in the questionnaire 
study as injection administrators. A study in Egypt reported that informal 
medical providers, including relatives, housekeepers of government clinics 
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and assistants of private medical doctors often administered injections.(333) 
(173) Reasons for choosing informal medical providers were explained by their 
availability and accessibility at low or without any extra cost.(333) (173)  The 
large number of doctors in Mongolia is a potential factor for doctors to seek 
additional income sources.   
7.6 Attitude towards treatment guidelines of CAP  
The prescription analysis showed that only 40% of drugs were appropriately 
selected and only 16% of prescriptions were appropriately prescribed in 
accordance with Mongolian guidelines. At the same time, a separate 
questionnaire study with doctors and pharmacists including pharmacy 
technicians indicated that only about 30% strongly agreed/agreed with the 
appropriateness of guidelines for the treatment of CAP.  
Reasons for poor adherence to guidelines can be related with the fact that 
the WHO adopted guidelines by the government authorities in Mongolia  may 
not be applicable to Mongolia with a severe winter climate and harsh 
environment. Prescriber’s perceptions about the effectiveness of 
recommended antibiotics and resistance patterns may also be important. 
Presently, there has been little done regarding the investigation of 
antimicrobial resistance in Mongolia to support these perceptions.(33, 35) In 
the questionnaire study, most doctors (83.1%) and pharmacists, plus 
pharmacy technicians (69.5%) strongly agreed/agreed that antibiotics were 
overused in Mongolia and common reasons included patients being able to 
easily purchase antibiotics with or without prescription. Perceptions regarding 
treatment with commonly purchased antibiotics among Mongolian doctors 
was surveyed by Nakajima, and doctors doubted the effectiveness of some 
antibiotics such as benzyl penicillin, gentamicin, metronidazole, ampicillin, 
phenoxymethyl penicillin, and ciprofloxacin, due to antibiotic resistance.(33)  
Some of the current choices can be predicated on past treatment failures. 
Past experience was also selected in the questionnaire study with doctors as 
a characteristic that was often/always considered when prescribing for 
patients with mild CAP (68%).     
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Poor awareness and not acknowledging the appropriateness of guidelines 
are reported to be the common reasons for not using guidelines.(334) A study 
has identified facilitators and barriers to compliance with an institutional 
antibiotic prescribing policy and antimicrobial stewardship committee 
members (prescribers) indicated lack of knowledge as the main barrier to 
compliance with the antibiotic prescribing policy.(335) In this study the 
prescribers were introduced to a case of moderate CAP and most prescribers 
were familiar with this scenario. While most said they would start with 
‘ceftriaxone’, a broad-spectrum antibiotic such as ‘ceftriaxone’ is not 
indicated in the hospital policy nor the Australian Therapeutic Guidelines. (142, 
335) Common barriers to guideline adherence were classified into 
‘knowledge’, ‘attitude’ and ‘external barriers such as guideline related, 
patient related and environmental.(336) A number of reasons for 
policy/guideline non-compliance were identified, including knowledge 
deficiency, uncertainty avoidance (reluctance to tolerate uncertainty risks), 
conflicts with patients’ interests and insufficient resources.(337, 338) As 
reviewed by Holloway, results from 900 studies over two decades showed 
suboptimal prescribing practice in primary care indicating than less than half 
of all patients treated in accordance with the STGs. In addition, the review 
concluded that medicines use overall has not improved in the most recent 
period. The reasons included increasing practice of prescribing antibiotics 
persistently over time and failure to reduce use of injections resulting in 
inappropriate practices for primary care patients. Moreover, the review 
concluded that there was little change in the results over two decades of 
WHO initiated indicators to measure medicine use.(289)       
Inadequate dissemination of the recommended information can also lead to 
poor guideline awareness and adherence to guidelines.(339, 340) Likewise, 
previous reports from Mongolia emphasized that there was no dissemination 
and implementation nor promotion through continuing medical education 
(CME) of these guidelines, (including treatment guidelines for pneumonia) for 
general doctors in Mongolia.(5) Detailed analysis of factors influencing the 
lack of adherence to guidelines need to be carried out in Mongolia.  
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Despite only 4% of doctors in the questionnaire study often considering 
incentives from drug companies when prescribing, almost half of doctors 
(48%) often/always preferred to prescribe newly marketed and broad 
spectrum antimicrobials for patients with mild/moderate CAP. This finding 
could be related to visits from representatives of pharmaceutical companies. 
As the Law on Medicine and Medical Devices of Mongolia (2010) states, “It is 
prohibited to advertise drugs that are issued by prescription in order to sell 
them”.(341) However, specific information regarding the audience and 
permitted details are lacking in the law(341) and there were reports related to 
public advertisements of prescription only medicines and unethical practices 
between wholesalers and doctors in Mongolia.(281) In contrast, the 
advertising and promotion of prescription only medicines is regulated in 
Australia by the Therapeutic Goods Act 1989, advertising prescription 
medicines directly to consumers is prohibited, whereas advertising to health 
professionals is permitted within the scope of the legislation. In addition, 
advertisements for prescription medicines must also meet the requirements of 
the Competition and Consumer Act 2010, Section 22(5).(342)  
Another possible explanation for poor guideline adherence in relation to 
antibiotics can be related to the prescriber’s perception about the increased 
risk of antibiotic resistance through intake of meat from animals. People in rural 
areas are more exposed to animals than in urban, and therefore doctors may 
be more sceptical about the efficacy of antibiotics that have been given to 
animals which can lead to the development of antimicrobial resistance in 
humans. However, no data are available regarding the use of antibiotics for 
animal husbandry in Mongolia to date.  
The questionnaire study with doctors and providers indicated further non-
adherent practices with current treatment guidelines for CAP, including the 
prescribing and dispensing standard of Mongolia. In particular, doctors 
(16.9%), pharmacists and pharmacy technicians (15%) often/always changed 
a prescribed antibiotic. Furthermore, 23% of doctors indicated that they 
often/always prescribe more than one antibiotic for patients with pneumonia 
at the same time, and this was confirmed by the providers (14.1%). Previous 
research has identified barriers to guideline use for CAP among junior doctors 
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working in hospitals in the UK and respondents were also sceptical about 
guidelines along with increasing clinical experience.(343) Similar to this finding, 
in the questionnaire study, doctors with more years of working experience 
tended to change a prescribed antibiotic for patients diagnosing the 
treatment of mild/moderate CAP compared to those with less years of 
working experience.  
7.7 Safe injection practice  
The questionnaire study with community members revealed that about 20% 
of respondents had experienced one of the proffered unwanted side effects 
of injections, such as experiencing a warm feeling under the skin, or a swollen 
or hard lump under the skin. In terms of reasons regarding side effects, about 
one-third did not know that these effects could occur as a reason of an 
injection or because of the injection. A study on adverse drug events (ADE)s 
was completed with 140 health professionals and 70 patients in Mongolia 
(unpublished).(344) It showed that of sixty-four cases of ADEs, 76.6% were 
associated with injections, including antibiotic injections. Frequent symptoms 
were abdominal pain, nausea and rash caused by dextran and ampicillin 
injection administration.(344) Consistent with our results, most patients did not 
know about ADEs.(344)  
In terms of safe injection practices, the questionnaire study with community 
members showed some advances in certain areas as no respondents 
reported the administration to have involved re-used needles and syringes 
and a majority was aware of using new clean needles and syringes for every 
injection. As proposed by Logez,(78) this improvement can be explained by 
three main changes in the health care practices of Mongolia: (i) improved 
knowledge about risks related with transmission of blood-bourne pathogens, 
(ii) a better supply of injection equipment with local production of needles 
and syringes and (iii) an introduction of methodical destroying of sharp waste 
after use in each health care facility.(78)  Such improved safe practices were 
found in other developing communities, reporting a high use of disposable 
syringes.(302, 345) However, contrary findings could be observed from other 
countries such as Pakistan(346)  indicating that only 53% of participants used 
freshly opened new syringes for administration of an injection and India,(347)  
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reporting about one-third of respondents having disposable syringes for 
injection administration.  
In addition, the findings of this study showed that doctors, pharmacists and 
pharmacy technicians had good knowledge, reporting using new needles 
and syringes for every injection administration. This was consistent with 
previous findings from Cambodia, with 90% of injection prescribers and 
providers being aware of HBV, HCV and HIV transmitted through unsafe 
injection practices.(330) Furthermore, reports from Mongolia indicated a 
comparably good knowledge among doctors.(78, 79) However, there are still 
challenges due to a high rate of injection use, potential break-down in 
infection control, and poor health care protection.(78, 79) The latest study on 
injection practice in Mongolia in 2007 indicated that only 7% of prescribers 
(doctors) and 12% of surveyed nurses were immunised against Hepatitis B.(79) 
No other data are available regarding the immunisation status of injection 
administrators, including doctors and nurses in Mongolia.   
7.8 Methodological aspects 
This study assessed the treatment practices for mild/ moderate CAP in 
Mongolia and the reliability of the study results was measured by a 
triangulation method, comparing the prescription data with questionnaire  
responses from doctors, pharmacists, pharmacy technicians and community 
members.  
Despite the strengths of this study, some methodological aspects must be 
considered when interpreting results.   
Prescription study 
The study has two main limitations. Firstly, the estimates were based on a one 
point in time observation completed in the winter period of 2010. Secondly, 
the relatively small number of pharmacies (about 4% of all main community 
pharmacies) selected for the prescription study may affect the generalisibility 
of the study results. To counterbalance this weakness, the sample was stratified 
by district and type of pharmacy and personal data collection assured that 
no particular pharmacy type was excluded from this study.  In addition, the 
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study assessed 394 prescriptions from 22 pharmacies which consented giving 
a high response rate (73%). These included twelve pharmacies in Ulaanbaatar 
area and ten pharmacies in eight provinces. All pharmacies that did not 
consent were in the urban area due to their busy workload.  
Moreover, the study selected only those prescriptions with only a diagnosis of 
CAP, approximately one in five of prescriptions were issued without a 
diagnosis creating a potential risk of not including those prescriptions for 
patients, some of whom have CAP and those without the diagnosis may 
neglect a particular type of prescriber. In practice, the pharmacy asks the 
patients what the diagnosis was and records it. These prescriptions were 
excluded because of the prescribing of patient inaccuracy. However it is the 
habits of prescribers that were assessed in this study. Therefore, the results 
should be reasonably representative of the prescribing practice for the 
treatment of CAP at the urban and rural levels.  
Questionnaire studies  
Pilot studies with validated questionnaires were completed in order to assure 
the accuracy. The selection of community members was not random, 
however the response rate of community members was high (79%). The study 
aimed to recruit community members that represented various 
socioeconomic groups, for example: age, marital status, employment status, 
educational and income level by selecting participants from 55 different 
regions of Ulaanbaatar city, shopping centres, hospitals and pharmacies that 
were located in the central and semi-rural parts. However, differences were 
apparent in demographic characteristics of respondents compared with the 
general population. Secondly, the responses from community members could 
be influenced by issues of social desirability. The questionnaires were however, 
anonymous and confidentiality was emphasized encouraging honesty. In 
addition, questionnaires were completed in public quiet areas, ensuring the 
sufficient time and lack of disturbances whilst completion of the questions. 
Some of the questions were based on recall of events; however, completed 
forms were assessed for completion by the researcher. Therefore, responses 
do provide some insight to community members’ behaviour and perception 
regarding the treatment of CAP.  
 170 
 
The selection of pharmacists and pharmacy technicians was based on 
convenience selection of 40 community pharmacies, aiming to include at 
least one pharmacist or pharmacy technician from each location (district 
type, location to the health facility). Based on a discussion with local 
professionals, the selection of pharmacies included a range of pharmacies 
regarding the size, accessibility and distance from clinics, ensuring that no 
particular type of pharmacies was excluded. Additionally, a personal delivery 
and collection of the questionnaires was used to improve the response rate. 
The high response rate (76%) obtained was likely to avoid significant responder 
bias. Non-respondents (19) were working in pharmacies located in large 
districts and was due to a busy workload.   
The relatively small number of samples of health settings (eleven hospitals and 
20 FGPs located in Ulaanbaatar city) may lead to selection bias and imprecise 
estimate. However,   the doctors in the questionnaire study were recruited 
randomly from the list provided by the human resource department of each 
hospital and a high response rate (89%) indicated low potential risk of 
selection bias. 
The study aimed to select at least two doctors, one general doctor and one 
specialist, from each setting. Similar to the questionnaire study with 
pharmacists and pharmacy technicians, where there were two at the same 
hospital, they completed the questionnaire independently from each other. 
This study recruited more specialists than general doctors, suggesting that the 
results may be more generalisable to them. However, the study included 
twenty-two general doctors, also providing information about their practice 
of treatment of CAP.   
The study has identified a lack of coherent antibiotic prescribing for 
mild/moderate CAP in Mongolia. It also reports inconsistent protocols applied 
to antibiotic and non-antibiotic treatments including the prescribing of 
injections. Some evidence points to a proportion antibiotic treatment failures, 
requiring other antibiotics to be subsequently prescribed. There maybe some 
influence of drug companies on the prescribing of the most recent antibiotics 
to be marketed. There is little evidence of prescribing “reserve” antibiotics at 
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a high level. However, this study has also identified issues that potentially 
negative impact on the long-term public health of the Mongolian population.  
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Chapter	8 Conclusion	
This is one of the most comprehensive studies carried out in a general practice 
setting in a developing country that has assessed the prescribing practice for 
mild/ moderate CAP. 
A prescription analysis showed a wide range of antibiotic and non-antibiotic 
prescribing for mild/moderate CAP in Mongolia and a low conformity with 
health department prescribing guidelines. In addition, the study used a 
triangulation method to assess the veracity of the obtained results. In addition 
to prescription data, findings from questionnaire studies with community 
members, doctors and pharmacists, including pharmacy technicians 
provided additional insight into current prescribing practices for treatment of 
CAP in Mongolia.  
The study revealed that there was no consensus on appropriate prescribing 
of antibiotics and non-antibiotic medicines for the treatment of CAP. Possible 
reasons for this include flaws and inconsistencies in the treatment guidelines 
which are based upon WHO recommendations and provide no guidance for 
children aged six to 16 years. This gives rise to a lack of respect for the current 
guidelines. In addition there has been inadequate promotion by health 
department authorities. Consequently, the currently adopted WHO guidelines 
need replacement with ones that are locally developed based upon local 
expertise including considerations of pathogen resistance patterns, the 
unusual climatic conditions and access of patients to medical care. With 
respect to CAP, the guidelines should include any non-antibiotic medicines 
considered appropriate for the Mongolian environment especially for the low 
winter temperatures. Techniques for successful implementation of guidelines 
are well-known in the literature, such as those adopted by the NPS 
MedicineWise in Australia.(348)     
The supply of antibiotics from pharmacies although currently indicating a 
similar range of selections being made to those prescribed by physicians 
should be ceased unless this would markedly reduce access to treatment for 
poorer patients.  
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Although adjunctive therapy was reported to be inefficacious in more 
moderate climates, these findings need to be reviewed by an expert panel 
representing senior physicians and government authorities for Mongolia.  
Differences in prescribing practices between rural and urban areas indicate 
that government control and monitoring of prescribing practices need to be 
improved, especially in the urban areas of Mongolia.  
The discrepancies between the expectations and attitudes towards 
therapeutic injections between prescribers, providers and public were 
evident in this study. Most prescribers and providers specified patient’s self-
diagnosis and expectation was an important factor for prescribing/dispensing 
injections for treatment of CAP. This was at variance with community views 
where only a small percentage of mainly older respondents preferred having 
an injection. In addition, OTC provision of injectables and antibiotics was 
evident in the study.The responses from the public was mainly focused on the 
general use of injections, however this finding shows that prescribers were 
poorly informed regarding the community attitudes towards injections. Long-
term medical education targeted at prescribers, providers and community 
members should be implemented regarding appropriate prescribing of 
injections. The study found that prescribers and providers had a good 
knowledge about safe injection practice; however health care protection 
needs to be improved due to the current high injection use in Mongolia. The 
high levels of inappropriate antibiotic prescribing is a public health hazard for 
Mongolia.  
  
  
 174 
 
Chapter	9 Recommendations	
The Mongolian government takes an active role in implementing policies, 
guidelines and processes that manages the use of antibiotics and non-
antibiotic medicines that reflect the requirements of the Mongolian people. 
This includes updating of treatment policies for mild/ moderate CAP relevant 
to Mongolia. Based on the findings from this study, the recommendations 
should include the following:  
 To meet public health requirements in Mongolia treatment guidelines 
for antibiotic use including for the ten most important diseases of 
Mongolia should be developed by independent expert teams 
involving senior physicians’ views on optimum treatment in the 
Mongolian context and an implementation strategy developed. 
 Current practice guidelines relevant for treating mild/moderate CAP 
with antibiotics at outpatient settings needs to be reviewed by 
appropriate Mongolian experts and should be followed by prescriber 
education and made widely available to health care professionals in 
Mongolia.  
 Adjunctive therapy for mild/moderate CAP should be investigated and 
assessed by an expert team. Outcomes should be included in revised 
guidelines. 
 Investigations regarding the underlying problems for non-adherence to 
treatment guidelines should be specifically carried out.  
 OTC sale of antibiotics should be banned from the community-based 
pharmacies. The current supply from community pharmacies should be 
investigated for public access for the needy and the government 
should move when appropriate to control the provision of antibiotics 
from pharmacies without a prescription.  
 OTC sale of injectable medicines should be ceased from the 
community-based pharmacies and legislative rules need to address a 
compliance procedure to ensure this is adhered with.   
 Educational programs targeted at improving prescribers’ and 
providers’ knowledge of the small level of public support for injectable 
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medicines and attitudes towards injectable medicines and safe 
injection practices should be implemented.  
 A mass educational campaign for the public regarding the 
inappropriate use of antibiotic and non-antibiotic medicines, including 
injections needs to be implemented in Mongolia.   
 A decision by experts needs to resolve the discontinuity if the case of 
injectable gentamicin in the guidelines but not allow prescribing of 
injections for community-based patients.    
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Appendix	B	‐	Systematic	Review	Data	Extraction	Sheet	
 
Table 9.1 Example of data extraction sheet for systematic review  
SIGN rating:                   
Country  
Sample   
Study type  
Objectives  
Statistical 
analysis 
 
Results  
Author 
specific 
comments   
 
Reviewers 
comments 
 
SIGN levels  Randomisation   High  Moderate  Low quality/ not 
applicable  
Controls  High  Moderate  Low quality/ not 
applicable  
Bias  High  Moderate  high risk  
Probability that 
relationship is causal 
 High  Moderate  Low quality/ not 
applicable  
Study design and 
quality  
 High  Moderate  Low quality  
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Table 9.2 Scottish Intercollegiate Guidelines Network levels of evidence  
1++ 
High quality metaanalyses, systematic reviews of RCTs, or RCTs with a 
very low risk of bias 
1+ 
Well conducted metaanalyses, systematic reviews of RCTs, or RCTs with 
a low risk of bias 
1- 
Metaanalyses, systematic reviews or RCTs, or RCTs with a high risk of 
bias 
2++ 
High quality systematic reviews of casecontrol or cohort studies, or high 
quality casecontrol or cohort studies with a very low risk of 
confounding, bias, or chance and a high probability that the 
relationship is causal 
2+ 
Well conducted casecontrol or cohort studies with a low risk of 
confounding, bias, or chance and a moderate probability that the 
relationship is causal 
2- 
Casecontrol or cohort studies with a high risk of confounding, bias, or 
chance and a significant risk that the relationship is not causal 
3 Nonanalytic studies e.g. case report 
4 Expert opinion 
 
 
 
Table 9.3 Scottish Intercollegiate Guidelines Network grades of 
recommendations 
A 
At least one meta-analysis, systematic review or RCT rated as 1++ and 
directly applicable to the target population or a systematic review of 
RCTS or a body of evidence consisting principally of studies rated as 1+ 
directly applicable to the target population and demonstrating overall 
consistency of results 
B 
A body of evidence including studies rated as 2++ directly applicable to 
the target population and demonstrating overall consistency of results or 
extrapolated evidence from studies rates as 1++ or 1+ 
C 
A body of evidence including studies rated as 2+ directly applicable to 
the target population and demonstrating overall consistency of results or 
extrapolated evidence from studies rated as 2++ 
D 
Evidence level 3 or 4 or extrapolated evidence from studies rated as 2+ 
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Appendix	D	Verbal	participant	consent	form		
 
 
 
 
EVALUATION OF THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP) 
IN MONGOLIA 
 
 
Date _____________________ 
 
 
You are being informed about the study on evaluation of the treatment of community-acquired 
pneumonia (CAP) in Mongolia. By participating in this study, you can withdraw any time 
without any reason or affecting your current and future treatment or practice.  
 
All information provided will be treated with strict confidentiality and will not be released unless 
required by law. The aim of the research, data will be collected and only de-identified data is 
stored and published  
 
 
I agree that research data from this project can be published provided my name or other 
identifying information is not used.  
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Participation information sheet 
 
 
EVALUATION OF THE TREATMENT OF  
COMMUNITY-ACQUIRED PNEUMONIA (CAP) IN MONGOLIA 
 
 
Date _____________________ 
 
This research is being undertaken by a PhD student of School of Pharmacy, Curtin University 
of Technology in collaboration with supervisors from the School of Public Health and School 
of Pharmacy, Curtin University of Technology of Western Australia.  
 
This research will study the use of injections and it is anticipated that the study will recommend 
strategies to reduce inappropriate prescribing practices in Mongolia. Therefore, this research 
will contribute to the development of scientific evidence in this area and provide useful 
information for policy makers. 
 
By participating in this study, you can withdraw any time without any reason or affecting your 
current and future treatment. 
All information provided will be treated with strict confidentiality and will not be released unless 
required by law.    
 
For further information on this research or queries regarding your participation please 
contact the researcher Gereltuya Dorj on +976-99968988 or email: 
gereltuya.dorj@postgrad.curtin.edu.au   
 
If you have any issues regarding the research, you can forward them by phone or writing to 
the following staff at Curtin:  
 
Ms. Delia Hendrie  
Lecturer 
School of Public Health 
Curtin University of Technology, WA 
Tel: (+618) 9266 9068 
Email: D.V.Hendrie@curtin.edu.au    
 
 
 
or alternatively to:   
The Secretary  
Human Research Ethics Committee 
Office of Research and Development 
Curtin University of Technology 
Tel: (+618)9266 2784 
Email: hrec@curtin.edu.au  
PO Box U 1987, Perth WA 6845 
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Appendix	E	Prescription	data	collection	form	
 
 
Part I.  
Patient details 
Code:  
Location /Name of retail pharmacy/:   
Date of birth: 
Gender: 
Date: 
Diagnosis:  
Part II. Prescribed drug details 
# 1.  2. 3. 4. 5. 6. 7.  8.  9. 10.  
 
Drug name    
Dosage form    
Dose    
Quantity    
Direction for use    
Brand/Generic    
Prescribed date    
Dispensed date    
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Appendix	F	Questionnaire	data	collection	form		
 
INTERVIEW WITH COMMUNITY MEMBERS 
DATA COLLECTION FORM 
_______________________        
Date 
Code _____________________          
Residential location (suburb/town)_______________________ 
                  
1.  Age:  20-30  30-50  60+                                                      
2. Gender:  M  F  
3. Marital Status:  Single  Married  Divorced  Separated   
Widowed 
4. Education:   Primary  Secondary  Tertiary  Other 
5. Occupation:  Unemployed    Civil servant Employed  
Military 
6. (a) Have you had an injection in the past?  Yes / No 
(b) If ‘Yes’, how long ago did you have your last injection?   
 
< 1 month  1-6 months  6-12 months  > 1 year 
 
7. What reason did you have the last injection? 
 Yes No 
01. Treatment of an illness    
02. Immunisation    
03. Contraception  (only female respondents)   
04. Other- vitamins, etc.    
 
8. Was the injection you had 
 
 
 
Yes No 
01. Single injection(s)    
02. Continuous drip    
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9. Can you remember how many injections you had for the last single course of 
treatment? 
  one  2 – 4  5 – 8  >8 
 
10. Do you remember if after some injections you then had similar medication by mouth?  
   Yes   No 
11. Do you remember what the illness was? 
________________________________________ 
12. Do you know what the medicine was? 
__________________________________________ 
 
These are questions related to your past experience with injections 
13. When you had an injection, did you have any of the following unwanted/adverse 
effects? 
  Yes No 
01. Persistent redness   
02. Warmth at the injection site   
03. Swelling or hardness under the skin   
04. Drainage of fluid from the injection site    
05. Fever caused by the injection    
06. Persistent pain at the injection site    
07. Felt weak   
08. Fainted   
 
14. What do you think was the cause of that complication/ side effect?  
 Yes No 
01. Person who administered the injection   
02. The drug itself   
03. Bad equipment, syringe, drip etc   
04. I do not know   
05. Others, specify    
 
 
15. What happened following your unwanted/side effect? 
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 Yes No 
01. Went to hospital   
02. Consulted doctor   
03. Consulted the pharmacist   
04. Nothing   
 
16. How long did it last? ________ 
17. Who prescribed injections for you? 
 Yes Sometimes No 
01. Doctor    
02. Pharmacist    
03. Nurse    
04. Traditional practitioner   
  
18. Where do you purchase your injections? 
 Yes Sometimes No 
01. Doctor    
02. Pharmacy    
03. Nurse    
04. Detailer  
 
19. Who administered your injections to you? 
 Yes Sometimes No 
01. Doctor    
02. Pharmacy    
03. Nurse    
04. Friend / relative                                
05. Traditional practitioner    
06. Other (specify)    
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 Amount 
/MNT/ 
Did you think 
that the price 
was affordable? 
Was it 
reimbursed? 
20. How much did you pay for 
your 
last visit to the doctor? 
 Yes No Yes No
    
21. How much did you pay for  
purchasing injections from a 
pharmacy? 
     
22. How much did you pay for  
administration of  injection 
purchased from a pharmacy? 
     
 
 
23. If you go to see the doctor, do you expect to receive injections for treatment?   
 Yes    Sometimes     No 
If yes, 
 
Yes Sometimes No 
   
 
01. The doctors prescribe injections    
02. I would prefer the doctor to 
prescribe me with an injection 
   
 
24. Do you think an injection is a better treatment? 
 Yes    Sometimes     No 
 
If yes,  
Yes Sometimes No 
01. The treatment with injection 
works faster                                     
   
02. The treatment with injection is 
more affordable    
03. You prefer injections because you 
would forget to take 
tablets/capsules 
   
04. If a doctor prescribes 
tablets/capsules do you think that 
treatment will work for you 
   
05. Injections are recommended by 
friends, relatives, colleagues     
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06. Injection advertisement by 
pharmaceutical companies                 
07. Habit/ custom     
 
25. Are you aware of the need for using new clean syringes and needles for every 
injection? 
 Yes                   Sometimes  No 
 
26. Which of the following is important to you when getting an injection? 
 Yes Sometimes No
01. Price    
02. Local or imported product    
03. Package condition     
(a) Expiry date    
 
27. Would you go to another doctor/ pharmacy, if an injection was not prescribed/ 
dispensed by the 
          first person? 
Yes   Sometimes   No 
28. Would you be disappointed if an injection was not prescribed/ dispensed? 
  Yes    Sometimes               No 
29. Do you refuse injections when prescribed/ dispensed? 
  Yes    Sometimes     No 
 
 
If yes, please explain the reasons: 
Yes Sometimes No 
01. Fear of pain    
02. Fear of needle, infection etc.     
03. Do not trust the doctor/  
pharmacist 
   
04. Other (specify)    
05. It is possible to get better without 
an injection    
06. There are many tablets available 
for many common diseases    
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07. The illness will go away on its 
own with time    
08. Lack of clean syringes and     
    needles 
   
 
30. Are you aware of counterfeit medicines in Mongolia?   Yes   No 
 
31. If yes, have you encountered problems with counterfeit medicines? 
 
 
 
 
 
32. May I ask about your approximate monthly income?  
≤ 90.000MNT    91-200.000MNT  201-300.000MNT  
301-400.000MNT    401-500.000MNT   ≥501.000MNT  
 
33. Do you want to discuss about any other issues related to the treatment of CAP 
and injection practices in Mongolia?  
 
______________________________________________ 
Thank you for your time 
  
 Yes Sometimes No 
01. Antibiotics    
02. Other medications    
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INTERVIEW WITH PHARMACISTS/PHARMACY TECHNICIANS 
DATA COLLECTION FORM 
_______________________        
Date 
Code _____________________         
Residential location_____________________ 
               
1. Age:  20-30  30-50  50-60  60+                                                 
2. Gender:  M  F  
3. Working level:         Owner      Employee  
4. Pharmaceutical role:    Pharmacist     Pharmacy technician 
5. Years of work as pharmacist/pharmacy technician: ______________________ 
 
 
The following questions are related to medicines that are prescribed. 
 
6. List the antibiotics that are being frequently dispensed for community-acquired 
pneumonia 
         (CAP) with a prescription from a doctor 
  Never
0%  
Rarel
y 
1-10% 
Sometimes 
11-40% 
Often 
41-80% 
Always
>80% 
01 Penicillin, oral      
02 Penicillin, injection      
03 Amoxicillin, oral      
04 Amoxicillin, injection      
05 Ampicillin, oral      
06 Ampicillin, injection      
07 Ciprofloxacin, oral      
08 Ciprofloxacin, injection      
09 Cefazolin, oral      
10 Cefazolin, injection      
11 Erythromycin, oral      
12 Erythromycin, injection      
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13 Amoxicillin/clavulanate, oral      
14 Clarythromycin, oral      
15 Clarythromycin, injection      
16 Azithromycin, oral      
17 Azithromycin, injection      
18 Levofloxacin, oral      
19 Tetracycline, oral      
20 Trimethopim- sulfamethoxazole, 
oral 
     
21 Doxycycline, oral      
 
7. What other prescribed medications are also prescribed with antibiotics for CAP? 
  Never
0%  
Rarel
y 
1-10% 
Sometimes 
11-40% 
Often 
41-80% 
Always
>80% 
01 Dexamethasone, oral      
02 Dexamethasone, injection      
03 Bromhexine, oral      
04 Acidi ascorbinici, oral      
05 Acidi ascorbinici, injection      
06 Chlorfenamin, tab      
07 Vitamin B complex, oral      
08 Vitamin B complex, injection      
09 Cocorcarboxylase, injection      
10 Euphyllin, oral      
11 Euphyllin, injection      
12 Analgin, oral      
13 Analgin, injection      
14 Dimedrol, oral      
15 Dimedrol, injection      
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8. How frequently do the doctors prescribe more than one antibiotic for patients 
with CAP at the same time? 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often 
41-80% 
Always
>80% 
      
 
 
9. When dispensing a particular dosage form that is prescribed by a doctor for 
patients with CAP, what are issues that influence your dispensing?  
 
SA: Strongly agree, A: Agree, D: Disagree, SD: Strongly Disagree, NR: No response 
 SA A D SD NR 
01. Essential drug list with reimbursement       
02. Medical profile of children      
03. Medical profile of adults      
04. Patient characteristics, severity      
05. Dosage forms of the prescribed medicine      
06. Duration of the prescribed medications      
07. Knowledge  about adverse reactions, side 
effects      
08. Medical- legal concerns      
09. Treatment guideline information      
10. Patient compliance with medications      
11. Patient is not satisfied if not injected      
12. Affordability of medications to the patient      
13. Cost of brand vs generic medicines is 
important when dispensing       
14. Expiry date of medication      
15. Need for reconstitution      
 
10. How frequently do you have to change the prescriptions for CAP because the 
prescription   
          appears to be inappropriate?   
 
 
Never
0% 
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
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11.  
01. The normal duration of prescribed antibiotics for CAP by injection 
is:  
 
 ≤3 days   4-5 days   > 5 days  
 
02. The normal duration of prescribed antibiotics for CAP orally is:  
 
 ≤ 3 days   4-5 days   > 5 days  
 
03. If the treatment of CAP is switched from injection to oral, the time of 
the switch from an injection is: 
 
 ≤ 24 hours   2 days   3 days   > 5 days after commencing 
treatment 
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The following questions are related to medicines that are   
dispensed in the pharmacy without prescription. 
 
12. List the antibiotics that are being frequently dispensed for community-acquired 
pneumonia 
 (CAP) without a prescription 
  Never
0% 
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
01. Penicillin, oral      
02. Penicillin, injection      
03. Amoxicillin, oral      
04. Amoxicillin, injection      
05. Ampicillin, oral      
06. Ampicillin, injection      
07. Ciprofloxacin, oral      
08. Ciprofloxacin, injection      
09. Cefazolin, oral      
10. Cefazolin, injection      
11. Erythromycin, oral      
12. Erythromycin, injection      
13. Amoxicillin/clavulanate, oral      
14. Clarythromycin, oral      
15. Clarythromycin, injection      
16. Azithromycin, oral      
17. Azithromycin, injection      
18. Levofloxacin, oral      
19. Tetracycline, oral      
20. Trimethopim- sulfamethoxazole, oral      
21. Doxycycline, oral      
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13. What other medications would you dispense with antibiotics for CAP without a 
prescription?  
 
  Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-
80% 
Always
>80% 
01. Dexamethasone, oral      
02. Dexamethasone, injection      
03. Bromhexine, oral      
04. Acidi ascorbinici, oral      
05. Acidi ascorbinici, injection      
06. Chlorfenamin, tab      
07. Vitamin B complex, oral      
08. Vitamin B complex, injection      
09. Cocorcarboxylase, injection      
10. Euphyllin, oral      
11. Euphyllin, injection      
12. Analgin, oral      
13. Analgin, injection      
14. Dimedrol, oral      
15. Dimedrol, injection      
 
14. When dispensing a particular dosage form for the treatment of CAP without a 
prescription, what issues influence that choice?   
 SA A D SD NR 
01. Injections are more effective than oral  
administration 
     
02. The medication product quality is better in an 
injection rather than tablet or capsule 
     
03. Adverse effects are less likely with an oral than 
injection treatment 
     
04. The doses of injections are chosen to provide 
better patient compliance 
     
05. New needles, syringes and single dose ampoules 
are necessary for injections 
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06. There is no treatment benefit to switch from 
injection to oral during an antibiotic course for 
CAP 
     
07. Your pharmaceutical training promoted the use of 
injections rather than oral medication 
     
08. Drug companies promote injectable rather than 
oral medications 
     
09. Prefer to dispense newly marketed products      
10. The total treatment with oral medications is a 
more costly form of treatment than with injections 
including the cost of syringes, needles and 
administration 
     
11. More repeat visits to the pharmacies are caused 
by injections 
     
12. Injections are chosen to provide better patient 
compliance 
     
13. Patients prefer an oral medication rather than 
treatment with injections 
     
14. The age and gender of the patients can have 
influence on dispensing injections 
     
15. The severity of the patient with CAP influences 
the dispensing of injections 
     
 
 
15. Do you dispense more than one antibiotic without prescription for CAP at the same 
time? 
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
      
01. The normal duration of dispensed antibiotics for CAP by injection 
is:  
 
 ≤3 days   4-5 days   > 5 days  
 
02. The normal duration of dispensed antibiotics for CAP orally is:  
 
 ≤ 3 days   4-5 days   > 5 days  
 
03. If the treatment of CAP is switched from injection to oral, the time of 
the switch from an injection is: 
 
 ≤ 24 hours   2 days   3 days   > 5 days after commencing 
treatment 
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16. How often do you receive governmental information about antibiotic sensitivity 
data? 
 Never Weekly Monthly 3 times a year  
Once a 
year 
      
 
 
17. Do you find the current Mongolian treatment guidelines for CAP appropriate? 
  
 Yes     No      NR 
 
18. How often would you refer a patient with CAP who comes to the pharmacy to a 
doctor?  
 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
      
 
19.       Do you consider injections s more effective treatment for CAP?     
 Yes      No    
 
 
20. If yes, what is the effect of injections? 
 
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
01. More rapid cure      
02. Adverse effects are 
less frequent than 
with oral treatment  
     
 
21. To what extent do you agree that there is more financial benefit with injections to 
the following people? 
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
01. Doctor      
02. Pharmacist       
03. Patient      
04. Nurse      
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22.       Do you charge a special fee for administering injections?  
 Yes, amount_______  No 
 
23. Do you think the fee for dispensing and administering injections is affordable to the 
patient?  
 Yes     No      NR 
 
 
24. When dispensing injections, which of the following are considered: 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
01. Supplied from reliable source      
02. Using sterile drips, syringes and 
needles 
     
03. Package condition of the 
medication 
     
04. Patient’s self diagnosis and 
request for injection  
     
05. Reconstitution of the antibiotic      
06. Expiry date of the reconstituted 
product 
     
25. Do you think that injections for treatment of diseases in general are overused in 
Mongolia?    
 SA A D SD NR 
       
 
26. If yes, please specify the reasons? 
 SA A D SD NR 
01. Patients are able to easily buy 
injections from many pharmacies 
     
02. Lack of government control on 
drug sale  
     
03. Public demand for injections is 
high 
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27. After using a disposable syringe: 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often 
41-80% 
Always
>80% 
01. You change the needle and retain 
the syringe for reuse  
     
02. You sterilize the syringe and 
needle and reuse it     
 
03. You discard all      
04. You discard and destroy it after the 
first time it was used     
 
 
28. When administering an intravenous drip: 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
01. You give the whole vial as a drip to 
a patient 
     
02. You retain the residual not required 
for that dose     
 
03. You reconstitute what remained of 
the powder for the next patient      
 
04. You discard everything the first  
time you used it     
 
29. From where do you obtain injectable drugs for the treatment of diseases? 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
01. Pharmaceutical wholesaler      
02. Pharmacy      
03. Detailer      
04. Others (private import)      
 
 
30. Are you aware of counterfeit medicines in Mongolia?   Yes    No 
 
31. If yes, have you experienced problems with counterfeit medicines? 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
a. Antibiotics      
b. Other medications       
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32. May I ask about your approximate monthly income?  
≤ 90.000MNT    91-200.000MNT  201-300.000MNT  
301-400.000MNT   401-500.000MNT   ≥501.000MNT  
 
33. Do you want to discuss any other issues related to prescribing for CAP and its 
treatment in Mongolia?  
 
 
 
Thank you for your time. 
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INTERVIEW WITH DOCTORS  
DATA COLLECTION FORM 
_______________________        
Date 
Code _____________________              
Residential location_____________________ 
 
               
1. Age:  20-30  31-50  51-60  61+                                                 
2. Gender:  M  F  
3. Work level:          FGP      Public hospital   Private hospital   
Others   
4. Medical Role:         G/P     Specialist 
5. Years of work in this field: _______ 
6. When prescribing antibiotics for patients with community-acquired pneumonia (CAP), 
what are the issues that influence your prescribing?  
 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
01. Patient expectations/demand      
02. Essential drug list with  
             reimbursement 
     
03. Drug company information      
04. Drug company representative visits      
05. Treatment guidelines for CAP       
06. Information from CPD programs/  
      seminars  
     
07. Likelihood of adverse effects       
08. Regional antibiotic sensitivity data      
09. Patient antibiotic sensitivity data      
10. Journals, publications, articles       
11. Influence of peers, fellow GP’s       
12. Influence of specialists      
13. Personal experience      
14. Information about previous use of  
      antibiotics obtained from a pharmacy 
by the patient 
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15. Drug availability      
16. Affordability of medications for 
      patient 
     
17. Broad spectrum of antibiotic activity 
are the best option      
18. Preference for recently marketed  
      medications 
     
19. Government monitoring of  
      prescribing 
     
20. Risk of being charged for litigation      
21. Incentives from pharmaceutical  
       companies 
     
 
 
7. When prescribing a particular dosage form for the treatment of CAP, what issues 
influence that choice?   
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
01. Injections are more effective than  
       oral administration 
     
02. Patients prefer an oral medication 
rather than treatment with 
injections 
     
03. The medication product quality is  
       better in an injection rather than 
tablet or capsule 
     
04. Adverse effects are less likely with 
an oral than injection treatment      
05. The treatment with oral 
medications is a more costly form 
of treatment than an injection 
including the cost of syringes, 
needles and the administration 
     
06. More repeat visits to the  
       hospital/clinic are caused by 
injections 
     
07. New needles, syringes and   
      single dose ampoules are      
      necessary for injections 
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08. To switch from injection to oral 
administration during an antibiotic 
course for CAP 
     
09. Drug companies promote  
       injectable rather than oral 
medications 
     
10. Injections are chosen to provide 
better patient compliance      
11. Your medical training promoted the 
use of injections rather than oral 
medication 
     
12. The severity of CAP influences the 
prescribing of injections      
13. Patient demographic 
characteristics have an influence 
on the prescribing  
     
 
 
 
8.  
01. The normal duration of prescribing antibiotics for CAP by injection is:  
 
 ≤3 days   4-5 days   > 5 days  
 
02. The normal duration of prescribing antibiotics for CAP orally is:  
 
 ≤ 3 days   4-5 days   > 5 days  
 
03. If you switch a patient with CAP from injection to oral when do you recommend 
that the oral dosage starts: 
 
 ≤ 24 hours   2 days   3-5 days   > 5 days after the initial treatment  
 
9. Do you find the Mongolian treatment guidelines for CAP appropriate?  
 
 Yes     No      Don’t know 
10. Do you prescribe more than one antibiotic for CAP at the same time? 
 
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
      
11. How often do you have to change the antibiotic as the first one did not work? 
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 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
      
 
12. List of antibiotics that you frequently prescribe for CAP 
  Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often 
41-80% 
Always
>80% 
22. Penicillin, oral      
23. Penicillin, injection      
24. Amoxicillin, oral      
25. Amoxicillin, injection      
26. Ampicillin, oral      
27. Ampicillin, injection      
28. Ciprofloxacin, oral      
29. Ciprofloxacin, injection      
30. Cefazolin, oral      
31. Cefazolin, injection      
32. Erythromycin, oral      
33. Erythromycin, injection      
34. Amoxicillin/clavulanate, oral      
35. Clarythromycin, oral      
36. Clarythromycin, injection      
37. Azithromycin, oral      
38. Azithromycin, injection      
39. Levofloxacin, oral      
40. Tetracycline, oral      
41. Trimethopim- sulfamethoxazole, 
oral 
     
42. Doxycycline, oral      
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13. What other medication group would you prescribe with antibiotics for CAP? 
 
  Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often 
41-80% 
Always
>80% 
16. Dexamethasone, oral      
17. Dexamethasone, injection      
18. Bromhexine, oral      
19. Acidi ascorbinici, oral      
20. Acidi ascorbinici, injection      
21. Chlorfenamin, tab      
22. Vitamin B complex, oral      
23. Vitamin B complex, injection      
24. Cocorcarboxylase, injection      
25. Euphyllin, oral      
26. Euphyllin, injection      
27. Analgin, oral      
28. Analgin, injection      
29. Dimedrol, oral      
30. Dimedrol, injection      
 
 
14. How often do you receive governmental information about prescribing antibiotics? 
 
 Never Weekly Monthly 3 times a year Once a year 
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15. To what extent do the patients come to you for treatment of CAP who have already 
purchased antibiotics from the following? 
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
01. Pharmacy      
02. Market      
03. Other, specify_____      
 
16. When you prescribe antibiotics what is the frequency of generic prescribing?  
 
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
      
 
17. Where do you obtain antibiotic sensitivity data from? 
 
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
01. Governmental 
information 
     
02. Governmental 
publications 
     
03. Antibiotic package 
leaflet 
     
04. Hospital      
05. Treated patients      
06. Colleagues      
07. Antibiotics not working      
08. Internet      
 
18. How frequently do you admit/send a patient to hospital with CAP? 
 
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
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19. Do you think that injections for treatment of diseases in general are overused in 
Mongolia?   
 
  
SA A D SD NR 
       
 
20. If yes, please specify the reasons? 
 SA A D SD NR 
01. Patients are able to easily buy the 
medicines from many pharmacies
     
02. Lack of government control on 
drug sale  
     
03. Public demand       
 
21. Are you aware of counterfeit medicines in Mongolia?  Yes                      No 
 
22. If yes, have you experienced problems with counterfeit medicines? 
 
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
01. Antibiotics 
 
     
02. Other medications  
 
     
 
23. May I ask about your approximate monthly income?  
≤ 90.000MNT    91-200.000MNT  201-300.000MNT  
301-400.000MNT   401-500.000MNT   ≥501.000MNT  
 
24. Do you want to discuss about any other issues related to CAP and its treatment in 
Mongolia?  
 
______________________________________________ 
 
Thank you for your time. 
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ИРГЭДЭД ЗОРИУЛСАН АМАН ЗӨВШӨӨРЛИЙН ХУУДАС 
 
 
 
 
 
МОНГОЛ УЛС ДАХЬ  
УУШИГНЫ ХАТГАЛГАА ӨВЧНИЙ ЭМЧИЛГЭЭНИЙ ҮНЭЛГЭЭ  
 
 
Огноо _____________________ 
 
 
Танд Монгол улс дахь уушигны хатгалгаа өвчний үнэлгээ сэдэвт судалгааны ажлын 
талаар танилцуулж байна. Энэ судалгаанд оролцсоноор та өмнө нь эмчилгээнд 
хэрэглэж байсан тарианы талаар хариулах болно.  
Та энэ судалгаанд зөвхөн өөрийн хүсэлтээр оролцох бөгөөд таны нэр болон бусад 
холбогдох мэдээлэл шаардлагагүй. Энэ судалгаанд оролцсоноор та дуртай үедээ 
татгалзах, зогсоох эрхтэй бөгөөд таны одоо болон ирээдүйн эмчилгээнд аливаа 
өөрчлөлт гарахгүй.   
 
Судалгаанд авах мэдээллийг чандлан нууцлах бөгөөд асуумжаас гарах аливаа бичлэг, 
протоколыг нэргүйгээр хадгалах болно.  
Судалгааны мэдээллийг миний нэр болон холбогдох мэдээлэлгүйгээр ашиглахыг 
оролцохыг зөвшөөрч байна.   
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ИРГЭДЭД ЗОРИУЛСАН СУДАЛГААНД ХАМРАГДАХ МЭДЭЭЛЛИЙН ХУУДАС  
 
МОНГОЛ УЛС ДАХЬ  
УУШИГНЫ ХАТГАЛГАА ӨВЧНИЙ ЭМЧИЛГЭЭНИЙ ҮНЭЛГЭЭ  
 
 
Огноо _____________________ 
 
Миний нэрийг Гэрэлтуяа гэдэг бөгөөд би Австрали улсын Куртины Их Сургуулийн Эм 
Зүйн Сургуулийн докторантурт сурч байна. Докторантурын ажлыг Нийгмийн Эрүүл 
Мэндийн Сургууль болон Эм Зүйн Сургуулийн 2 багш удирдаж байна.  
Докторантурын ажил Монгол улс дахь эмчилгээнд зориулсан тарианы хэрэглээг судлах 
бөгөөд шаардлагагүй, тохиромжгүй зуршилыг багасгах зорилготой юм. Тийм учир энэ 
судалгаа нь гадна шинжлэх ухааны баримт боловсруулахад тус болохоос гадна 
шийдвэр гаргагч нарт хэрэгцээтэй мэдээлэл болно.  
 
Энэ судалгаанд оролцсоноор та өмнө нь эмчилгээнд хэрэглэж байсан тарианы талаар 
хариулах болно. Та энэ судалгаанд зөвхөн өөрийн хүсэлтээр оролцох бөгөөд таны нэр 
болон бусад холбогдох мэдээлэл шаардлагагүй. Энэ судалгаанд оролцсоноор та дуртай 
үедээ татгалзах, зогсоох эрхтэй бөгөөд таны одоо болон ирээдүйн эмчилгээнд аливаа 
өөрчлөлт гарахгүй.   
 
Судалгаанд авах мэдээллийг чандлан нууцлах бөгөөд асуумжаас гарах аливаа бичлэг, 
протоколыг нэргүйгээр хадгалах болно.  
Энэ судалгааг Куртин Их сургуулийн Хүний Ёс зүйн хороо зөвшөөрөн баталсан. Нэмэлт 
мэдээлэл болон асуух зүйл байвал та судлаач Д. Гэрэлтуяа /утас: 99968988, и-мэйл: 
gereltuya.dorj@postgrad.curtin.edu.au/ -тай холбогдох буюу доорхи хүмүүст хандана 
уу:  
Делиа Хендрие  
Куртин Их Сургуулийн Нийгмийн эрүүл мэндийн сургуулийн  ахлах багш 
Утас: (+618) 9266 9068 
И-мэйл: D.V.Hendrie@curtin.edu.au    
 
эсвэл:   
Хүний Ёс Зүйн Хороо  
Куртин Их Сургуулийн Судалгаа болон Хөгжлийн Газар  
Утас: (+618)9266 2784 
И-мэйл: hrec@curtin.edu.au  
PO Box U 1987, Perth WA 6845 
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ИРГЭДТЭЙ ХИЙХ ЯРИЛЦЛАГА  
Мэдээлэл цуглуулах маягт 
           
__________________        
Огноо  
Дугаар _____________________          
Харъяалал (дүүрэг/хот)_______________________ 
                  
1.    Нас:  20-30  31-50  51-60      61+                                                      
2. Хүйс: Эр  Эм  
3. Гэрлэлтийн байдал:  Ганц бие  Гэрлэсэн   Салсан   
  Тусдаа амьдардаг          Бэлэвсэн 
4. Боловсролын түвшин:  Анхан Бүрэн дунд  Дээд  Бусад 
5. Ажил:  Ажилгүй     Төрийн албан хаагч Ажилтай   
Цэргийн 
  Оюутан   
6. (a) Урьд нь тариа тариулж байсан уу?           Тийм      Үгүй 
(b) Хэрэв тийм бол хамгийн сүүлд хэзээ хийлгэсэн бэ?   
< 1 сар  1-6 сар  6-12 сар  > 1 жил 
Та 7-12 асуултад хариулахдаа 6 (b) хариулсан хугацаагаа бодож 
хариулна уу. 
7. Та ямар учраас тариа хийлгэсэн бэ? 
 Тийм Үгүй 
1. Өвчин   
2. Дархлаажуулалт (вакцин)    
3. Хамгаалалт  (зөвхөн эмэгтэй хүмүүс)   
4. Бусад- витамин, гэх мэт.    
 
8. Та ямар тариа хийлгэсэн бэ?  
 
 
9. Нэг удаагийн эмчилгээнд хэдэн төрлийн тариа хийлгэсэн бэ? 
 
 
Тийм Үгүй
1. Нэг удаагийн (булчин, судас тариа)    
2. Дусал    
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  нэг   2 – 4  5 – 8  >8 
 
10. Тариа хийлгэсний дараа төстэй эм ууж байсан уу?  
   Тийм   Үгүй 
11. Ямар өвчин байсан бэ? ________________________________________ 
12. Ямар эм ууж байсан бэ? __________________________________________ 
Дараах асуултууд таны өмнө нь хийлгэж байсан тариатай холбоотой 
13. Тариа хийлгэсний дараа танд дараах гаж урвал/ нөлөөнөөс аль нэг нь илэрч 
байсан уу? 
  Тийм Үгүй 
1. Байнгын улаалт   
2. Тариа хийлгэсэн газар халуу оргих    
3. Арьсан дор хавдах эсвэл хатуурах    
4. Тариа хийлгэсэн газраас шингэн гарах     
5. Тарианаас шалтгаалсан халууралт    
6. Тариа хийлгэсэн газар байнга өвдөх    
7. Бие сул болох    
8. Ухаан алдах    
 
14. Таны бодлоор дээрх гаж нөлөө юунаас болж илэрсэн бэ?   
 Тийм Үгүй 
1. Тариа хийсэн хүнээс шалтгаалсан   
2. Тарианаас болсон    
3. Чанар муутай багаж, хатгуур, зүү зэргээс болсон   
4. Мэдэхгүй   
5. Бусад, тодруулна уу.................................................   
 
15. Та гаж нөлөө илэрсэн үед ямар арга хэмжээ авсан бэ?  
 Тийм  Үгүй 
1. Эмнэлэг явсан    
2. Эмчээс зөвлөлгөө авсан   
3. Эм зүйчээс зөвлөлгөө авсан    
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4. Юу ч хийгээгүй    
5. Бусад, тодруулна уу.................................................   
 
16. Хэр удаан үргэлжилсэн бэ? ______(хоног/цаг) 
17. Тариа хийлгэхийг хэн танд зөвлөж, бичиж өгдөг вэ? 
 Тийм Заримдаа Үгүй 
1. Эмч     
2. Эмч зүйч     
3. Сувилагч     
4. Уламжлалтын эмч   
18. Та тариаг ихэвчлэн хаанаас авдаг вэ? 
 Тийм Заримдаа Үгүй 
1. Эмч/ эмнэлэг    
2. Эм зүйч/эмийн сан     
3. Сувилагч     
4. Хувиараа эм худалдагч   
 
19. Танд тариа хэн хийдэг вэ? 
 Тийм Заримдаа Үгүй 
1. Эмч    
2. Эм зүйч     
3. Сувилагч     
4. Найз / хамаатан                                 
5. Уламжлалтын эмч    
6. Бусад (тодруулна уу)_______    
 
 Мөнгөн 
дүн /₮/ 
Энэ төлбөр 
таны хувьд 
бололцооны 
байсан уу? 
Даатгалаас 
нөхөн 
олгогдсон уу? 
20. Эмч дээр хамгийн сүүлд  
          очихдоо ямар төлбөр 
төлсөн  
 Тийм Үгүй Тийм Үгүй
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          бэ? (ойролцоогоор) 
21. Эмийн сангаас тариа 
авахдаа  
          ямар төлбөр төлсөн бэ?       
          (ойролцоогоор) 
     
22. Эмийн сангаас авсан тариа  
          хийлгэхдээ хэдэн төгрөг  
          төлсөн бэ? (ойролцоогоор) 
     
 
23. Та эмч рүү очихдоо тариа бичүүлнэ гэж боддог уу?   
 Тийм   Заримдаа     Үгүй 
Шалтгаан нь юу вэ?  
 
Тийм Заримдаа Үгүй 
 
1. Эмч тариа бичдэг     
2. Эмч надад тариа бичээсэй гэж 
би хүсдэг     
 
 
24. Тариагаар эмчлэх нь илүү үр дүнтэй гэж боддог уу? 
 Тийм    Заримдаа     Үгүй 
 
 
Шалтгаан нь юу вэ?  
Тийм Заримдаа Үгүй 
1. Тариагаар эмчлэхэд илүү   
 хурдан эдгэрдэг                                
2. Тариагаар эмчлэх нь илүү  
 хямд     
3. Эм уухаа мартаад байдаг учир  
 тариагаар эмчлэхийг илүүд  
 үздэг  
   
4. Эмч шахмал капсултай эм   
 бичиж өгөхөд уг эмчилгээ үр  
 дүнтэй гэж боддог 
   
5. Миний найз нөхөд, хамаатан,  
 хамт ажилладаг хүмүүс надад   
 тариа хийлгэхийг зөвлөдөг  
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6. Эмийн компаниуд тариаг   
 сурталчилдаг                                   
7. Тариа хийлгэх зуршил     
 
25. Тариа хийлгэх болгонд шинэ цэвэр зүү тариур хэрэглэх ёстой гэж та мэддэг үү? 
 Тийм                   Заримдаа             Үгүй 
26. Таны бодлоор доорх сонголтуудаас тариа хийлгэхэд юу нь чухал бэ? 
 Тийм Заримдаа Үгүй
1. Үнэ     
2. Импортын эсвэл дотоодын     
          бүтээгдэхүүн     
3. Савлалтын байдал     
4. Дуусах хугацаа     
 
27. Хэрвээ анх очсон эмч, эмийн санч танд тариа өгөхгүй бол та өөр газар луу 
явдаг уу? 
Тийм   Заримдаа   Үгүй 
 
28. Хэрвээ танд тариа өгөхгүй бол та сэтгэл дундуур байдаг уу? 
  Тийм    Заримдаа    Үгүй 
29. Тариаг хэрвээ танд бичсэн, олгосон тохиолдолд та татгалзах уу? 
  Тийм    Заримдаа     Үгүй 
 
Шалтгааныг тайлбарлана уу: 
Тийм Заримдаа Үгүй 
1. Өвдөхөөс айдаг     
2. Зүү, халдвар зэргээс айдаг      
3. Эмч, эмийн санчид итгэдэггүй    
4. Цэвэр тариур, зүү байхгүй бол 
    татгалзана    
5. Тариа хийлгэхгүйгээр эдгэрэх 
    боломжтой     
6. Ихэнх өвчнийг эдгээх эм байдаг     
7. Хэсэг хугацааны дараа өвчин   
   өөрөө эдгэрнэ    
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8. Бусад (тодруулна уу)________ 
   
 
30. Монголд хуурамч эм байдаг эсэхийг та мэдэх үү?   Тийм    
Үгүй 
 
31. Хэрэв тийм бол ямар эм хуурамч байсан бэ? 
 
 
32. Таны дундаж орлогыг мэдэж болох уу?  
≤ 90.000₮    91-200.000₮  201-300.000₮  
301-400.000₮    401-500.000₮   ≥501.000₮  
33. Уушигны хатгалгаа өвчин болон бусад өвчний үед тариа хэрэглэхийг та юу гэж 
боддог вэ? Саналаа бичнэ үү.   
______________________________________________________________________ 
Танд баярлалаа 
  
 Тийм Заримдаа Үгүй
1. Антибиотик    
03. Бусад эм (тодруулна уу)_____________    
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ЭМ ЗҮЙЧ, ЭМ НАЙРУУЛАГЧТАЙ ХИЙХ ЯРИЛЦЛАГА  
Мэдээлэл цуглуулах маягт 
_______________________        
Огноо 
Код _____________________         
Харъяалал_____________________ 
               
1. Нас:  20-30  30-50  50-60  60+                                                 
2. Хүйс:  Эр  Эм   
3. Ажлын зэрэглэл:         Эзэмшигч      Ажилтан  
4. Мэргэжил:    Эм зүйч     Эм найруулагч  
5. Ажилласан жил: ______________________ 
 
Жоронд бичигдсэн эмүүдэд дараах асуултууд хамаатай  
6. Уушигны Хатгалгаатай /УХ/-тай өвчтөнд эмч жор бичихдээ дараах эмүүдийг 
бичдэг 
  Хэзээ ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Пенициллин,уух      
2. Пенициллин, тариа      
3. Амоксициллин, уух      
4. Амоксициллин, тариа      
5. Ампициллин, уух      
6. Ампициллин, тариа      
7. Ципрофлоксацин, уух      
8. Ципрофлоксацин, тариа      
9. Цефазолин, уух      
10. Цефазолин, тариа      
11. Эритромицин, уух      
12. Эритромицин, тариа      
13. Амоксициллин/клавунат, уух      
14. Кларитромицин, уух      
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15. Кларитромицин, тариа      
16. Азитромицин, уух      
17. Азитромицин, тариа      
18. Левофлоксацин, уух      
19. Тетрациклин, уух      
20. Триметопим-сульфаметоксазол, 
уух 
     
21. Доксициллин, уух      
 
7. УХ-тай өвчтөнд ямар эмүүдийг давхар бичдэг вэ?  
  Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Дексаметазон, уух      
2. Дексаметазон, тариа      
3. Бромгексин, уух      
4. Витамин С, уух      
5. Витамин С, тариа      
6. Хлорфенамин, уух      
7. Витамин В, уух      
8. Витамин В, тариа      
9. Кокоркарбоксилаз, тариа      
10. Эуфиллин, уух      
11. Эуфиллин, тариа      
12. Анальгин, уух      
13. Анальгин, тариа      
14. Димедрол, уух      
15. Димедрол, тариа      
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8. УХ-тай өвчтөнд эм бичихдээ эмч нар нэгээс олон антибиотик хэр их бичдэг вэ? 
 Хэзээ ч үгүй
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
      
 
9. УХ-тай өвчтөнд жоронд бичигдсэн эм олгоход дараах хүчин зүйлс нөлөөтэй?   
ХЗ: Хүчтэй зөвшөөрч байна, З: Зөвшөөрч байна, Т: Татгалзаж байна, ХТ: Хүчтэй 
татгалзаж байна, ХБ: Хариулт байхгүй 
 
 ХЗ З Т ХТ ХБ 
1. Хөнгөлөлттэй олгогдох зайлшгүй 
        шаардлагатай эм       
2. Хүүхдийн эмчилгээ      
3. Насанд хүрсэн хүний эмчилгээ      
4. Өвчтөний байдал, онцлог        
5. Жоронд бичигдсэн эмийн тун      
6. Жоронд бичигдсэн эмэн эмчилгээний 
        хугацаа      
7. Эмийн гаж нөлөөний тухай мэдлэг       
8. Эмнэлэг, хууль      
9. Эмчилгээний удирдамж       
10. Өвчтөний эмчилгээ дагах чадвар      
11. Өвчтөн тариа хийлгэхгүй бол сэтгэл  
        дундуур байна       
12. Өвчтөний эм худалдан авах чадвар       
13. Эм олгоход женерик болон брэнд эмийн 
үнэ чухал байдаг      
14. Эмийн дуусах хугацаа      
15. Дахин хэрэглэх шаардлага       
 
10. УХ-тай өвчтөнд бичигдсэн жор тохиромжгүй учир өөрчлөх шаардлага хэр их 
гардаг вэ?   
 
 
Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
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11.  
04. УХ-тай өвчтөнд эмчийн бичсэн тариан эмчилгээ дунджаар ... 
хоног үргэлжилдэг:  
 
 ≤3 өдөр   4-5 өдөр   > 5 өдөр  
 
05. УХ-тай өвчтөнд эмчийн бичсэн уух эмийн хугацаа ... байдаг:  
 
 ≤ 3 өдөр   4-5 өдөр   > 5 өдөр  
 
06. УХ-тай өвчтөнийг тариан эмчилгээнээс уух хэлбэр лүү 
шилжүүлэхэд дараах хугацаа болно: 
 
 ≤ 24 цаг   2 өдөр   3 өдөр   > 5 өдөр /эмчилгээ эхэлсэний 
дараа / 
 
Дараах асуултууд жоргүй олгогдож буй эмэнд хамаарагдана  
 
12. УХ-тай өвчтөнд дараах эмүүдийг жоргүй олгодог  
  Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Пенициллин,уух      
2. Пенициллин, тариа      
3. Амоксициллин, уух      
4. Амоксициллин, тариа      
5. Ампициллин, уух      
6. Ампициллин, тариа      
7. Ципрофлоксацин, уух      
8. Ципрофлоксацин, тариа      
9. Цефазолин, уух      
10. Цефазолин, тариа      
11. Эритромицин, уух      
12. Эритромицин, тариа      
13. Амоксициллин/клавунат, уух      
14. Кларитромицин, уух      
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15. Кларитромицин, тариа      
16. Азитромицин, уух      
17. Азитромицин, тариа      
18. Левофлоксацин, уух      
19. Тетрациклин, уух      
20. Триметопим-сульфаметоксазол, 
уух      
21. Доксициллин, уух      
 
13. Антибиотикаас гадна УХ-тай өвчтөнд ямар эм олгодог вэ /жоргүй/?   
 
  Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1.  Дексаметазон, уух      
2.  Дексаметазон, тариа      
3. Бромгексин, уух      
4. Витамин С, уух      
5. Витамин С, тариа      
6. Хлорфенамин, уух      
7. Витамин В, уух      
8. Витамин В, тариа      
9. Кокоркарбоксилаз, тариа      
10. Эуфиллин, уух      
11. Эуфиллин, тариа      
12. Анальгин, уух      
13. Анальгин, тариа      
14. Димедрол, уух      
15. Димедрол, тариа      
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14. УХ-тай өвчтөнд жоргүйгээр эм олгоход дараах хүчин зүйлс хамаатай?  
ХЗ: Хүчтэй зөвшөөрч байна, З: Зөвшөөрч байна, Т: Татгалзаж байна, ХТ: Хүчтэй 
татгалзаж байна ХБ: Хариулт байхгүй 
  
 XЗ З Т ХТ ХБ 
1. Тариа уух хэлбэрээс илүү үйлчилгээ сайтай       
2. Тарианы чанар шахмал/капсултай эмийн чанараас 
илүү сайн 
     
3. Эмийг ууж хэрэглэхэд тарьснаас илүү гаж нөлөө 
гардаг 
     
4. Тарианы тун тухайн өвчтөн эмчилгээг илүү сайн 
дагахад сонгогдсон 
     
5. Тариа хийхэд шинэ зүү, тариур, ампул 
шаардлагатай  
     
6. УХ өвчний үед өвчтөнийг антибиотикаар эмчилж 
байх үед тарианаас уух хэлбэр лүү шилжүүлэхэд 
ямар нэгэн ашиг байхгүй  
     
7. Таны сургалтанд тариаг уух хэлбэрийн эмнээс илүү 
их заадаг   
     
8. Эмийн компаниуд тариаг илүү ихээр сурталчилдаг       
9. Шинээр гарч буй бүтээгдэхүүнийг олгохыг илүүд 
үздэг  
     
10. Уух хэлбэрийн эмийн зардал тариан эмчилгээний 
зардлаас/үүнд зүү тариурны үнэ багтсан/ илүү 
үнэтэй болдог  
     
11. Тариан эмчилгээ хийлгэхэд эмийн сан руу илүү 
олон удаа явах хэрэгтэй болдог  
     
12. Өвчтөн эмчилгээг илүү сайн даган мөрдүүлэхийн 
тулд тариаг сонгосон  
     
13. Өвчтөн шахмал эмийг тарианаас илүүд үздэг       
14. Тариаг олгоход өвчтөний нас, хүйс хамаатай       
15. Тариаг олгоход УХ-тай өвчтөний байдал хамаатай       
 
 
15. Та УХ-тай өвчтөнд жоргүйгээр эм олгохдоо нэгээс олон антибиотик нэгэн зэрэг 
өгдөг үү? 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
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1. УХ өвчинд хэрэглэх олгосон антибиотик эм тарих хугацаа дунджаар:   
 
 ≤3 өдөр   4-5 өдөр   > 5 өдөр  
 
2. УХ өвчинд хэрэглэх олгосон антибиотик эмийг уух дундаж хугацаа:   
 
 ≤ 3 өдөр   4-5 өдөр   > 5 өдөр  
 
3. УХ –тай өвчтөнийг тариан эмчилгээнээс уух хэлбэр лүү шилжүүлсэн 
бол дундаж хугацаа: 
 
 ≤ 24 цаг   2 өдөр   3 өдөр   > 5 өдөр /эмчилгээ эхэлсэний 
дараа/ 
 
16. Антибиотик эмийн мэдрэг чанарын талаар улсаас мэдээлэл хэр их авдаг 
вэ?  
 Хэзээ ч үгүй 
7 хоног 
тутам  
Сар 
болгон 
Жилд 3 
удаа  
Жилд 1 
удаа 
      
 
17. Монгол улсын УХ өвчний эмчилгээний удирдамжийг та тохиромжтой гэж 
үздэг үү?  
 Тийм     Үгүй      
ХБ 
 
 
18. Эмийн санд ирж буй УХ-тай өвчтөнийг та хэр их эмнэлэг рүү явуулдаг вэ?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
      
 
19.      Та УХ өвчинд тариа илүү сайн үр дүнтэй эмчилгээ гэж боддог уу?     
    Тийм       Үгүй    
20. Хэрэв тийм бол тарианы үйлчилгээ юу вэ?  
 Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
1. Илүү хурдан эдгэнэ       
2. Гаж нөлөө 
шахмал/капсултай эм 
ууж хэрэглэснээс арай 
бага гардаг  
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21. Тариа хийхэд/эмчлэхэд дараах хүмүүст илүү их ашигтай байдаг гэж та 
бодож байна вэ?  
 Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
1. Эмч      
2. Эм зүйч       
3. Өвчтөн      
4. Сувилагч      
 
 
22.       Тариа хийхэд та нэмэлт төлбөр авдаг уу?  
 Тийм, _______₮  Үгүй 
 
23. Таны бодлоор тариа худалдаж авах болон хийлгэх төлбөр өвчтөний хувьд 
боломжийн байсан уу?   
 Тийм     Үгүй    ХБ  
 
24. Тариа олгоход дараах зүйлүүдийг та яаж анхаардаг вэ?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Найдвартай газраас ханган 
нийлүүлсэн 
     
2. Ариун зүү тариур болон дусал 
ашиглах  
     
3. Эмийн савлалтын байдал       
4. Өвчтөний өөрийн онош болон 
тариа авах хүсэл  
     
5. Антибиотикийг дахин хэрэглэх       
6. Дахин хэрэглэсэн 
бүтээгдэхүүний дуусах хугацаа  
     
 
25. Монгол улсын аливаа өвчинд тариаг хэтрүүлэн ашигладаг гэж та боддог 
уу? 
 МЗ З Т МТ ХБ 
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26. Хэрэв тийм бол шалтгааныг нэрлэнэ үү? 
 МЗ З Т МТ ХБ 
1. Тариаг эмийн сангуудаас маш 
хялбар аргаар худалдан авах 
боломжтой  
     
2. Эмийн худалдааг улсаас хянах 
шалгалт хангалтгүй 
     
3. Олон нийт тариаг их шаарддаг/ 
хэрэглэдэг   
     
 
 
 
27. Нэг удаагийн тариур ашигласны дараа:   
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Зүүг солин тариурыг дахин 
хэрэглэж болно  
     
2. Зүү тариурыг ариутгаад 
дахин хэрэглэж болно      
3. Бүгдийг хаяна       
4. Эхний удаа хэрэглэсний 
дараа бүгдийг устгаад хаяна     
 
 
 
28. Дусал хийсний дараа:  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Бүтэн шил/савыг өвчтөнд 
тарина      
2. Илүү гарсан үлдэгдэлийг 
хадгална       
3. Илүү гарсан нунтагийг 
дараачийн өвчтөнд 
хэрэглэнэ   
     
4. Эхний удаа хэрэглэсний 
дараа бүгдийг устгана       
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29. Эм тариаг хаанаас авдаг вэ? 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Эмийн бөөний худалдаа       
2. Эмийн сан       
3. Борлуулагч       
4. Бусад (хувийн импорт)      
30. Монголд хуурамч эм байдаг эсэхийг та мэдэх үү?   Тийм    Үгүй 
 
31. Хэрэв тийм бол ямар эм хуурамч байсан бэ? 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
a. Антибиотик      
b. Бусад эм        
 
32. Таны дундаж орлогыг мэдэж болох уу?  
≤ 90.000₮    91-200.000₮  201-300.000₮  
301-400.000₮    401-500.000₮   ≥501.000₮  
33. Уушигны хатгалгаа болон тарианы хэрэглээний талаар та өөр юу гэж боддог вэ?  
 
 
Танд баярлалаа 
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ЭМЧ НАРТАЙ ХИЙХ ЯРИЛЦЛАГА  
Мэдээлэл цуглуулах загвар 
_______________________        
Огноо  
Дугаар  _____________________              
Байршил_____________________ 
               
1. Нас:  20-30  31-50  51-60  61+                                                 
2. Хүйс:  Эр  Эм  
3. Ажлын түвшин:  өрхийн эмч      улсын эмнэлэг   хувийн эмнэлэг    
бусад   
4. Мэргэжил:         ерөнхий эмч     нарийн мэргэжлийн  
5. Хэдэн жил ажиллаж байгаа вэ? _______ 
6. Уушигны хатгалгаатай өвчтөнд эмчилгээ бичихэд юу нөлөөлдөг вэ?  
 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Өвчтөний хүлээлт / шаардлага       
2. Зайлшгүй шаардлагатай  
 хөнгөлөлттэй олгогдох эм       
3. Эмийн компаний мэдээлэл       
4. Эмийн компанийн  
 төлөөлөгчийн айлчлал       
5. Уушигны хатгалгаа өвчний  
 оношлогоо, эмчилгээний 
 удирдамж  
     
6. Тасралтгүй сургалт,  
  хичээлийн мэдээлэл        
7. Гаж нөлөө үүсэх магадлал       
8. Орон нутгийн антибиотикийн  
 даслын тухай мэдээлэл       
9. Өвчтөний антибиотикийн  
         даслын мэдээлэл       
10. Ном, сэтгүүл       
11. Хамт ажилладаг дарга,  
       хүмүүс, эмч нарын нөлөө       
12. Нарийн мэргэжлийн эмч       
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    нарын нөлөө  
13. Хувийн туршлага       
14. Өвчтөний урьд нь эмийн  
    сангаас авсан, хэрэглэж  
    байсан антибиотикийн тухай  
    мэдээлэл 
     
15. Эмийн хүртээмж       
16. Өвчтөний эм худалдан авах  
    Чадвар      
17. Өргөн хүрээний идэвхтэй 
       антибиотик хамгийн шилдэг   
       сонголт  
     
18. Зах зээлд шинээр гарч буй  
    эмүүдийг сонгох/ илүүд үзэх       
19. Жор бичилтийг хянах улсын  
   шалгалт       
20. Хууль бус зүйл хийх эрсдэл       
21. Эмийн компаниас авах  
   урамшуулал, шагнал       
 
7. Уушигны хатгалгаатай өвчтөнд тодорхой эмийн тун бичихэд ямар хүчин зүйлс 
нөлөөлдөг вэ?   
 Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Тариан эмчилгээ уух эмнээс   
       илүү үр дүнтэй байдаг       
2. Өвчтөн уух эмийг тарианаас илүүд 
үздэг       
3. Тарилгын эмийн чанар уух эмнээс 
     илүү сайн       
4. Эмийг ууж хэрэглэхэд тарьснаас 
       илүү их гаж нөлөө үүсдэг       
5. Тарилгын эмээс зүү тариурын хамт, 
     уух эмийн зардал илүү үнэтэй      
6. Тариан эмчилгээ хийлгэж байгаа 
    тохиолдолд эмнэлэг  рүү илүү олон    
    удаа явах хэрэгтэй байдаг  
     
7. Тариа хийхэд шинэ, ариун зүү       
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      тариур ашиглах шаардлагатай 
8. Уушигны хатгалгаатай өвчтөнг 
    эмчилж байх явцад тарианаас уух  
    антибиотик эмийн хэлбэр лүү  
    шилжих хэрэгтэй  
     
9. Эмийн компаниуд тарилгын эмийг    
    илүү ихээр сурталчилдаг       
10. Өвчтөнийг эмчилгээг илүү сайн 
     даган мөрдүүлэхийн тулд тариаг  
     сонгосон   
     
11. Сургалтанд тариаг шахмал/ 
капсултай эмнээс илүү ихээр 
хэрэглэхийг заадаг  
     
12. Тариа бичихэд УХ өвчний  
     явц/хүндрэл нөлөөлдөг       
13. Эм бичихэд өвчтөний онцлог, нас  
     хүйс хамаатай       
 
8.  
1. УХ өвчнийг тариагаар эмчлэх дундаж хугацаа:   
 
 ≤3 өдөр   4-5 өдөр   > 5 өдөр эмчилгээ эхэлсний дараа 
 
2. УХ өвчнийг эмээр эмчлэх дундаж хугацаа:   
 
 ≤ 3 өдөр   4-5 өдөр   > 5 өдөр эмчилгээ эхэлсний дараа 
 
3. УХ-тай өвчтөнийг тариан эмчилгээнээс эмийн эмчилгээнд шилжүүлэхэд ямар 
хугацаа шаардлагатай вэ?  
 
 ≤ 24 цаг   2 өдөр   3-5 өдөр   > 5 өдөр эмчилгээ эхэлсний 
дараа  
 
9. Монгол улсын УХ өвчний удирдамжмийг та тохиромжтой гэж боддог уу?  
 Тийм     Үгүй    ХБ 
 /Хариулах боломжгүй/ 
 
10. УХ-тай өвчтөнд та нэгээс илүү антибиотик нэгэн зэрэг бичдэг үү?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
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11. Эхний бичсэн антибиотик амжилтгүй байсан тул антибиотикийг солих шаардлага  
   хэр олон удаа байсан бэ?  
 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
      
 
12. УХ-тай өвчтөнд ихэвчлэн бичдэг антибиотикийн жагсаалт  
  Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1.  Пенициллин,уух      
2. Пенициллин, тариа      
3. Амоксициллин, уух      
4. Амоксициллин, тариа      
5. Ампициллин, уух      
6. Ампициллин, тариа      
7. Ципрофлоксацин, уух      
8. Ципрофлоксацин, тариа      
9. Цефазолин, уух      
10. Цефазолин, тариа      
11. Эритромицин, уух      
12. Эритромицин, тариа      
13. Амоксициллин/клавунат, уух      
14. Кларитромицин, уух      
15. Кларитромицин, тариа      
16. Азитромицин, уух      
17. Азитромицин, тариа      
18. Левофлоксацин, уух      
19. Тетрациклин, уух      
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20. Триметопим-
сульфаметоксазол, уух 
     
21. Доксициллин, уух      
 
 
13.  УХ-тай өвчтөнд антибиотикаас гадна ямар эм бичдэг вэ?  
  Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1.  Дексаметазон, уух      
2.  Дексаметазон, тариа      
3. Бромгексин, уух      
4. Витамин С, уух      
5. Витамин С, тариа      
6. Хлорфенамин, уух      
7. Витамин В, уух      
8. Витамин В, тариа      
9. Кокоркарбоксилаз, тариа      
10. Эуфиллин, уух      
11. Эуфиллин, тариа      
12. Анальгин, уух      
13. Анальгин, тариа      
14. Димедрол, уух      
15. Димедрол, тариа      
 
14. Антибиотикийг жороор бичих талаар улсаас хэдэн удаа мэдээлэл авдаг вэ?  
 Хэзээ 
ч үгүй 
7 хоног 
тутам 
Сар 
болгон 
Жилд 3 удаа Жилд 1 удаа 
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15. УХ-тай өвчтөн тань дээр ирэхээсээ өмнө антибиотик хаанаас ихэвчлэн худалдан 
авсан  
          байдаг вэ?  
 Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
1. Эмийн сан      
2. Зах      
3. Бусад/хувиараа/__      
 
16. Антибиотик бичихдээ та хэр их женерик эм бичдэг вэ?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
      
 
17. Антибиотикийн мэдрэг чанар, идэвхийн талаар хаанаас мэдээлэл авдаг вэ?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
1. Улсын мэдээлэл       
2. Улсын ном, сэтгүүл       
3. Антибиотик эмийн 
савны хуудас       
4. Эмнэлэг      
5. Эмчлэгдсэн өвчтөн       
6. Хамт ажилладаг  
       хүмүүс       
7. Антибиотик идэвхгүй       
8. Интернэт       
 
18. УХ-тай өвчтөнг хэр их эмнэлэг рүү явуулдаг вэ? 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
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19. Монгол улсад тариаг хэтрүүлэн хэрэглэдэг гэж та боддог уу?  
МЗ- Маш их зөвшөөрч байна, З- Зөвшөөрч байна, Т- Татгалзаж байна 
МТ- Маш их татгалзаж байна, ХБ- Хариулах боломжгүй   
 
  
МЗ З Т МТ ХБ 
       
 
20. Хэрэв тийм бол тодруулна уу? 
 МЗ З Т МТ ХБ 
1. Өвчтөн эмийн сангаас тариа 
худалдан авах боломжтой       
2. Улсаас эмийн худалдааг хянах 
шалгалт хангалтгүй       
3. Олон нийтийн шаардлага, хэрэгцээ       
21. Монголд хуурамч эм байдаг эсэхийг та мэдэх үү?  Тийм                      Үгүй 
22.       Хэрэв тийм бол ямар эм хуурамч байсан бэ? 
 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
a. Антибиотик  
 
     
b. Бусад эм       
 
23. Таны дундаж орлогыг мэдэж болох уу?  
≤ 90.000₮    91-200.000₮  201-300.000₮  
301-400.000₮    401-500.000₮   ≥501.000₮  
24. Уушигны хатгалгаа болон тарианы хэрэглээний талаар та өөр юу гэж боддог вэ?  
______________________________________________ 
Танд баярлалаа 
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Appendix	G	Revised	questionnaire	forms		
 
After piloting questionnaires to ensure that questions were clear and 
understandable, some word modifications and order of the questions were 
made.  
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INTERVIEW WITH COMMUNITY MEMBERS (REVISED)  
DATA COLLECTION FORM 
_______________________        
Date 
Code _____________________          
Residential location (suburb/town)_______________________ 
                  
1.  Age:  20-30  30-50  60+                                                      
2. Gender:  M  F  
3. Marital Status:  Single  Married  Divorced  Separated   
Widowed 
4. Education:   Primary  Secondary  Tertiary  Other 
5. Occupation:  Unemployed    Civil servant Employed  
Military 
6. (a) Have you had an injection in the past?  Yes / No 
(b) If ‘Yes’, how long ago did you have your last injection?   
 
< 1 month  1-6 months  6-12 months  > 1 year 
7. What reason did you have the last injection? 
 Yes No 
1. Treatment of an illness    
2. Immunisation    
3. Contraception  (only female respondents)   
4. Other- vitamins, etc.    
 
8. Was the injection you had? 
 
 
 
 
 
 
Yes No 
1. Single injection(s)    
2. Continuous drip    
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9.  Can you remember how many injections you had for the last single course of 
treatment? 
  one  2 – 4  5 – 8  >8 
10. Do you remember if after some injections you then had similar medication by mouth?  
   Yes   No 
11. Do you remember what the illness was? 
________________________________________ 
12. Do you know what the medicine was? 
__________________________________________ 
 
These are questions related to your past experience with injections 
13. When you had an injection, did you have any of the following unwanted/adverse 
effects? 
  Yes No 
1. Persistent redness   
2. Warmth at the injection site   
3. Swelling or hardness under the skin   
4. Drainage of fluid from the injection site    
5. Fever caused by the injection    
6. Persistent pain at the injection site    
7. Felt weak   
8. Fainted   
 
14. What do you think was the cause of that complication/ side effect?  
 Yes No 
1. Person who administered the injection   
2. The drug itself   
3. Bad equipment, syringe, drip etc   
4. I do not know these effects could occur    
5. Others, specify    
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15. What happened following your unwanted/side effect? 
 Yes No 
1. Went to hospital   
2. Consulted doctor   
3. Consulted the pharmacist   
4. Nothing   
 
16. How long did it last? ________ 
17. Who prescribed injections for you? 
 Yes Sometimes No 
1. Doctor    
2. Pharmacist    
3. Nurse    
4. Traditional practitioner   
18. Where do you purchase your injections? 
 Yes Sometimes No 
1. Doctor    
2. Pharmacy    
3. Nurse    
4. Detailer  
19. Who administered your injections to you? 
 Yes Sometimes No 
1. Doctor    
2. Pharmacy    
3. Nurse    
4. Friend / relative                                
5. Traditional practitioner    
6. Other (specify)    
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 Amount 
/MNT/ 
Did you think 
that the price 
was affordable? 
Was it 
reimbursed? 
20. How much did you pay for 
your last visit to the doctor? 
 Yes No Yes No
    
21. How much did you pay for  
purchasing injections from a 
pharmacy? 
     
22. How much did you pay for  
administration of  injection 
purchased from a pharmacy? 
     
23. If you go to see the doctor, do you expect to receive injections for treatment?   
 Yes    Sometimes     No 
If yes, 
 
Yes Sometimes No 
   
 
1. The doctors prescribe injections 
when I don’t want to have     
2. I would prefer the doctor to 
prescribe me with an injection 
   
 
24. Do you think an injection is a better treatment? 
 Yes    Sometimes     No 
 
 
If yes,  
Yes Sometimes No 
1. The treatment with injection 
works faster                                        
2. The treatment with injection is 
more affordable    
3. You prefer injections because you 
would forget to take 
tablets/capsules 
   
4. If a doctor prescribes 
tablets/capsules do you think that 
treatment will work for you 
   
5. Injections are recommended by 
friends, relatives, colleagues     
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6. Injections are advertised more by 
pharmaceutical companies than 
oral drugs                                   
   
7. Having an injection is a personal 
preference      
25. Are you aware of the need for using new clean syringes and needles for every 
injection? 
 Yes                   Sometimes  No 
 
 
26. Which of the following is important to you when getting an injection? 
 Yes Sometimes No
1. Price    
2. Local or imported product    
3. Package condition     
4. Expiry date    
 
27. Would you go to another doctor/ pharmacy, if an injection was not prescribed/ 
dispensed by the  first person? 
Yes   Sometimes   No 
 
 
28. Would you be disappointed if an injection was not prescribed/ dispensed? 
  Yes    Sometimes               No 
 
29. Do you refuse injections when prescribed/ dispensed? 
  Yes    Sometimes     No 
 
 
If yes, please explain the reasons: 
Yes Sometimes No 
1. Fear of pain    
2. Fear of needle, infection etc.     
3. Do not trust the doctor/  
          pharmacist 
   
4. It is possible to get better without an 
injection 
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5. There are many tablets available for 
many common diseases    
6. The illness will go away on its own 
with time    
7. Lack of clean syringes and     
         needles 
   
8. Other (specify)    
 
 
30. Are you aware of counterfeit medicines in Mongolia?   Yes    No 
 
 
 
31. If yes, have you encountered problems with counterfeit medicines? 
 
 
 
 
 
 
 
 
32. May I ask about your approximate monthly income?  
≤ 90.000MNT    91-200.000MNT  201-300.000MNT  
301-400.000MNT    401-500.000MNT   ≥501.000MNT  
 
 
33. Do you want to discuss about any other issues related to the treatment of CAP and 
injection practices in Mongolia?  
 
______________________________________________ 
Thank you for your time 
   
 Yes Sometimes No 
a. Antibiotics    
b. Other medications    
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INTERVIEW WITH PHARMACITS, PHARMACY TECHNICIANS (REVISED)  
DATA COLLECTION CARD 
_______________________        
Date 
Code _____________________         
Location_____________________ 
               
1. Age:  20-30  30-50  50-60  60+                                                 
2. Sex:  Male  Female   
3. Occupation level:         Owner      Employer 
4. Profession:    Pharmacist     Pharmacy technician 
5. Working years: ______________________ 
 
 
Following questions are related to the prescribed medicines  
 
6.  
List of antibiotics dispensed for patients with pneumonia with prescription from a 
doctor: 
  Never
0%  
Rarely
1-10% 
Sometimes   
11-40% 
Often
41-80% 
Always
>80% 
1 Penicillin, oral      
2 Penicillin, injection      
3. Amoxicillin, oral      
4. Amoxicillin, injection      
5. Ampicillin, oral      
6. Ampicillin, injection      
7. Ciprofloxacin, oral      
8. Ciprofloxacin, injection      
9. Cefazolin, oral      
10. Cefazolin, injection      
11. Erythromycin, oral      
12. Erythromycin, injection      
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13. Amoxicillin/clavulanate, oral      
14. Clarythromycin, oral      
15. Clarythromycin, injection      
16. Azithromycin, oral      
17. Azithromycin, injection      
18. Levofloxacin, oral      
19. Tetracycline, oral      
20. Trimethopim- sulfamethoxazole, 
oral 
     
21. Doxycycline, oral      
 
7. Which other medicines the physician also prescribes for patients with pneumonia?   
  Never
0%  
Few
1-10% 
 Sometimes   
11-40% 
Mostly
41-80% 
Always
>80% 
1. Dexamethasone, oral      
2. Dexamethasone, injection      
3. Bromhexine, oral      
4. Acidi ascorbinici, oral      
5. Acidi ascorbinici, injection      
6. Chlorfenamin, tab      
7. Vitamin B complex, oral      
8. Vitamin B complex, injection      
9. Cocorcarboxylase, injection      
10. Euphyllin, oral      
11. Euphyllin, injection      
12. Analgin, oral      
13. Analgin, injection      
14. Dimedrol, oral      
15. Dimedrol, injection      
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8. How often the physician prescribes more than one antibiotic for patients with 
pneumonia at the same time? 
 Never 
0%  
Rarely
1-10% 
Sometimes   
11-40% 
Often
41-80% 
Always
>80% 
      
 
 
9. The following influence your dispensing the prescribed medicines for patient with 
pneumonia?   
 
 SA A D
A
SD NR 
1. Selection of reimbursable generic drugs via 
    EDLM (concession rates)        
    
2. Appropriate children’s treatment (dosage  
   adjustment) 
    
3. Appropriate adults treatment (dosage  
    adjustment) 
    
4. Patient’s severity      
5. Duration of treatment of medicines in the 
   prescription 
    
6. Knowledge of adverse effects of drugs (e.g. 
drug allergies)     
7. Legislative documents, such as standard on 
       prescribing and dispensing practice of    
          Mongolia  
    
8. Guidelines for treatment of CAP      
9. Patient’s compliance with treatment      
10. Patient is not satisfied with the treatment if 
injection is not prescribed     
11. Ability of patient to buy prescription 
medicines without prescription     
12. The price is important when dispensing 
       generic and brand medicines   
    
13. Expiry date of medicine      
14. Practice to re-use medicines      
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10. How often do you have to change the prescriptions for CAP because the prescription 
was inappropriate? 
 
 
Never 
0%  
Rarely
1-10% 
Sometimes  
11-40% 
Often 
41-80% 
Always
>80% 
      
 
11.  
1. Duration of treatment by prescribed injections continues… days:  
 
 ≤3 days   4-5 days   > 5 days  
 
2. Duration of treatment by prescribed oral medicines  lasts for … days:  
 
 ≤ 3 days   4-5 days   > 5 days 
 
3. To transfer the patient with pneumonia from injection to oral medicines 
the switch time is: 
 
 ≤ 24 hours   2 days   3 days   > 5 days /after the beginning of 
treatment/ 
 
 
 
The following questions are related to non prescribed medicines   
 
12. Following drugs are dispensed for the patients with pneumonia without prescription: 
  Never
 0%  
Rarely
1-10% 
Sometimes  
11-40% 
Often
41-80% 
Always
>80% 
1. Penicillin, oral      
2. Penicillin, injection      
3. Amoxicillin, oral      
4. Amoxicillin, injection      
5. Ampicillin, oral      
6. Ampicillin, injection      
7. Ciprofloxacin, oral      
8. Ciprofloxacin, injection      
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9. Cefazolin, oral      
10. Cefazolin, injection      
11. Erythromycin, oral      
12. Erythromycin, injection      
13. Amoxicillin/clavulanate, oral      
14. Clarythromycin, oral      
15. Clarythromycin, injection      
16. Azithromycin, oral      
17. Azithromycin, injection      
18. Levofloxacin, oral      
19. Tetracycline, oral      
20. Trimethopim- sulfamethoxazole, oral      
21. Doxycycline, oral      
 
 
 
 
13. Which medicines are dispensed without prescription for the patient with pneumonia?   
 
  Never 
0%  
Rarely
1-10% 
Sometimes  
11-40% 
Often
41-80% 
Always
>80% 
1.  Dexamethasone, oral      
2. Dexamethasone, injection      
3. Bromhexine, oral      
4. Acidi ascorbinici, oral      
5. Acidi ascorbinici, injection      
6. Chlorfenamin, tab      
7. Vitamin B complex, oral      
8. Vitamin B complex, injection      
9. Cocorcarboxylase, injection      
10. Euphyllin, oral      
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11. Euphyllin, injection      
12. Analgin, oral      
13. Analgin, injection      
14. Dimedrol, oral      
15. Dimedrol, injection      
 
14. The followings influence the dispensing the not prescribed medicines for patient with 
pneumonia?  
 SA A DA SD NR 
1. The clinical effect of injections is more potent 
than oral medicines’  
     
2. The quality of injections better than tablets/ 
capsules   
     
3. The adverse events occur with oral drugs more 
than with injections  
     
4. The dosage form of injection is chosen for better 
compliance of a patient  
     
5. The injection requires new syringes and needles       
6. There is no benefit for the transfer of patient with 
pneumonia from injection to oral medicines   
     
7. Training promotes more about treatment with an 
injection than oral medicines     
     
8. There is lot of advertisement about injection by 
drug companies compared to oral medicines   
     
9. Prefer to dispense newly distributed medicines in 
the market  
     
10. Cost of treatment by oral medicines is more than 
the treatment cost with injections /including cost of 
syringes and needles/ 
     
11. If patients are prescribed an injection, they are 
required to visit a pharmacy several times  
     
12. Better patient compliance is achieved by 
choosing an injection  
     
13. Patient prefer to use tablets rather than injection       
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14. When dispensing injection, patient’s age, gender 
are important  
     
15. Injection is chosen if patient had severe CAP      
 
15. When you dispense not prescribed drugs for patient with pneumonia how often do 
you give more than one antibiotic at the same time? 
 Never 
0%  
Rarely
1-10% 
Sometimes  
11-40% 
Often 
41-80% 
Always
>80% 
      
 
1. The normal duration of dispensed antibiotics for CAP by injection is:   
 
 ≤3 days   4-5 days   > 5 days 
 
2. The normal duration of dispensed antibiotics for CAP orally is:  
 
 ≤ 3 days   4-5 days   > 5 days  
 
3. If the treatment of CAP is switched from injection to oral, the time of the 
switch from an injection is: 
 
 ≤ 24 hours   2 days   3 days   > 5 days after commencing 
treatment 
 
16.  How often do you receive governmental information of antibiotic’s resistance? 
 Never Weekly  Monthly 3 times a year  
Once a 
year 
      
 
17. Do you think that Mongolian pneumonia treatment guide is appropriate?   
 Yes     No      NR 
 
18. How often do you send the patients with pneumonia who come to your pharmacy to 
hospital?   
 
 Never
0%  
Rarely
1-10% 
Sometimes  
11-40% 
Often
41-80% 
Always
>80% 
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19. Do you think treatment of patient with pneumonia by injection is more effective than 
oral medicines?     
    Yes       No  
 
 
20. If yes, what is effect of injection?    
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
1. The effect is quick      
2. Adverse effect is less 
frequent than with 
tablets/capsules  
     
 
21. Who financially benefits most from treatment with an injection?  
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
1. Physician      
2. Pharmacist      
3. Patient      
4. Nurse      
 
22. Do you charge money for administering injection to the patient?  
 Yes, _______₮  No 
 
23. Do you think that the price is affordable for dispensing and administering the 
injection to patient?  
 Yes    No    NR 
 
 
24. When dispensing injections what do you think about the most?  
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
1. Supply of injectables from 
registered and wholesaling 
companies with authorization 
     
2. Use of sterile syringes and 
needles  
     
3. Completeness of injection’s 
package  
     
4. Self-diagnosis of patient and 
his/her wishes to buy injection   
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5. Re-use of antibiotic      
6. Expired date of re-used product      
 
 
25.  Do you think in Mongolia people overuse antibiotics? 
 SA A D SD NR 
       
 
26. If yes, please describe the reasons? 
 SA A D SD NR 
1. Ability to easily buy injection from 
pharmacies  
     
2. Insufficient government control 
for retail sale  
     
3. Strong public desire of injection      
 
27. After use of syringe:   
 Never
0%  
Rarely
1-10% 
Sometimes   
11-40% 
Often
41-80% 
Always
>80% 
1. You can change the needle 
and keep the syringes to 
reuse 
     
2. Use and reuse the needle and 
syringe after sterilizing       
3. Discard      
4. Use once and destroy      
28. After administering an intravenous drip:  
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
1. You give bottle to patient       
2. Keep the remaining volume of 
injection for next use        
3. Use remaining powder for 
next patient         
4. Use once and discard all       
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29. Where do you obtain the pharmaceutical? 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
1. Drug wholesaler      
2. Pharmacy      
3. Seller/ Agent      
4. Other (personal import)      
 
 
30. Do you know if there are any counterfeit medicines in Mongolia?   Yes    
No 
 
31. If yes what kind of? 
 Never
0%  
Rarely
1-10% 
Sometimes 
11-40% 
Often
41-80% 
Always
>80% 
a. Antibiotic      
b. Other drugs       
 
32. May I ask your monthly average income?  
≤ 90.000₮    91-200.000₮  201-300.000₮  
301-400.000₮    401-500.000₮   ≥501.000₮  
 
33. Do you want to discuss about any other issues related to prescribing for CAP and its 
treatment in Mongolia?   
 
Thank you very much! 
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INTERVIEW WITH DOCTORS (REVISED)  
DATA COLLECTION CARD 
_______________________        
Date 
Code      _____________________              
Location            ____________________ 
 
               
1. Age:  20-30  31-50  51+                                                     
2. Sex:  Male  Female  
3. Occupation level:  Family doctor      Governmental hospital   
                              Private hospital        Other   
4. Profession:         General doctor     specialist  
5. How many years are you working? _______ 
6. What influences to prescribe a treatment on patients with pneumonia?   
 
 Never
0%  
Rarely
1-10% 
Sometimes   
11-40% 
Often
41-80% 
Always
>80% 
1. Patient expectation/ need       
2. Reimbursable drugs of EDL              
3. Pharmaceutical company information       
4. Pharmaceutical company 
     representatives visit    
     
5. Pneumonia treatment guidelines       
6. Intensive training and lessons  
     information   
     
7. Likelihood of side effects      
8. Local antibiotic resistance data      
9. Information about patient’s  
       antibiotic sensitivity   
     
10. Journals, books and professional  
      publications   
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11. Influence from co-workers, doctors 
and directors      
12. Influence from specialists       
13. Own experience       
14. Information on previously used 
       antibiotics bought from pharmacy    
       by a patient   
     
15. Medicine’s availability        
16. Patient’s ability to buy medicine       
17. The best choice is effective 
   antibiotic with proven low     
   resistance 
     
18. Prefer to choose newly distributed 
         brands in the market   
     
19. Government control on prescribing       
20. Incentive from drug  companies       
 
7. What influences your choice when prescribing medicines to patient with pneumonia?  
  
 Never
0%  
Rarely
1-10% 
Sometimes   
11-40% 
Often
41-80% 
Always
>80% 
1. Injection has a better effect than 
oral medicine       
2. Patients prefer oral medicine than 
injection       
3. The pharmaceutical quality of 
injection is better than oral medicine       
4. Oral medicines have more side 
effects        
5. Cost of treatment by  injection 
(incl. syringes and needles) is more 
than cost of treatment by oral 
medicines 
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6. If patient has an injection, he/she 
is required to visit a hospital several 
times  
     
7. The injection requires new sterile 
syringes and needles  
     
8. When treating patient with 
pneumonia it is better to shift injection 
treatment to oral medicine treatment 
once the patient’s condition had 
improved 
     
9. Medicine companies advertise 
more about injection treatment than 
oral forms  
     
10. In order to follow treatment more 
effectively by patient, injection was 
chosen     
     
11. Trainings teach the usage of 
injections more than usage of 
tablets/capsules   
     
12. The severity of pneumonia 
influences the prescribing of injection        
13. Patient’s characteristics, such as 
age, gender and severity have 
influence on prescribing   
     
 
8.  
1. Average treatment days with injection for patients with pneumonia:   
 
 ≤3 days    4-5 days  > 5 days after treatment started 
2. Average treatment days with oral medicine for patients with pneumonia:   
 
 ≤ 3 days   4-5 days   > 5 days after treatment started 
 
             3. How many days required shifting injection treatment to oral medicine treatment?  
 
 ≤ 24 hours   2 days   3-5 days   > 5 days after treatment started 
 
9. Do you think that Mongolian pneumonia treatment guide is appropriate?   
 Yes    No    don’t know 
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10. Do you prescribe more than one antibiotic to patient with pneumonia at the same 
time?    
 Never
0%  
Rarely
1-10% 
Sometimes
11-40% 
Often 
41-80% 
Always
>80% 
      
 
11. How many times did you change antibiotics when first antibiotic did not have any 
effect?    
 
 Never
0%  
Rarely
1-10% 
Sometimes
   
11-40% 
Often 
41-80% 
Always
  
>80% 
      
 
 
12. What kind of antibiotic do you prescribe usually for patients with pneumonia?   
  Never
0%  
Rarely
1-10% 
Sometimes 
 11-40% 
Often 
41-80% 
Always
>80% 
1. Penicillin, oral      
2. Penicillin, injection      
3. Amoxicillin, oral      
4. Amoxicillin, injection      
5. Ampicillin, oral      
6. Ampicillin, injection      
7. Ciprofloxacin, oral      
8. Ciprofloxacin, injection      
9. Cefazolin, oral      
10. Cefazolin, injection      
11. Erythromycin, oral      
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12. Erythromycin, injection      
13. Amoxicillin/clavulanate, oral      
14. Clarythromycin, oral      
15. Clarythromycin, injection      
16. Azithromycin, oral      
17. Azithromycin, injection      
18. Levofloxacin, oral      
19. Tetracycline, oral      
20. Trimethopim- sulfamethoxazole, 
oral 
     
21. Doxycycline, oral      
 
13.  Beside antibiotics, what other kind of medicines do you prescribe to patient with 
pneumonia?  
  Never
0%  
Rarely
1-10% 
Sometimes   
11-40% 
Often 
41-80% 
Always
>80% 
1. Dexamethasone, oral      
2. Dexamethasone, injection      
3. Bromhexine, oral      
4. Acidi ascorbinici, oral      
5. Acidi ascorbinici, injection      
6. Chlorfenamin, tab      
7. Vitamin B complex, oral      
8. Vitamin B complex, injection      
9. Cocorcarboxylase, injection      
10. Euphyllin, oral      
11. Euphyllin, injection      
12. Analgin, oral      
13. Analgin, injection      
14. Dimedrol, oral      
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15. Dimedrol, injection      
 
 
 
14. How often do you receive information from government to prescribe antibiotics?  
 Never Every 
week 
Every 
month 
3 times a year Once a year
      
 
15. Where do your patients obtain/ buy antibiotics prior coming to you?  
 Never
0%  
Rarely
1-10% 
Sometimes
 11-40% 
Often 
41-80% 
Always
>80% 
1. Pharmacy      
2. Market      
3. Other /specify/__      
 
16. How often do you prescribe generic medicine when you prescribe antibiotics?  
 Never
0%  
Rarely
1-10% 
Sometimes
  11-40% 
Often 
41-80% 
Always
>80% 
      
 
17. Where do you obtain information about antibiotic’s effect, sensitivity data?   
 Never
0%  
Rarely
1-10% 
Sometimes
 11-40% 
Often 
41-80% 
Always
>80% 
1. Government information       
2. Professional books, 
journals   
     
3. Package of antibiotic      
4. Patient samples      
5. Cured patient       
6. Co-workers, colleagues       
7. No effect of antibiotic      
8. Internet source      
 
18. How often do you send patients with pneumonia to hospital? 
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 Never
0%  
Rarely
1-10% 
Sometimes
  11-40% 
Often 
41-80% 
Always
>80% 
      
 
19. Do you think in Mongolia people overuse antibiotics?   
 
 
  
SA A DA SD NR 
       
 
20. If yes, indicate please? 
 SA A DA SD NR 
1. Patients are able to buy medicine 
from pharmacy   
     
2. Insufficient control of medicine from 
government   
     
3. Public need and demand        
 
21. Do you know, is there any counterfeit/artificial medicines in Mongolia?  
 
 Yes                      No 
22. If yes, what kind of? 
 Never
0%  
Rarely
1-10% 
Sometimes
 11-40% 
Often 
41-80% 
Always
>80% 
a. Antibiotic 
 
     
b. Other       
 
23. May I ask your monthly average income?  
≤ 90.000₮    91-200.000₮  201-300.000₮  
301-400.000₮    401-500.000₮   ≥501.000₮  
 
24. Do you want to discuss about any other issues related to prescribing for pneumonia and 
its treatment in Mongolia?  
 
______________________________________________ 
Thank you very much! 
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Mongolian data collection forms (revised) 
 
ИРГЭДТЭЙ ХИЙХ ЯРИЛЦЛАГА (ШИНЭЧИЛСЭН) 
Мэдээлэл цуглуулах маягт 
           
__________________        
Огноо  
Дугаар _____________________          
Харъяалал (дүүрэг/хот)_______________________ 
                  
1. Нас:  20-30  31-50  51-60      61+                                                      
2. Хүйс: Эр  Эм  
3. Гэрлэлтийн байдал:  Ганц бие  Гэрлэсэн   Салсан   
  Тусдаа амьдардаг          Бэлэвсэн 
4. Боловсролын түвшин:  Анхан Бүрэн дунд  Дээд  Бусад 
5. Ажил:  Ажилгүй     Төрийн албан хаагч Ажилтай   
Цэргийн 
  Оюутан   
6. (a) Урьд нь тариа тариулж байсан уу?           Тийм      Үгүй 
(b) Хэрэв тийм бол хамгийн сүүлд хэзээ хийлгэсэн бэ?   
< 1 сар  1-6 сар  6-12 сар  > 1 жил 
Та 7-12 асуултад хариулахдаа 6 (b) хариулсан хугацаагаа бодож 
хариулна уу. 
7. Та ямар учраас тариа хийлгэсэн бэ? 
 Тийм Үгүй 
1. Өвчин   
2. Дархлаажуулалт (вакцин)    
3. Хамгаалалт (зөвхөн эмэгтэй хүмүүс)   
4. Бусад- витамин, гэх мэт.    
 
8. Та ямар тариа хийлгэсэн бэ?  
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9. Нэг удаагийн эмчилгээнд хэдэн төрлийн тариа хийлгэсэн бэ? 
  нэг   2 – 4  5 – 8  >8 
 
10. Тариа хийлгэсний дараа төстэй эм ууж байсан уу?  
   Тийм   Үгүй 
11. Ямар өвчин байсан бэ? ________________________________________ 
12. Ямар эм ууж байсан бэ? __________________________________________ 
Дараах асуултууд таны өмнө нь хийлгэж байсан тариатай холбоотой 
13. Тариа хийлгэсний дараа танд дараах гаж урвал/ нөлөөнөөс аль нэг нь илэрч 
байсан уу? 
  Тийм Үгүй 
1. Байнгын улаалт   
2. Тариа хийлгэсэн газар халуу оргих    
3. Арьсан дор хавдах эсвэл хатуурах    
4. Тариа хийлгэсэн газраас шингэн гарах     
5. Тарианаас шалтгаалсан халууралт    
6. Тариа хийлгэсэн газар байнга өвдөх    
7. Бие сул болох    
8. Ухаан алдах    
 
14. Таны бодлоор дээрх гаж нөлөө юунаас болж илэрсэн бэ?   
 Тийм Үгүй 
1. Тариа хийсэн хүнээс шалтгаалсан   
2. Тарианаас болсон    
3. Чанар муутай багаж, хатгуур, зүү зэргээс болсон   
4. Гаж нөлөө илэрнэ гэж мэдээгүй   
5. Бусад, тодруулна уу.................................................   
 
15. Та гаж нөлөө илэрсэн үед ямар арга хэмжээ авсан бэ?  
 
 
Тийм Үгүй
1. Нэг удаагийн (булчин, судас тариа)    
2. Дусал    
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 Тийм  Үгүй 
1. Эмнэлэг явсан    
2. Эмчээс зөвлөлгөө авсан   
3. Эм зүйчээс зөвлөлгөө авсан    
4. Юу ч хийгээгүй    
5. Бусад, тодруулна уу.................................................   
16. Хэр удаан үргэлжилсэн бэ? ______(хоног/цаг) 
17. Тариа хийлгэхийг хэн танд зөвлөж, бичиж өгдөг вэ? 
 Тийм Заримдаа Үгүй 
1. Эмч     
2. Эмч зүйч     
3. Сувилагч     
4. Уламжлалтын эмч   
18. Та тариаг ихэвчлэн хаанаас авдаг вэ? 
 Тийм Заримдаа Үгүй 
1. Эмч/ эмнэлэг    
2. Эм зүйч/эмийн сан     
3. Сувилагч     
4. Хувиараа эм худалдагч   
 
19. Танд тариа хэн хийдэг вэ? 
 Тийм Заримдаа Үгүй 
1. Эмч    
2. Эм зүйч     
3. Сувилагч     
4. Найз / хамаатан                                 
5. Уламжлалтын эмч    
6. Бусад (тодруулна уу)_______    
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 Мөнгөн 
дүн /₮/ 
Энэ төлбөр 
таны хувьд 
бололцооны 
байсан уу? 
Даатгалаас 
нөхөн 
олгогдсон уу? 
20. Эмч дээр хамгийн сүүлд  
          очихдоо ямар төлбөр төлсөн  
          бэ? (ойролцоогоор) 
 Тийм Үгүй Тийм Үгүй
    
21. Эмийн сангаас тариа 
авахдаа  
          ямар төлбөр төлсөн бэ?       
          (ойролцоогоор) 
     
22. Эмийн сангаас авсан тариа  
          хийлгэхдээ хэдэн төгрөг  
          төлсөн бэ? (ойролцоогоор) 
     
 
23. Та эмч рүү очихдоо тариа бичүүлнэ гэж боддог уу?   
 Тийм   Заримдаа     Үгүй 
Шалтгаан нь юу вэ?  
 
Тийм Заримдаа Үгүй 
 
1. Эмч намайг хүсээгүй байхад 
тариа бичдэг     
2. Эмч надад тариа бичээсэй гэж 
би хүсдэг     
24. Тариагаар эмчлэх нь илүү үр дүнтэй гэж боддог уу? 
 Тийм    Заримдаа     Үгүй 
 
Шалтгаан нь юу вэ?  
Тийм Заримдаа Үгүй 
1. Тариагаар эмчлэхэд илүү   
хурдан эдгэрдэг                                 
2. Тариагаар эмчлэх нь илүү  
хямд     
3. Эм уухаа мартаад байдаг учир  
тариагаар эмчлэхийг илүүд  
үздэг  
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4. Эмч шахмал капсултай эм   
бичиж өгөхөд уг эмчилгээ үр  
дүнтэй гэж боддог 
   
5. Миний найз нөхөд, хамаатан,  
хамт ажилладаг хүмүүс надад   
тариа хийлгэхийг зөвлөдөг  
   
6. Эмийн компаниуд тариаг уух 
эмийн хэлбэрээс илүү   
сурталчилдаг                                
   
7. Хувьдаа тариа хийлгэхийг 
илүүд үздэг     
25. Тариа хийлгэх болгонд шинэ цэвэр зүү тариур хэрэглэх ёстой гэж та мэддэг үү? 
 Тийм                   Заримдаа             Үгүй 
 
26. Таны бодлоор доорх сонголтуудаас тариа хийлгэхэд юу нь чухал бэ? 
 Тийм Заримдаа Үгүй
1. Үнэ     
2. Импортын эсвэл дотоодын     
    бүтээгдэхүүн     
3. Савлалтын байдал     
4. Дуусах хугацаа     
 
27. Хэрвээ анх очсон эмч, эмийн санч танд тариа өгөхгүй бол та өөр газар луу 
явдаг уу? 
Тийм   Заримдаа   Үгүй 
 
28. Хэрвээ танд тариа өгөхгүй бол та сэтгэл дундуур байдаг уу? 
  Тийм    Заримдаа    Үгүй 
29. Тариаг хэрвээ танд бичсэн, олгосон тохиолдолд та татгалзах уу? 
  Тийм    Заримдаа     Үгүй 
 
Шалтгааныг тайлбарлана уу: 
Тийм Заримдаа Үгүй 
1. Өвдөхөөс айдаг     
2. Зүү, тариа зэргээс айдаг      
3. Эмч, эмийн санчид итгэдэггүй    
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4. Тариа хийлгэхгүйгээр эдгэрэх 
боломжтой     
5. Ихэнх өвчнийг эдгээх уух шахмал 
    эм, капсул байдаг     
6. Хэсэг хугацааны дараа өвчин   
    өөрөө эдгэрнэ    
7. Цэвэр тариур, зүү байхгүй бол 
Татгалзана    
8. Бусад (тодруулна уу)________    
 
30. Монголд хуурамч эм байдаг эсэхийг та мэдэх үү?   Тийм    
Үгүй 
 
31. Хэрэв тийм бол ямар эм хуурамч байсан бэ? 
 
 
 
32. Таны дундаж орлогыг мэдэж болох уу?  
≤ 90.000₮    91-200.000₮  201-300.000₮  
301-400.000₮    401-500.000₮   ≥501.000₮  
 
33. Уушигны хатгалгаа өвчин болон бусад өвчний үед тариа хэрэглэхийг та юу гэж 
боддог вэ? Саналаа бичнэ үү.   
 
______________________________________________________________________ 
 
Танд баярлалаа 
	
 Тийм Заримдаа Үгүй 
a. Антибиотик    
b. Бусад эм (тодруулна уу)__________    
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ЭМ ЗҮЙЧ, ЭМ НАЙРУУЛАГЧТАЙ ХИЙХ ЯРИЛЦЛАГА (ШИНЭЧИЛСЭН) 
Мэдээлэл цуглуулах маягт 
_______________________        
Огноо 
Код _____________________         
Харъяалал_____________________ 
               
1. Нас:  20-30  30-50  50-60  60+                                                 
2. Хүйс:  Эр  Эм   
3. Ажлын зэрэглэл:         Эзэмшигч      Ажилтан  
4. Мэргэжил:    Эм зүйч     Эм найруулагч  
5. Ажилласан жил: ______________________ 
 
Жоронд бичигдсэн эмүүдэд дараах асуултууд хамаатай  
6. Уушигны Хатгалгаатай /УХ/-тай өвчтөнд эмч жор бичихдээ дараах эмүүдийг 
бичдэг 
  Хэзээ ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Пенициллин,уух      
2. Пенициллин, тариа      
3. Амоксициллин, уух      
4. Амоксициллин, тариа      
5. Ампициллин, уух      
6. Ампициллин, тариа      
7. Ципрофлоксацин, уух      
8. Ципрофлоксацин, тариа      
9. Цефазолин, уух      
10. Цефазолин, тариа      
11. Эритромицин, уух      
12. Эритромицин, тариа      
13. Амоксициллин/клавунат, уух      
14. Кларитромицин, уух      
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15. Кларитромицин, тариа      
16. Азитромицин, уух      
17. Азитромицин, тариа      
18. Левофлоксацин, уух      
19. Тетрациклин, уух      
20. Триметопим-сульфаметоксазол, 
уух 
     
21. Доксициллин, уух      
 
7. УХ-тай өвчтөнд ямар эмүүдийг давхар бичдэг вэ?  
  Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Дексаметазон, уух      
2. Дексаметазон, тариа      
3. Бромгексин, уух      
4. Витамин С, уух      
5. Витамин С, тариа      
6. Хлорфенамин, уух      
7. Витамин В, уух      
8. Витамин В, тариа      
9. Кокоркарбоксилаз, тариа      
10. Эуфиллин, уух      
11. Эуфиллин, тариа      
12. Анальгин, уух      
13. Анальгин, тариа      
14. Димедрол, уух      
15. Димедрол, тариа      
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8. УХ-тай өвчтөнд эм бичихдээ эмч нар нэгээс олон антибиотик хэр их бичдэг вэ? 
 Хэзээ ч үгүй
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
      
9. УХ-тай өвчтөнд жоронд бичигдсэн эм олгоход дараах хүчин зүйлс нөлөөтэй?   
ХЗ: Хүчтэй зөвшөөрч байна, З: Зөвшөөрч байна, Т: Татгалзаж байна, ХТ: Хүчтэй 
татгалзаж байна, ХБ: Хариулт байхгүй 
 ХЗ З Т ХТ ХБ 
1. Хөнгөлөлттэй үнээр олгогдох зайлшгүй 
        шаардлагатай эм       
2. Хүүхдийн эмчилгээ (тун, хэлбэрийг 
   тохируулах)      
3. Насанд хүрсэн хүний эмчилгээ (тун, 
   хэлбэрийг тохируулах)      
4. Өвчтөний биеийн байдал        
5. Жоронд бичигдсэн эмийн хугацаа      
6. Эмийн гаж нөлөөний тухай мэдлэг       
7. Жоронд бичигдсэн эмэн эмчилгээний 
        хугацаа      
8. Эм олгох журам, стандарт зэрэг баримт      
9. Эмчилгээний удирдамж       
10. Өвчтөний эмчилгээ дагах чадвар      
11. Өвчтөн тариа хийлгэхгүй бол сэтгэл  
           дундуур байна       
12. Өвчтөний жоргүй эм худалдан авах 
чадвар       
13. Эм олгоход женерик болон брэнд 
эмийн үнэ чухал байдаг      
14. Эмийн дуусах хугацаа      
15. Дахин хэрэглэх шаардлага       
 
10. УХ-тай өвчтөнд бичигдсэн жор тохиромжгүй учир өөрчлөх шаардлага хэр их 
гардаг вэ?   
 
 
Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
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11.  
1. УХ-тай өвчтөнд эмчийн бичсэн тариан эмчилгээ дунджаар ... хоног 
үргэлжилдэг:  
 
 ≤3 өдөр   4-5 өдөр   > 5 өдөр  
 
2. УХ-тай өвчтөнд эмчийн бичсэн уух эмийн хугацаа ... байдаг:  
 
 ≤ 3 өдөр   4-5 өдөр   > 5 өдөр  
 
3. УХ-тай өвчтөнийг тариан эмчилгээнээс уух хэлбэр лүү шилжүүлэхэд дараах 
хугацаа болно: 
 
 ≤ 24 цаг   2 өдөр   3 өдөр   > 5 өдөр /эмчилгээ эхэлсэний дараа / 
 
Дараах асуултууд жоргүй олгогдож буй эмэнд хамаарагдана  
 
12. УХ-тай өвчтөнд дараах эмүүдийг жоргүй олгодог  
  Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1.  Пенициллин,уух      
2. Пенициллин, тариа      
3. Амоксициллин, уух      
4. Амоксициллин, тариа      
5. Ампициллин, уух      
6. Ампициллин, тариа      
7. Ципрофлоксацин, уух      
8. Ципрофлоксацин, тариа      
9. Цефазолин, уух      
10. Цефазолин, тариа      
11. Эритромицин, уух      
12. Эритромицин, тариа      
13. Амоксициллин/клавунат, уух      
14. Кларитромицин, уух      
15. Кларитромицин, тариа      
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16. Азитромицин, уух      
17. Азитромицин, тариа      
18. Левофлоксацин, уух      
19. Тетрациклин, уух      
20. Триметопим-сульфаметоксазол, 
уух      
21. Доксициллин, уух      
 
13. Антибиотикаас гадна УХ-тай өвчтөнд ямар эм олгодог вэ /жоргүй/?   
 
  Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1.   Дексаметазон, уух      
2.  Дексаметазон, тариа      
3. Бромгексин, уух      
4. Витамин С, уух      
5. Витамин С, тариа      
6. Хлорфенамин, уух      
7. Витамин В, уух      
8. Витамин В, тариа      
9. Кокоркарбоксилаз, тариа      
10. Эуфиллин, уух      
11. Эуфиллин, тариа      
12. Анальгин, уух      
13. Анальгин, тариа      
14. Димедрол, уух      
15. Димедрол, тариа      
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14. УХ-тай өвчтөнд жоргүйгээр эм олгоход дараах хүчин зүйлс хамаатай?  
ХЗ: Хүчтэй зөвшөөрч байна, З: Зөвшөөрч байна, Т: Татгалзаж байна, ХТ: Хүчтэй 
татгалзаж байна ХБ: Хариулт байхгүй 
  
 XЗ З Т ХТ ХБ 
1. Тариа уух хэлбэрээс илүү клиникийн үйлчилгээ 
сайтай  
     
2. Тарианы чанар шахмал/капсултай эмийн 
чанараас илүү сайн 
     
3. Эмийг ууж хэрэглэхэд тарьснаас илүү гаж нөлөө 
гардаг 
     
4. Эмийн хэлбэр тухайн өвчтөн эмчилгээг илүү 
сайн дагахад сонгогдсон 
     
5. Тариа хийхэд шинэ зүү, тариур, ампул 
шаардлагатай  
     
6. УХ өвчний үед өвчтөнийг антибиотикаар эмчилж 
байх үед тарианаас уух хэлбэр лүү шилжүүлэхэд 
ямар нэгэн ашиг байхгүй  
     
7. Таны сургалтанд тариаг уух хэлбэрийн эмнээс 
илүү их заадаг   
     
8. Эмийн компаниуд тариаг уух хэлбэрээс илүү 
ихээр сурталчилдаг  
     
9. Шинээр гарч буй бүтээгдэхүүнийг олгохыг илүүд 
үздэг  
     
10. Уух хэлбэрийн эмийн зардал тариан 
эмчилгээний зардлаас/үүнд зүү тариурны үнэ 
багтсан/ илүү үнэтэй болдог  
     
11. Тариан эмчилгээ хийлгэхэд эмийн сан руу илүү 
олон удаа явах хэрэгтэй болдог  
     
12. Өвчтөн эмчилгээг илүү сайн даган мөрдүүлэхийн 
тулд тариаг сонгосон  
     
13. Өвчтөн шахмал эмийг тарианаас илүүд үздэг       
14. Тариаг олгоход өвчтөний нас, хүйс хамаатай       
15. Тариаг УХ-тай өвчтөний байдал хүнд бол олгоно      
 
 
15. Та УХ-тай өвчтөнд жоргүйгээр эм олгохдоо нэгээс олон антибиотик нэгэн зэрэг 
өгдөг үү? 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
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15.  
1. УХ өвчинд хэрэглэх олгосон антибиотик эм тарих хугацаа дунджаар:   
 
 ≤3 өдөр   4-5 өдөр   > 5 өдөр  
 
2. УХ өвчинд хэрэглэх олгосон антибиотик эмийг уух дундаж хугацаа:   
 
 ≤ 3 өдөр   4-5 өдөр   > 5 өдөр  
 
3. УХ –тай өвчтөнийг тариан эмчилгээнээс уух хэлбэр лүү шилжүүлсэн бол 
дундаж хугацаа: 
 
 ≤ 24 цаг   2 өдөр   3 өдөр   > 5 өдөр /эмчилгээ эхэлсэний дараа/ 
 
16. Антибиотик эмийн мэдрэг чанарын талаар улсаас мэдээлэл хэр их авдаг вэ?  
 
Хэзээ ч 
үгүй 
7 хоног 
тутам  
Сар 
болгон 
Жилд 3 
удаа  
Жилд 1 
удаа 
      
 
17. Монгол улсын УХ өвчний эмчилгээний удирдамжийг та тохиромжтой гэж үздэг үү?  
 Тийм     Үгүй     ХБ 
 
 
18. Эмийн санд ирж буй УХ-тай өвчтөнийг та хэр их эмнэлэг рүү явуулдаг вэ?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
      
 
19.     Та УХ өвчинд тариа илүү сайн үр дүнтэй эмчилгээ гэж боддог уу?     
    Тийм       Үгүй    
20. Хэрэв тийм бол тарианы үйлчилгээ юу вэ?  
 Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
1. Илүү хурдан эдгэнэ       
2. Гаж нөлөө 
шахмал/капсултай эм 
ууж хэрэглэснээс 
арай бага гардаг  
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21. Тариа хийхэд/эмчлэхэд дараах хүмүүст илүү их ашигтай байдаг гэж та бодож 
байна вэ?  
 Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
1. Эмч      
2. Эм зүйч       
3. Өвчтөн      
4. Сувилагч      
 
 
22.      Тариа хийхэд та нэмэлт төлбөр авдаг уу?  
 Тийм, _______₮  Үгүй 
 
23. Таны бодлоор тариа худалдаж авах болон хийлгэх төлбөр өвчтөний хувьд 
боломжийн байсан уу?   
 Тийм     Үгүй    ХБ  
 
24. Тариа олгоход дараах зүйлүүдийг та яаж анхаардаг вэ?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Тариаг найдвартай газраас 
ханган нийлүүлсэн 
     
2. Ариун зүү тариур болон дусал 
ашиглах  
     
3. Эмийн савлалтын бүрэн бүтэн 
байдал  
     
4. Өвчтөний өөрийн онош болон 
тариа авах хүсэл  
     
5. Антибиотикийг дахин хэрэглэх      
6. Дахин хэрэглэсэн 
бүтээгдэхүүний дуусах 
хугацаа  
     
 
25. Монгол улсын аливаа өвчинд тариаг хэтрүүлэн ашигладаг гэж та боддог уу? 
 МЗ З Т МТ ХБ 
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26. Хэрэв тийм бол шалтгааныг нэрлэнэ үү? 
 МЗ З Т МТ ХБ 
1. Тариаг эмийн сангуудаас маш 
хялбар аргаар худалдан авах 
боломжтой  
     
2. Эмийн худалдааг улсаас хянах 
шалгалт хангалтгүй 
     
3. Олон нийт тариаг их шаарддаг/ 
хэрэглэдэг   
     
 
 
 
27. Нэг удаагийн тариур ашигласны дараа:   
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Зүүг солин тариурыг дахин 
хэрэглэж болно  
     
2. Зүү тариурыг ариутгаад 
дахин хэрэглэж болно      
3. Бүгдийг хаяна       
4. Эхний удаа хэрэглэсний 
дараа бүгдийг устгаад хаяна     
 
 
28. Дусал хийсний дараа:  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Бүтэн шил/савыг өвчтөнд 
тарина      
2. Илүү гарсан үлдэгдэлийг 
хадгална       
3. Илүү гарсан нунтагийг 
дараачийн өвчтөнд 
хэрэглэнэ   
     
4. Эхний удаа хэрэглэсний 
дараа бүгдийг устгана       
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29. Эм тариаг хаанаас авдаг вэ? 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Эмийн бөөний худалдаа       
2. Эмийн сан       
3. Борлуулагч       
4. Бусад (хувийн импорт)      
30. Монголд хуурамч эм байдаг эсэхийг та мэдэх үү?   Тийм    
Үгүй 
 
30. Хэрэв тийм бол ямар эм хуурамч байсан бэ? 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
a. Антибиотик      
b. Бусад эм        
 
 
32. Таны дундаж орлогыг мэдэж болох уу?  
≤ 90.000₮    91-200.000₮  201-300.000₮  
301-400.000₮    401-500.000₮   ≥501.000₮  
 
33. Уушигны хатгалгаа болон тарианы хэрэглээний талаар та өөр юу гэж боддог 
вэ?  
 
 
 
 
Танд баярлалаа 
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ЭМЧ НАРТАЙ ХИЙХ ЯРИЛЦЛАГА (ШИНЭЧИЛСЭН) 
Мэдээлэл цуглуулах загвар 
_______________________        
Огноо  
Дугаар  _____________________              
Байршил_____________________ 
 
               
1. Нас:  20-30  31-50  51-60  61+                                                 
2. Хүйс:  Эр  Эм  
3. Ажлын түвшин:  өрхийн эмч      улсын эмнэлэг   хувийн 
эмнэлэг    бусад   
4. Мэргэжил:         ерөнхий эмч     нарийн мэргэжлийн  
5. Хэдэн жил ажиллаж байгаа вэ? _______ 
6. Уушигны хатгалгаатай өвчтөнд эмчилгээ бичихэд юу нөлөөлдөг вэ?  
 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Өвчтөний хүлээлт /     
   шаардлага       
2. Зайлшгүй шаардлагатай  
   хөнгөлөлттэй олгогдох эм       
3. Эмийн компаний мэдээлэл       
4. Эмийн компанийн  
    төлөөлөгчийн айлчлал       
5. Уушигны хатгалгаа өвчний  
   оношлогоо, эмчилгээний 
   удирдамж  
     
6. Тасралтгүй сургалт,  
    хичээлийн мэдээлэл        
7. Гаж нөлөө үүсэх магадлал       
8. Орон нутгийн антибиотикийн  
   даслын тухай мэдээлэл       
9. Өвчтөний антибиотикийн  
   даслын мэдээлэл       
10. Ном, сэтгүүл       
11. Хамт ажилладаг дарга,       
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      хүмүүс, эмч нарын нөлөө  
12. Нарийн мэргэжлийн эмч  
      нарын нөлөө       
13. Хувийн туршлага       
14. Өвчтөний урьд нь эмийн  
       сангаас авсан, хэрэглэж  
       байсан антибиотикийн тухай  
       мэдээлэл 
     
15. Эмийн хүртээмж       
16. Өвчтөний эм худалдан авах  
чадвар      
17. Гаж нөлөө багатай нь 
батлагдсан антибиотик хамгийн 
шилдэг сонголт  
     
18. Зах зээлд шинээр гарч буй  
       эмүүдийг сонгох/ илүүд үзэх       
19. Жор бичилтийг хянах улсын  
      шалгалт       
20. Эмийн компаниас авах  
       урамшуулал, шагнал       
 
7. Уушигны хатгалгаатай өвчтөнд тодорхой эмийн тун бичихэд ямар хүчин зүйлс 
нөлөөлдөг вэ?   
 Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1. Тариан эмчилгээ уух эмнээс   
    илүү үр дүнтэй байдаг       
2.  Өвчтөн уух эмийг тарианаас илүүд 
    үздэг       
3. Тарилгын эмийн чанар уух  
    эмнээс илүү сайн       
4. Эмийг ууж хэрэглэхэд тарьснаас 
    илүү их гаж нөлөө үүсдэг       
5. Тарилгын эмээс зүү тариурын 
   хамт, уух эмийн зардал илүү     
   үнэтэй 
     
6. Тариан эмчилгээ хийлгэж  
    байгаа тохиолдолд эмнэлэг  
рүү илүү олон удаа явах  
хэрэгтэй байдаг  
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7. Тариа хийхэд шинэ, ариун зүү  
    тариур ашиглах шаардлагатай      
8. УХ-тай өвчтөнг эмчилж байх явцад 
өвчтөний биеийн байдал 
сайжирсаг тохиолдолд тарианаас 
уух антибиотик эмийн хэлбэр лүү 
шилжих хэрэгтэй  
     
9. Эмийн компаниуд тарилгын  
эмийг илүү ихээр    
сурталчилдаг  
     
10. Өвчтөнийг эмчилгээг илүү сайн 
даган мөрдүүлэхийн тулд тариаг 
сонгосон   
     
11. Сургалтанд тариаг шахмал/ 
капсултай эмнээс илүү ихээр 
хэрэглэхийг заадаг  
     
12. Тариа бичихэд УХ-тай өвчний 
явц/хүндрэл нөлөөлдөг       
13. Эм бичихэд өвчтөний онцлог, 
нас хүйс хамаатай       
 
8.  
1. УХ өвчнийг тариагаар эмчлэх дундаж хугацаа:   
 
 ≤3 өдөр   4-5 өдөр   > 5 өдөр эмчилгээ эхэлсний дараа 
 
2. УХ өвчнийг эмээр эмчлэх дундаж хугацаа:   
 
 ≤ 3 өдөр   4-5 өдөр   > 5 өдөр эмчилгээ эхэлсний дараа 
 
3. УХ-тай өвчтөнийг тариан эмчилгээнээс эмийн эмчилгээнд шилжүүлэхэд ямар 
хугацаа шаардлагатай вэ?  
 
 ≤ 24 цаг   2 өдөр   3-5 өдөр   > 5 өдөр эмчилгээ эхэлсний 
дараа  
 
9. Монгол улсын УХ өвчний удирдамжмийг та тохиромжтой гэж боддог уу?  
 Тийм     Үгүй    ХБ /Хариулах боломжгүй/ 
10. УХ-тай өвчтөнд та нэгээс илүү антибиотик нэгэн зэрэг бичдэг үү?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
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11. Эхний бичсэн антибиотик амжилтгүй байсан тул антибиотикийг солих 
шаардлага хэр олон удаа байсан бэ?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
      
 
12. УХ-тай өвчтөнд ихэвчлэн бичдэг антибиотикийн жагсаалт  
  Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1.  Пенициллин,уух      
2.  Пенициллин, тариа      
3.  Амоксициллин, уух      
4.  Амоксициллин, тариа      
5.  Ампициллин, уух      
6.  Ампициллин, тариа      
7.  Ципрофлоксацин, уух      
8.  Ципрофлоксацин, тариа      
9.  Цефазолин, уух      
10.  Цефазолин, тариа      
11.  Эритромицин, уух      
12.  Эритромицин, тариа      
13.  Амоксициллин/клавунат, уух      
14.  Кларитромицин, уух      
15.  Кларитромицин, тариа      
16.  Азитромицин, уух      
17.  Азитромицин, тариа      
18.  Левофлоксацин, уух      
19.  Тетрациклин, уух      
20.  Триметопим-
сульфаметоксазол, уух 
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21.  Доксициллин, уух      
 
13.  УХ-тай өвчтөнд антибиотикаас гадна ямар эм бичдэг вэ?  
  Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа   
11-40% 
Ихэнхдээ
41-80% 
Байнга 
>80% 
1.  Дексаметазон, уух      
2.  Дексаметазон, тариа      
3.  Бромгексин, уух      
4.  Витамин С, уух      
5.  Витамин С, тариа      
6.  Хлорфенамин, уух      
7.  Витамин В, уух      
8.  Витамин В, тариа      
9.  Кокоркарбоксилаз, тариа      
10.  Эуфиллин, уух      
11.  Эуфиллин, тариа      
12.  Анальгин, уух      
13.  Анальгин, тариа      
14.  Димедрол, уух      
15.  Димедрол, тариа      
 
14. Антибиотикийг жороор бичих талаар улсаас хэдэн удаа мэдээлэл авдаг вэ?  
 Хэзээ 
ч үгүй 
7 хоног 
тутам 
Сар 
болгон 
Жилд 3 удаа Жилд 1 удаа 
      
 
15. УХ-тай өвчтөн тань дээр ирэхээсээ өмнө антибиотик хаанаас ихэвчлэн 
худалдан авсан  байдаг вэ?  
 Хэзээ 
ч үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
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1. Эмийн сан      
2. Зах      
3. Бусад/хувиараа/__      
 
16. Антибиотик бичихдээ та хэр их женерик эм бичдэг вэ?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
      
 
17. Антибиотикийн мэдрэг чанар, идэвхийн талаар хаанаас мэдээлэл авдаг вэ?  
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
1. Улсын мэдээлэл       
2. Улсын ном, сэтгүүл       
3. Антибиотик эмийн 
савны хуудас       
4. Өвчтөнөөс авсан  
шинжилгээнд 
хэрэглэх дээж  
     
5. Эмчлэгдсэн өвчтөн       
6. Хамт ажилладаг  
       хүмүүс       
7. Антибиотик идэвхгүй       
8. Интернэт       
 
 
 
18. УХ-тай өвчтөнг хэр их эмнэлэг рүү явуулдаг вэ? 
 Хэзээ ч 
үгүй 
0%  
Цөөхөн
1-10% 
Заримдаа  
11-40% 
Ихэнхдээ 
41-80% 
Байнга 
>80% 
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19. Монгол улсад тариаг хэтрүүлэн хэрэглэдэг гэж та боддог уу?  
МЗ- Маш их зөвшөөрч байна, З- Зөвшөөрч байна, Т- Татгалзаж байна 
МТ- Маш их татгалзаж байна, ХБ- Хариулах боломжгүй   
 
  
МЗ З Т МТ ХБ 
       
 
20. Хэрэв тийм бол тодруулна уу? 
 МЗ З Т МТ ХБ 
1. Өвчтөн эмийн сангаас тариа 
худалдан авах боломжтой       
2. Улсаас эмийн худалдааг хянах 
шалгалт хангалтгүй       
3. Олон нийтийн шаардлага, хэрэгцээ       
 
 
21. Монголд хуурамч эм байдаг эсэхийг та мэдэх үү?  Тийм                      Үгүй 
 
22.  Хэрэв тийм бол ямар эм хуурамч байсан бэ? 
 
 
23. Таны дундаж орлогыг мэдэж болох уу?  
≤ 90.000₮    91-200.000₮  201-300.000₮  
301-400.000₮    401-500.000₮   ≥501.000₮  
 
       24. Уушигны хатгалгаа өвчин болон бусад өвчний үед тариа хэрэглэхийг та юу гэж    
             боддог вэ? Саналаа бичнэ үү.   
 
______________________________________________________________________ 
 
Танд баярлалаа. 
 
 
 
 Тийм Заримдаа Үгүй 
a. Антибиотик    
b. Бусад эм (тодруулна уу)__________    
